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ABSTRACT 
 
Non-alcoholic fatty liver disease (NAFLD) 
is characterized by excess hepatic 
triglyceride (TG) accumulation that can 
originate from the dietary fat, adipose 
tissue lipolysis or hepatic de novo 
lipogenesis. NAFLD is strongly associated 
with insulin resistance and increased risk 
of type 2 diabetes, cardiovascular disease 
and advanced liver disease.  
 
However, several single nucleotide 
polymorphisms in genes such as PNPLA3, 
MBOAT7 and TM6SF2 have been found 
to increase the risk of NAFLD and 
associated liver injury in the absence of 
insulin resistance. TGs themselves are 
metabolically inert lipids, while bioactive 
lipids such as ceramides and 
diacylglycerols have been suggested to 
mediate insulin resistance. Phospholipids 
are important for hepatic TG export. 
Whether the dissociation between hepatic 
steatosis and insulin resistance can be 
attributed to differences in the molecular 
lipid profile in the human liver is 
unknown. 
 
In study I, we profiled the lipidome of 
liver biopsies from 125 obese subjects 
undergoing bariatric surgery using ultra-
high performance liquid chromatography 
and gas chromatography combined with 
mass spectrometry. The subjects were 
divided based on median HOMA-IR, a 
marker of insulin resistance, to ’High 
HOMA-IR’ and ’Low HOMA-IR’. ’High 
HOMA-IR’ was used as a model of  
’Metabolic NAFLD’. The same subjects 
were also divided into groups based on 
their PNPLA3 genotype to carriers and 
non-carriers of the I148M variant. 
Variant allele carriers were used as a 
model of ’PNPLA3 NAFLD’.  
 
Steatosis and prevalence of NASH were 
similarly increased in ’Metabolic NAFLD’ 
and ’PNPLA3 NAFLD’. The liver lipidome 
in ’Metabolic NAFLD’ was characterized 
by saturated and monounsaturated TGs 
and free fatty acids, diacylglycerols and 
ceramides. Markers of the de novo 
ceramide synthetic pathway were 
increased in ’Metabolic NAFLD’. In 
contrast, in ’PNPLA3 NAFLD’ the 
increase in liver fat was due to 
polyunsaturated TGs while other lipids 
were unchanged. 
 
In study II, we investigated the effects of 
the MBOAT7 variant at rs641738 on liver 
histology and lipidome in biopsies from 
115 bariatric surgery patients. The variant 
allele was associated with increased 
prevalence of liver fibrosis and altered 
concentrations of several polyunsaturated 
phosphatidylinositols, but not other lipids 
or markers of insulin resistance.   
 
In study III, we examined the 
pathogenesis of the ‘TM6SF2 NAFLD’ by 
comparing the human liver and serum 
lipidome and liver transcriptome in 10 
carriers and 80 non-carriers of the 
TM6SF2 E167K variant, and by 
determining the effects of TM6SF2 
knockdown on fatty acid metabolism in 
vitro. In variant allele carriers, liver TG 
and cholesteryl-ester content was higher 
while that of phosphatidylcholines was 
lower as compared to non-carriers. 
Polyunsaturated fatty acids were deficient 
in liver and serum TGs and 
phosphatidylcholines but enriched in 
hepatic free fatty acids. The incorporation 
of polyunsaturated fatty acids into 
triglycerides and phosphatidylcholines 
(PCs) was decreased in TM6SF2 deficient 
cells. Hepatic gene expression of TM6SF2 
was decreased in carriers, and correlated 
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with those genes regulated by PUFAs. 
Thus, hepatic lipid synthesis from PUFAs 
was impaired which could contribute to 
deficiency of PCs and increased hepatic 
TGs in TM6SF2 E167K variant carriers 
compared to non-carriers. 
 
In study IV, we examined whether the 
dietary macronutrient composition 
influences the pathways, mediators and 
magnitude of overfeeding-induced 
changes in intrahepatic triglycerides and 
insulin resistance in 38 overweight 
subjects. We used a combination of state-
of-the-art in vivo (imaging, stable isotope 
tracers and hyperinsulinemic-euglycemic 
clamp) and ex vivo (plasma lipidome, 
adipose tissue transcriptome and gut 
microbiome) techniques. Three weeks of 
overfeeding of saturated fat increased 
hepatic TGs more than that of 
unsaturated fat by increasing adipose 
tissue lipolysis. Moreover, the saturated 
fat-enriched diet increased insulin 
resistance, circulating ceramides and 
gram-negative gut bacteria. Simple sugars 
increased hepatic TGs by stimulating 
hepatic de novo lipogenesis. Each diet 
had distinct effects on the adipose tissue 
transcriptome. These results showed that 
the effect of overfeeding on hepatic 
metabolism depends on the dietary 
macronutrient composition. Saturated fat 
may be metabolically more harmful than 
unsaturated fat or simple sugars. 
 
In summary, the present series of studies 
show that human NAFLD is a 
heterogenous disease. Both genetic 
factors and the macronutrient 
composition of the diet have distinct 
effect on hepatic lipid metabolism and the 
resulting phenotype.  
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1. INTRODUCTION 
 
The spectrum of ‘Metabolic NAFLD’ and 
associated risk of disease. Non-alcoholic 
fatty liver disease (NAFLD) is a spectrum 
of disease ranging from simple steatosis 
(non-alcoholic fatty liver, NAFL) to 
nonalcoholic steatohepatitis (NASH) to 
cirrhosis (Yki-Järvinen, 2014).  It has 
become the most prevalent cause of liver 
disease worldwide affecting up to one-
quarter of population, increasing in 
parallel with obesity (Younossi et al., 
2016). 
 
NAFLD is strongly associated with 
hepatic insulin resistance and features of 
the metabolic syndrome (MetS) 
(‘Metabolic NAFLD’) (Yki-Järvinen, 
2014). In ‘Metabolic NAFLD’, insulin fails 
to suppress the production of glucose and 
triglycerides in the liver, resulting in 
hyperinsulinemia, hyperglycemia, 
hypertriglyceridemia and low high-
density lipoprotein concentrations (Yki-
Järvinen, 2014). This common form of 
NAFLD is associated with increased risk 
of type 2 diabetes, cardiovascular disease 
and advanced liver disease (Figure 1) 
(Anstee et al., 2013).  
 
Insulin action and sources of FAs in 
‘Metabolic NAFLD’. Intrahepatic 
triglycerides (IHTGs), the hallmark of 
NAFLD, are synthesized from fatty acids 
originating either from the adipose tissue, 
dietary fat, or hepatic de novo lipogenesis 
(Donnelly et al., 2005). Adipose tissue 
lipolysis is the major source, contributing 
to more than half of the fatty acids in 
IHTGs. In addition, the liver partially 
takes up dietary fat, and can also produce 
fatty acids from non-lipid substrates, such 
as sugars via the de novo lipogenesis 
(DNL) pathway (Donnelly et al., 2005). 
DNL is the relatively most increased fatty 
acid source in NAFLD, and produces 
exclusively saturated fatty acids (Lambert 
et al., 2014). 
 
Bioactive lipids. IHTGs themselves are 
inert lipids, while at least two classes of 
bioactive lipids, diacylglycerols (DAGs) 
and ceramides have been suggested to 
mediate insulin resistance (Petersen et 
al., 2017). DAGs are the immediate 
precursors of TGs, while ceramides can be 
synthesized via the de novo synthetic 
pathway from saturated fatty acids, via 
sphingomyelin hydrolysis or via the 
salvage pathway from hexosylceramides 
(Chaurasia et al., 2015). Recent studies in 
mice have identified C16:0-ceramide, 
formed via the de novo ceramide 
synthetic pathway as the principal 
mediator of obesity-related insulin 
resistance (Hla et al., 2014). There are no 
human data to examine which if any of 
these pathways contributes to changes in 
ceramide concentrations in the human 
liver.  
 
‘PNPLA3 NAFLD’. Not all phenotypes of 
NAFLD are associated with insulin 
resistance. In 2008, a single-nucleotide 
polymorphism (rs738409 [G], encoding 
I148M) in the patatin-like phospholipase 
domain-containing 3 (PNPLA3) was 
found to increase liver fat content but not 
insulin resistance (Figure 1) (Romeo et 
al., 2008). Depending on ethnicity, 20-
50% of all subjects carry this gene variant 
(Romeo et al., 2008). In vitro, this gene 
variant inhibits lipolysis of TGs in the 
liver (Huang et al., 2011) and may also act 
as a gain-of-function mutation to increase 
TG synthesis by acting as a 
lysophosphatidic acyltransferase (LPAAT) 
converting lysophosphatidic acid into 
phosphatitidic acid (Kumari et al., 2012).  
 
‘MBOAT7 NAFLD’. A common variant in 
membrane bound O-acyltransferase 
domain containing 7 (MBOAT7) at 
rs641738, carried by 58-67% of 
population, was discovered to increase 




Figure 1. Heterogeneity of the metabolic features and disease risks associated with 
subtypes of NAFLD. 
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insulin resistance (Figure 1) (Mancina et 
al., 2016). MBOAT7 functions as a 
lysophosphatidylinositol acyltransferase, 
catalyzing the fatty acyl-chain remodeling 
of phosphatidylinositols (PIs). In keeping 
with this function, carriers of the variant 
have lower plasma concentrations of 
polyunsaturated PIs (Mancina et al., 
2016). 
 
 ‘TM6SF2 NAFLD’. A third genetic variant 
increasing the risk of NAFLD, 
transmembrane 6 superfamily member 2 
(TM6SF2) at rs58542926, was described 
in 2014 (Kozlitina et al., 2014). In 
contrast to ‘Metabolic NAFLD’, carriers of 
this variant (‘TM6SF2 NAFLD’) are not 
more insulin resistant than non-carriers 
and have normal or decreased plasma TG 
concentrations and a decreased risk of 
cardiovascular disease (Figure 1) 
(Kozlitina et al., 2014; Mahdessian et al., 
2014). Knockdown of TM6SF2 increases 
intracellular TG content and decreases TG 
secretion, while overexpression has an 
opposite effect (Mahdessian et al., 2014). 
In animal models, a similar phenotype, 
i.e. hepatic steatosis, decreased TG 
secretion and protected against 
cardiovascular disease, can result from 
impaired synthesis or remodeling of 
phosphatidylcholines (Rong et al., 2015).  
 
Dissociation of IHTG and IR. All of these 
genetic variants increase liver fat content 
and histological severity of NAFLD, but in 
contrast to the ‘Metabolic NAFLD’, none 
are associated with metabolic 
disturbances (Figure 1) (Romeo et al., 
2008; Mancina et al., 2016; Kozlitina et 
al., 2014). Whether these dissociations 
can be attributed to different lipid profiles 
in the human liver remains unknown.  
 
Dietary modulation of NAFLD. While 
excessive energy consumption is the 
primary acquired risk factor of NAFLD, it 
does not occur in all subjects who are 
overweight (Browning et al., 2004). 
Whether macronutrient composition 
modulates metabolic effects of the diet 
overconsumed is unclear. Excess intakes 
of sugar (Sevastianova et al., 2012), and 
saturated but not polyunsaturated fat 
(Rosqvist et al., 2014) have been reported 
to increase IHTGs. Overfeeding of simple 
sugars increases IHTG via DNL 
(Sevastianova et al., 2012). However, 
there are no studies investigating the 
effects of overfeeding saturated or 
unsaturated fat or simple sugars on IHTG 
content, sources of hepatic fatty acids 
(adipose tissue lipolysis and hepatic 
DNL), insulin resistance, and associated 
metabolic effects in the gut, adipose tissue 
and plasma. 
 
The present series of studies aimed to 
elucidate the heterogeneity of human 
NAFLD, with a special emphasis on the 
regulation of hepatic lipid metabolism by 
genetic and nutritional factors. In study I, 
we characterized the human liver 
lipidome in the insulin-resistant 
‘Metabolic NAFLD’ and the insulin-
sensitive ‘PNPLA3 NAFLD’. In study II, 
we investigated the effects of the 
MBOAT7 variant at rs641738 on the 
human liver histology and lipidome. In 
study III, we sought to elucidate the 
pathogenesis of the ‘TM6SF2 NAFLD’ by 
characterizing the human liver and serum 
lipidome and liver transcriptome in 
carriers of the TM6SF2 E167K variant, 
and by determining the effects of TM6SF2 
knockdown on fatty acid metabolism in 
vitro. Finally, we examined the metabolic 
effects of three weeks of overfeeding of 
diets enriched either in saturated or 
unsaturated fat or simple sugars using a 
combination of state-of-the-art in vivo 
(imaging, stable isotope tracers and 
hyperinsulinemic-euglycemic clamp) and 
ex vivo (plasma lipidome, adipose tissue 
transcriptome and gut microbiome) 
techniques.
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2. REVIEW OF THE LITERATURE 
 
2.1 INTRODUCTION TO NAFLD 
2.1.1. Definitions 
 
NAFLD is defined as hepatic steatosis in 
the absence of other causes such as excess 
alcohol intake (> 30 g/day in men, > 20 
g/day in women), viral or autoimmune 
hepatitis, or use of hepatotoxic drugs or 
other compounds (Yki-Järvinen, 2014). It 
comprises a spectrum of disease ranging 
from NAFL to NASH, a more aggressive 
form characterized by hepatocellular 
injury (ballooning necrosis, mild 
inflammation and possibly fibrosis), and 
cirrhosis (Yki-Järvinen, 2014).  
 
Although NAFLD commonly coexists with 
insulin resistance and the features of the 
metabolic syndrome (‘Metabolic 
NAFLD’), three common genetic variants 
increase the risk of NAFLD (‘Genetic 
NAFLD’) without affecting insulin 
sensitivity (Figure 1). A single-
nucleotide polymorphism in PNPLA3 
(rs738409 [G], encoding I148M) 
increases the risk of NAFL, NASH and 
fibrosis (‘PNPLA3 NAFLD’) (Romeo et 
al., 2008). Genetic variations in MBOAT7 
(rs641738 [T]) and TM6SF2 (rs58542926 
[T], encoding E167K) also increase the 
risk of full spectrum of liver disease in 
NAFLD (‘MBOAT7 NAFLD’ and ‘TM6SF2 
NAFLD’, respectively) (Mancina et al., 
2016; Kozlitina et al., 2014). Given the 
high prevalence of the metabolic 
syndrome and these genetic variants, 
both metabolic and genetic causes of 
NAFLD may coexist.  
2.1.2. Diagnosis 
 
The gold standard method for the 
diagnosis of NAFLD is histological 
evaluation of a liver biopsy, which 
provides quantification of all qualities of 
the disease: steatosis, ballooning, lobular 
inflammation and fibrosis (Brunt et al., 
1999). NASH can only be diagnosed using 
a liver biopsy. Despite being highly 
informative, the utility of a liver biopsy is 
limited by its invasiveness, cost and 
sampling variability (European 
Association for the Study of the Liver 
(EASL) et al., 2016).  
 
Hepatic steatosis can be assessed using 
non-invasive imaging modalities such as 
proton magnetic resonance spectroscopy 
(1H-MRS), magnetic resonance imaging 
(MRI), ultrasound, and computer 
tomography (European Association for 
the Study of the Liver (EASL) et al., 
2016). Using 1H-MRS, NAFLD is 
commonly defined as intrahepatocellular 
triglyceride content exceeding 5.56%, 
based on the 95th percentile of IHTG in 
the healthy subjects in the population-
based Dallas Heart Study (Szczepaniak et 
al., 2005). 
 
Fibrosis can be assessed indirectly by 
measuring liver stiffness, using non-
invasive techniques such as transient 
elastography (Fibroscan®) or magnetic 
resonance elastography. In addition, 
several risk scores have been developed 
based on biochemical and anthropometric 
measurements for assessing the risk of 
advanced fibrosis in NAFLD, such as the 
FIB-4 and the NAFLD fibrosis score 
(European Association for the Study of 
the Liver (EASL) et al., 2016).  
2.1.3. Prevalence and significance  
 
NAFLD has become the most prevalent 
cause of chronic liver disease worldwide 
affecting up to one-quarter of population, 
increasing in parallel with obesity 
(Younossi et al., 2018). The prevalence of 
NASH is difficult to estimate, as it 
requires a liver biopsy. The prevalence of 
NASH in Finland was estimated by first 
developing a score based on liver biopsies 
obtained from 296 patients undergoing 
bariatric surgery, and then by validating 
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the score in 380 Italian mainly non-
bariatric surgery patients. The score was 
applied to a Finnish population-based 
cohort in which the prevalence of NASH 
was found to be approximately 5% in 45-
74-year olds (Hyysalo et al., 2014). This 
prevalence is consistent with the 3-6% 
reported in studies of healthy liver donors 
(Anstee et al., 2013). 
 
Subjects with NAFLD have an increased 
risk of mortality from cardiovascular 
disease, liver cirrhosis and hepatocellular 
carcinoma (Ekstedt et al., 2015). Amongst 
the histological features of NAFLD, 
especially fibrosis has been shown to 
predict overall and liver-related mortality 
(Dulai et al., 2017, Hagström et al., 2017).  
2.1.3.1. Type 2 diabetes and the 
metabolic syndrome 
 
The liver is the main glucose-producing 
organ in the body after an overnight fast 
(Yki-Järvinen, 1993). In the insulin-
resistant ‘Metabolic NAFLD’, insulin fails 
to inhibit hepatic glucose production, 
leading to hyperglycemia. In order to 
maintain euglycemia, the pancreas 
compensatorily secretes more insulin, 
resulting in hyperinsulinemia. If this 
compensatory capacity of the pancreatic 
beta cells is exceeded, overt 
hyperglycemia and type 2 diabetes ensues 
(Yki-Järvinen, 2014). 
 
According to a recent systematic review,  
NAFLD predicted the development of 
type 2 diabetes independently of age and 
BMI in 4 out of 6 studies in which NAFLD 
was diagnosed by ultrasound, and in 12 
out of 14 studies in which the diagnosis 
was based on liver enzymes (ALT, AST or 
GGT) (Lallukka et al., 2016). 
 
Liver fat content correlates tightly with 
the features of the metabolic syndrome 
(i.e. waist circumference, hypertension, 
hyperglycemia, hypertriglyceridemia and 
low HDL cholesterol concentrations) 
(Kotronen et al., 2007). 
2.1.3.2. Cardiovascular disease 
 
The liver is the major organ producing 
triglyceride-rich lipoproteins into the 
circulation after an overnight fast. In the 
insulin-resistant ‘Metabolic NAFLD’, 
insulin fails to suppress the hepatic 
secretion of large very low-density 
lipoprotein particles (Adiels et al., 2007). 
This results in high triglyceride and low 
HDL cholesterol concentrations in 
plasma. In addition, the ‘Metabolic 
NAFLD’ is associated with increased 
activities of coagulation factors (Kotronen 
et al., 2011; Lallukka et al., 2016) and 
impaired fibrinolysis (Verrijken et al., 
2014; Tripodi et al., 2011), which may 
further contribute to an increased risk of 
cardiovascular disease in subjects with 
NAFLD.  
 
Indeed, cardiovascular disease is the 
leading cause of death in subjects with 
NAFLD (Ekstedt et al., 2006).  
2.1.3.3. Advanced liver disease and 
hepatocellular carcinoma 
 
NAFLD can progress from NAFL to 
NASH and cirrhosis. NAFLD also 
increases the risk of hepatocellular 
carcinoma (HCC) (Anstee et al., 2013). 
According to a recent meta-analysis the 
rate of disease progression is slower in 
patients with NAFL (one fibrosis stage 
over 14.3 years) as compared to patients 
with NASH (7.1 years) (Singh et al., 
2015). In paired-biopsy studies, steatosis 
(Pais et al., 2013) and fibrosis stage (Nasr 
et al., 2017) have been shown to predict 
the progression from NAFL to NASH and 
fibrosis. The only curative treatment for 
end-stage cirrhosis is liver 
transplantation, for which NAFLD is 
currently the second most common 
indication in the US (Wong et al., 2015). 
NAFLD is the most common cause of 
HCC in both the United States (Sanyal et 
al., 2010) and the United Kingdom 
(Dyson et al., 2014). 
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2.1.4. Risk factors for NAFLD  
 
Age is associated with the prevalence of 
ultrasound-diagnosed NAFLD, increasing 
approximately by 3-fold in subjects over 
60 years old compared to those under 30 
years of age in the population-based 
Third National Health and Nutrition 
Examination Survey comprising of 12,454 
subjects (Lazo et al., 2013). Male gender 
is also associated with increased 
prevalence of NAFLD (Lazo et al., 2013). 
 
The prevalence and severity of NAFLD is 
positively correlated with obesity (Lazo et 
al., 2013; Fabbrini et al., 2010). 
Histological assessment of liver biopsies 
obtained from liver donors, car crash 
victims, autopsies and clinical liver 
biopsies indicate that the prevalence of 
steatosis and steatohepatitis are 
approximately 15% and 3% in non-obese 
subjects, 65% and 20% in subjects with a 
BMI 30.0-39.9 kg/m2, and 85% and 40% 
in subjects with a BMI over 40 kg/m2 
(Fabbrini et al., 2010). 
 
Subjects with NAFLD are characterized 
by low level of physical activity (Gerber et 
al., 2012), while lifestyle interventions 
have been consistently shown to reduce 
liver fat content (Thoma et al., 2012; 
Vilar-Gomez et al., 2015). Nutritional 
factors also play a major role in the 
pathophysiology of NAFLD, and are 
discussed in detail later.  
 
Liver fat content is closely correlated with 
insulin resistance in the adipose tissue 
(Marchesini et al., 2001; Bugianesi et al., 
2005; Gastaldelli et al., 2007; Kotronen 
et al., 2008; Seppälä-Lindroos et al., 
2002), the skeletal muscle (Marchesini et 
al., 2001; Bugianesi et al., 2005; 
Kotronen et al., 2008; Korenblat et al., 
2008) and the liver (Seppälä-Lindroos et 
al., 2002; Kotronen et al., 2008).  
 
NAFLD is found in up to 70 % of subjects 
with type 2 diabetes, the prevalence being 
up to 3-fold higher than in the population 
(Doycheva et al., 2016). This is not 
explained by obesity since subjects with 
type 2 diabetes have significantly higher 
IHTG content than age-, gender-, and 
BMI-matched subjects without diabetes 
(Kotronen et al., 2008). 
 
A growing body of evidence indicates that 
NAFLD is heritable. Family histories of 
both diabetes (Loomba et al., 2012) and 
advanced liver disease (Caussy et al., 
2017) are associated with increased risk of 
NASH and fibrosis. Heritability estimates 
of NAFLD have ranged between 20 and 
70 %, depending on the study design, 
ethnicity and the diagnostic methods used 
(Sookoian et al., 2017). A portion of this 
heritability may be mediated by common 
genetic variants in PNPLA3, MBOAT7 
and TM6SF2 (vide infra). 
2.2. PATHOGENESIS OF NAFLD 
2.2.1. ‘Metabolic NAFLD’ 
2.2.1.1. Sources of hepatic fatty 
acids 
 
Increased intrahepatic triglyceride 
(IHTG) content is the defining feature of 
NAFLD. TGs are composed of a glycerol 
backbone and three variable fatty acyl-
groups. Hepatic uptake of fatty acids is 
mainly determined by their delivery 
(Frayn et al., 2006). These fatty acids can 
originate either from the adipose tissue, 
dietary fat, or from non-lipid substrates 
via hepatic de novo lipogenesis (Donnelly 
et al., 2005) (Figure 2).  
2.2.1.1.1. Adipose tissue lipolysis 
 
Contribution to IHTG. After an overnight 
fast, adipose tissue lipolysis is the major 
source of hepatic fatty acids. Direct 
measurements using stable isotopes in 
humans have shown that more than half 
of the fatty acids in IHTGs in subjects 
with NAFLD originate from lipolysis 
(Donnelly et al., 2005).  
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In response to a meal, insulin inhibits 
lipolysis by inhibiting hormone-sensitive 
lipase (HSL) and adipose tissue switches 
from net release to net uptake of free fatty 
acids (FFAs) (Frayn et al., 2006). This 
decreases the delivery of FFAs to the liver 
(Frayn et al., 2006).  
 
Regulation of lipolysis. In healthy 
subjects, adipose tissue lipolysis is 
stimulated under conditions of energy 
demand (e.g. stress and fasting) and 
suppressed after a meal under conditions 
of energy surplus (Frayn et al., 2006). 
Hormones such as catecholamines, 
growth hormone and glucocorticoids, and 
cytokines such as tumor necrosis factor 
alpha stimulate lipolysis in humans. 
Inhibitors of lipolysis include insulin and 
nicotinic acid (Langin, 2006). 
Polyunsaturated fatty acids may also 
inhibit adipose tissue lipolysis via 
activation of G-protein coupled receptor 
120 (GPR120), which mediates anti-
inflammatory and insulin-sensitizing 
effects and is expressed in adipocytes and 
macrophages (Oh et al., 2010; Wang et 
al., 2017; Satapati et al., 2017). HSL, 
adipose triglyceride lipase (ATGL) and 
monoacylglycerol lipase (MGL) are the 
main lipases that mediate the responses 
to regulators of lipolysis (Frayn et al., 
2006; Nielsen et al., 2014).  
 
Insulin resistance in adipose tissue in 
NAFLD. The increase in lipolysis in 
NAFLD is characterized by an inability of 
insulin to normally inhibit lipolysis 
(Marchesini et al., 2001; Bugianesi et al., 
2005; Gastaldelli et al., 2007; Kotronen 
et al., 2008; Seppälä-Lindroos et al., 
2002), thereby increasing the flux of free 
fatty acids and glycerol into circulation 
and their availability for uptake in the 
liver. 
 
The exact mechanism leading to adipose 
tissue insulin resistance in humans is 
unclear but it is well established that 
adipose tissue is inflamed in insulin-
resistant conditions such as obesity 
(Weisberg et al., 2003) and NAFLD 
(Kolak et al., 2007). Inflamed adipose 
tissue is characterized by adiponectin 
deficiency (Arita et al., 1999) and it 
overproduces adipokines such as 
monocyte chemotactic protein-1, tumour 
necrosis factor alpha and interleukins 1 
and 6, which in mouse models induce 
insulin resistance (Shoelson et al., 2006). 
Adiponectin deficiency seems of 
particular relevance in human NAFLD. 
Multiple studies have documented serum 
adiponectin concentrations to be 
inversely related with liver fat content 
(Turer et al., 2012; Polyzos et al., 2016).  
 
Increased adipose tissue lipolysis could 
stimulate glucose production and induce 
insulin resistance in the liver by several 
mechanisms. Free fatty acids taken up by 
the liver can be metabolized into 
bioactive, insulin resistance-inducing 
intermediates, such as ceramides and 
diacylglycerols (vide infra) (Samuel et al., 
2016). Hepatic free fatty acids can also be 
oxidised in the liver into acetyl coenzyme 
A (acetyl-CoA), which in turn can 
allosterically activate pyruvate 
carboxylase and thereby stimulate 
gluconeogenesis (Perry et al., 2015). 
Finally, increased glycerol availability can 
increase gluconeogenesis by a substrate 
push mechanism (Perry et al., 2015).  
 
According to a systematic review 
comprising 7,354 healthy subjects, oleic 
acid (C18:1) makes up 43.5%, palmitic 
acid (C16:0) 21.5%, linoleic acid (C18:2) 
13.9%, palmitoleic acid (C16:1) 7.2%, and 
stearic acid (C18:0) 3.4% of the fatty acids 
in TGs of subcutaneous adipose tissue 
(Hodson et al., 2008). Thereby lipolysis 
in the adipose tissue could be expected to 
supply the liver with mostly saturated and 
monounsaturated fatty acids. 
2.2.1.1.2. Dietary fat 
 
In the postprandial state, dietary 
triglycerides undergo hydrolysis in the 
intestinal lumen by lipases and are then 
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taken up by enterocytes and re-esterified 
into TGs (Frayn et al., 2006). These TGs 
are secreted into the lymph in 
chylomicron particles. The majority of 
chylomicron triglycerides are hydrolysed 
intravascularly by lipoprotein lipase and 
taken up by peripheral tissues. The 
resulting chylomicron remnant particles 
are taken up by the liver. The fraction of 
fatty acids that are released in the 
hydrolysis of chylomicrons 
intravascularly but are not immediately 
taken up by adipose tissue and skeletal 
muscle spill over to the circulation and 
are available for  uptake by the liver 
(Lambert et al., 2014). This spillover 
pathway appears to be unchanged in 
subjects with high as compared to those 
with low liver fat content (Lambert et al., 
2014).  
2.2.1.1.3. De novo lipogenesis 
 
Hepatic de novo lipogenesis synthesizes 
saturated fatty acid palmitate (C16:0) 
from cytosolic citrate (Postic et al., 2008) 
(Figure 2). Conversion of citrate to 
acetyl-CoA is catalyzed by ATP citrate 
lyase, which is subsequently metabolized 
to malonyl-CoA by acetyl-CoA 
carboxylase (ACC) and subsequently 
elongated by fatty acid synthase (FAS). 
Cytosolic citrate is produced in the Krebs 
cycle in mitochondria during oxidation of 
substrates such as glucose, fructose and 
amino acids. Unlike glucose, fructose is 
metabolized only in the liver and 
stimulates DNL more than glucose in 
humans (Hellerstein et al., 1996).  
 
Palmitate can be elongated by elongases 
such as fatty acid elongase 6 (ELOVL6) to 
form longer saturated fatty acids such as 
oleate (C18:0) (Postic et al., 2008). 
Saturated fatty acids are converted to 
monounsaturated fatty acids via the 
action of stearoyl-CoA desaturase 1 (SCD-
1). Importantly, saturated fatty acids 
cannot be converted to polyunsaturated 
fatty acids because their synthesis 
requires essential fatty acids such as 
linoleate (C18:2) as a precursor (Hodson 
et al., 2008).  
  
Hyperglycemia upregulates DNL by 
stimulating activation of the transcription 
factor carbohydrate-responsive element-
binding protein (ChREBP) which 
increases the synthesis of FAS and SCD-1, 
and also simply by increasing the 
availability of pyruvate in mitochondria 
(Hellerstein et al., 1996) (Figure 2). 
Insulin stimulates sterol regulatory 
element-binding protein 1c (SREBP1c) 
expression in the liver, which increases 
the transcription of ACC, FAS and 
ELOVL6 (Yilmaz et al., 2016).  
 
Stimulation of glucose utilization by 
exercise in skeletal muscle acutely 
decreases hepatic DNL (Rabøl et al., 
2011). 
 
In normal subjects studied after an 
overnight fast, 4.6-10.1% of fatty acids in 
VLDL-TGs, which reflect the composition 
IHTGs, originate from DNL (Diraison et 
al., 2003; Donnelly et al., 2005). In 
subjects with high liver fat content, the 
contribution of DNL to VLDL-TG 
averaged 14.9-23.2% which was 
approximately 3-fold higher than in 
subjects with low liver fat content 
(Diraison et al., 2003; Lambert et al., 
2014). These data imply that that the fatty 
acid composition of IHTG could be 
relatively enriched with saturated TGs at 
least in part because of increased DNL. 
When measured directly across the 
splanchnic bed using the hepatic venous 
catheterization technique, the human 
fatty liver overproduces triacylglycerols 
containing saturated fatty acids 
(Westerbacka et al., 2010). Adipose tissue 
DNL appears neglible in humans 
(Diraison et al., 2003). 
2.2.1.2. Fates of hepatic fatty acids 
 
In the liver, fatty acids can be channeled 
into distinct metabolic pathways (Figure 
2). They can be utilized for synthesis of 
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TGs, which may either be stored in lipid 
droplets, or secreted into circulation in 
VLDL particles (Grevengoed et al., 2014). 
By definition, the amount of TGs in 
hepatic lipid droplets is increased in 
NAFLD.  In subjects with NAFLD, TGs 
are overproduced to the circulation in 
VLDL particles, and this production is 
less inhibited by insulin as compared to 
normal subjects independent of age, 
gender and obesity (Adiels et al., 2007). 
 
Another fate of fatty acids is metabolism 
into non-TG lipid species such as 
diacylglycerols, ceramides, phospholipids 
or cholesterol esters (vide infra).  
 
Fatty acids can undergo oxidation in 
mitochondria (or in peroxisomes in case 
of very long chain polyunsaturated fatty 
acids) to produce acetyl-CoA, which can 
be utilized to generate adenosine 
triphosphate (ATP) or ketone bodies 
(Grevengoed et al., 2014). In studies 
assessing hepatic lipid oxidation either 
indirectly by measuring plasma 3-
hydroxybutyrate concentrations 
(Kotronen et al., 2009), or directly by in 
vivo 13C magnetic resonance spectroscopy 
(Petersen et al., 2016), no changes have 
been found in subjects with NAFLD as 
compared to healthy controls. Whether 
hepatic lipid oxidation is altered in more 
advanced disease states, such as in NASH, 
remains unclear (Männistö et al., 2015; 
Sunny et al., 2017). 
 
Polyunsaturated fatty acids can also be 
metabolized into bioactive derivatives 
such as eicosanoids, which are important 
modulators of inflammation (Grevengoed 
et al., 2014). Increased circulating 
concentrations of polyunsaturated fatty 
acid-derived eicosanoids characterize 
patients with NASH (Puri et al., 2009; 
Loomba et al., 2015).  
 
In addition to being substrates for the 
aforementioned various metabolic 
pathways, FFAs may modulate 
metabolism via acting as ligands for 
nuclear transcriptional factors, such as 
peroxisome proliferator activators alpha, 




TGs, i.e. triacylglycerols, are composed of 
three variable fatty acyl-groups and a 
glycerol backbone. The energy density of 
TGs is approximately 37 kJ/g, while that 
of glycogen is approximately 17 kJ/g, and 
further decreased as glycogen binds three 
times its own mass of water.  Therefore, 
TGs are a bioenergetically efficient 
storage form of chemical energy in the 
body (Frayn et al., 2006).  
 
Synthesis of TGs starts by formation of 
the glycerol backbone. Glycerol 3-
phosphate acyltransferase (GPAT) 
acylates glycerol 3-phosphate (G3P) with 
a fatty acid to form lysophosphatidic acid 
(LPA). This is acylated by 
lysophosphatidic acid acyltransferase 
(LPAAT) to form phosphatidic acid, 
which can be metabolized into 
diacylglycerol. Finally, diacylglycerol is 
acylated by diacylglycerol acyltransferase 
(DGAT) into a TG (Postic et al., 2008) 
(Figure 2). 
 
As mentioned earlier, the fatty acids in 
intrahepatic TGs can be derived from the 
dietary fat, adipose tissue lipolysis, or 
hepatic de novo lipogenesis. The fatty 
acid composition of VLDL-TGs reflects 
that of their fatty acid sources (Lambert et 
al., 2014), and that of hepatic TGs in the 
fasting state (Donnelly et al., 2005).  
 
A previous study on hepatic lipidome in 
27 subjects (9 controls, 9 subjects with 
NAFL and 9 subjects with NASH) using 
thin-layer chromatography reported that 
IHTGs were 9.4-fold increased in NAFL 
and 7.6-fold in NASH as compared to 
controls. Saturated, monounsaturated 
and polyunsaturated fatty acids 
represented approximately 40, 40 and 20 
mol-% of fatty acids in IHTGs, 
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respectively. Saturated and 
monounsaturated fatty acids  tended to 
increase and polyunsaturated fatty acids 
were decreased in IHTGs in NAFL and 
NASH as compared to controls (Puri et 
al., 2007). 
 
Even though hepatic TG content 
correlates closely with insulin resistance 
(Ryysy et al., 2000; Sanyal et al., 2001; 
Seppälä-Lindroos et al., 2002; Gastaldelli 
et al., 2007; Kotronen et al., 2008; 
Korenblat et al., 2008), several 
phenotypes characterized by hepatic 
steatosis without features of insulin 
resistance also exist, such as in subjects 
with familial hypobetalipoproteinemia 
(Amaro et al., 2010), or carrying genetic 
variants in PNPLA3, MBOAT7 and 
TM6SF2 (vide infra). These findings in 
humans, and in a plethora of animal 
models (Sun et al., 2013) suggest that TGs 
are inert and by themselves not sufficient 
or necessary to cause insulin resistance 
(Cohen et al., 2011). Rather than TGs, 
accumulation of lipotoxic derivatives of 
fatty acids, such as diacylglycerols and 
ceramides (vide infra) have been 
suggested to mediate insulin resistance 




Diacylglycerols (DAGs) are the immediate 
precursors of TGs (Figure 2). These 
bioactive lipids are composed of two 
variable fatty acyl chains and a glycerol 
backbone. DAGs were first associated 
with insulin resistance in the skeletal 
muscle, where they impair insulin 
signaling by activating protein kinase C 
theta (PKCθ) (Samuel et al., 2016).  
 
DAGs were subsequently hypothesized to 
mediate IR in the liver. Indeed, in the rat 
liver, increased concentrations of DAGs 
activate protein kinase C epsilon (PKCε), 
which is associated with decreased 
activation of insulin receptor tyrosine 
kinase (Samuel et al., 2004; Samuel et al., 
2007). This mechanism may mainly affect 
insulin regulation of net hepatic glycogen 
synthesis (ter Horst et al., 2017). The 
specific molecular mechanism underlying 
inhibition of insulin receptor kinase by 
PKCε was found to be the 
phosphorylation site Thr1160 (Petersen et 
al., 2016b). Both deletion of prkce, and 
inactivation of this phosphorylation site 
protects mice from high fat diet-induced 
insulin resistance (Raddatz et al., 2011; 
Petersen et al., 2016b).  
 
Total hepatic DAG concentrations have 
been shown to correlate with insulin 
resistance in two human studies with 37 
and 16 subjects (Kumashiro et al., 2011; 
Magkos et al., 2012). One study with 29 
subjects did not find significant 
correlation between total hepatic DAG 
content and insulin resistance (ter Horst 
et al., 2017). However, when subcellular 
fractions were analysed separately, 
cytosolic DAG content was found to be 
increased while membrane DAG content 
was decreased in insulin resistant as 
compared to insulin sensitive subjects. 
Amongst 13 different cytosolic species, 
four correlated positively with insulin 
resistance: C18:1-C16:0, C18:0-C18:0, 
C16:0-C16:0 and C18:1-C18:1, i.e. species 
with saturated and monounsaturated 
fatty acyl chains (ter Horst et al., 2017). 
 
Regarding hepatic DAG content in 
NAFLD, a 4-fold increase was reported in 
8 subjects with NAFL as compared to 8 
healthy controls matched for age, gender 
and BMI (Kotronen et al., 2009). Another 
study described a 2.6-fold increase in 
hepatic DAG content in 9 subjects with 
NAFL and a 1.7-fold increase in 9 subjects 
with NASH as compared to 9 controls 
(Puri et al., 2007). One study examined 
the hepatic DAGs with respect to distinct 
species in 12 subjects with normal liver, 
17 subjects with steatosis and 9 subjects 
with cirrhosis (Gorden et al., 2011). In 
this study, the increase in hepatic DAGs 
in steatotic as compared to normal liver 
was due to increase in species with  32 to 
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36 carbons and 0 to 3 double bonds. Of 
note, in this study the groups differed 
with respect to size, gender distribution, 
body mass index and age. 
 
There are no studies comparing the 
hepatic DAG content and composition in 
insulin-resistant ‘Metabolic NAFLD’ and 
in insulin-sensitive ‘PNPLA3 NAFLD’. 
2.2.1.2.3. Ceramides 
 
Ceramides, a part of the sphingolipid 
family, are another type of fatty acid 
intermediates which have been suggested 
to mediate insulin resistance. Like DAGs, 
ceramides were first reported to mediate 
insulin resistance in the skeletal muscle 
and subsequently hypothesized to 
mediate it also in the liver (Chavez et al., 
2012). They can be synthesized either 
from saturated fatty acids (e.g. palmitate) 
via de novo synthesis, or via 
sphingomyelin hydrolysis, or from 
hexosylceramides via salvage pathway 
(Chaurasia et al., 2015) (Figure 3). In 
studies using lipid infusions or cell 
cultures, ceramides have been associated 
especially with saturated-, but not 
unsaturated fatty acid-induced insulin 
resistance (Holland et al., 2007; Hu et al., 
2011). 
 
Recently, a distinct species of ceramides, 
C16:0-ceramide, from the de novo 
synthetic pathway was described as 
principal mediator of obesity-related 
insulin resistance in the liver (Hla et al., 
2014; Turpin et al., 2014; Raichur et al., 
2014). First substrates in the de novo 
ceramide synthetic pathway are 
palmitoyl-CoA and serine (Figure 3). 
After two intermediate steps, a 
sphinganine molecule is formed. Then, 
one of ceramide synthase (CerS) enzymes 
acylates the sphinganine, producing a 
dihydroceramide, the immediate 
precursor of ceramides. There are six 
different isoforms of CerS (CerS1-6), 
which have a variable substrate 
preference. For example, C16:0-
dihydroceramides are produced mainly 
by CerS5 and CerS6 (Figure 3). The 
resulting dihydroceramides are 
metabolized by dihydroceramide 
desaturase to form ceramide (Chaurasia 
et al., 2015). 
 
In high-fat diet-fed mice, both whole-
body and liver-specific deletion of CerS6 
decreases concentrations of C16:0-
ceramides in the liver and increases fatty 
acid oxidation and glucose tolerance 
(Turpin et al., 2014). Consistently, CerS2 
haploinsufficient mice fed a high-fat diet 
are characterized by increased C16:0-
ceramide concentration in the liver, 
decreased lipid oxidation, decreased 
glucose tolerance and hepatic steatosis 
(Raichur et al., 2014). CerS6 knockdown 
by anti-sense oligonucleotides in ob/ob 
mice decreases CerS6 expression 
selectively in the liver by ~80% and 
hepatic C16:0-ceramide concentration by 
~50% while increasing glucose tolerance 
by ~50% as compared to control ob/ob 
mice (Bielohuby et al., 2017).  
 
Inflammation. In addition to availability 
of the substrate, i.e. palmitoyl-CoA, the de 
novo ceramide synthetic pathway is 
upregulated by inflammatory mediators 
via nuclear factor kappa-light-chain-
enhancer of activated B cells B (NFκB) 
(Chavez et al., 2012). These inflammatory 
mediators include ligands of the Toll-like 
receptor 4 (TLR-4), such as endotoxin 
(also known as lipopolysaccharide, LPS), 
a component of gram-negative bacteria 
(Holland et al., 2007) (Figure 3).  
 
Degradation. Ceramide concentrations in 
the liver may also increase via diminished 
degradation. Adiponectin, an insulin-
sensitizing and anti-inflammatory 
cytokine produced by adipocytes (Scherer 
et al., 1995), exhibits ceramidase activity 
(Holland et al., 2011b; Holland et al., 
2017) (Figure 3). In mice, 
overexpression of acid ceramidase in the 
liver reduces hepatic C16:0-, C18:0- and 
C20:0-ceramides, decreases hepatic
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Figure 3. Pathways of ceramide metabolism. TLR-4 = toll-like receptor 4; NFKB = nuclear 
factor kappa-light-chain-enhancer of activated B cells; CerS = ceramide synthase. 
 
steatosis and hepatic glucose production, 
and improves glucose tolerance (Xia et 
al., 2015). 
 
Mechanisms. Ceramides may promote 
insulin resistance via several 
mechanisms. In muscle, ceramide 
accumulation has been shown to inhibit 
protein kinase B (Akt/PKB) 
phosphorylation by activating protein 
phosphatase 2A (PP2A), and blocking the 
translocation of Akt/PKB to the plasma 
membrane through activation of PKCζ 
(Stratford et al., 2004; Hajduch et al., 
2008). 
In the adipose tissue, ceramides can 
activate the nucleotide-binding 
oligomerization domain-like receptor 
containing pyrin domain 3 (NLRP3) 
inflammasome and thereby induce 
inflammation, which is associated with 
insulin resistance in mice (Vandanmagsar 
et al., 2011). The adipose tissue in 
subjects with high liver fat content is 
infiltrated with macrophages and 
enriched in ceramides as compared to 
weight-, age- and gender-matched 
subjects with normal liver fat content 
(Kolak et al., 2007). In another study, 
adipose tissue was enriched in ceramides 
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in visceral obesity, and their 
concentration correlated with the gene 
expression of the components of the 
inflammasome in the adipose tissue 
(Kursawe et al., 2016). Thus, ceramides 
may promote insulin resistance by 
promoting inflammation in the adipose 
tissue via activation of the 
inflammasome. 
 
In the mouse liver, ceramides induce 
translocation of the lipid transport 
protein CD36 to the cell membrane via 
PKCζ to stimulate fatty acid uptake 
(Turpin et al., 2014; Xia et al., 2015). 
Hepatic ceramides also impair lipid 
oxidation by inhibiting mitochondrial 
citrate synthase and electron transport 
chain activities (Xie et al., 2017; Turpin et 
al., 2014; Raichur et al., 2014). In 
addition, ceramides increase hepatic 
mitochondrial acetyl-CoA concentrations 
and pyruvate carboxylase activities, 
thereby stimulating gluconeogenesis (Xie 
et al., 2017).  
 
Human liver studies in IR. Three small 
studies with 37 (Kumashiro et al., 2011), 
16 (Magkos et al., 2012) and 29 (ter Horst 
KW et al., 2017) subjects have found no 
correlation between total hepatic 
ceramide concentration and insulin 
resistance. However, different ceramides 
species exhibit markedly different 
metabolic effects, and only specific ones 
have been associated with insulin 
resistance in mice (Hla T et al., 2014; Xia 
et al., 2015). Only one study has 
examined the correlation of different 
species of hepatic ceramides and insulin 
resistance in humans (ter Horst KW et 
al., 2017). In this study, neither total 
hepatic ceramides or total hepatic DAGs 
differed between insulin sensitive and 
insulin resistant subjects, and no 
correlation was found between hepatic 
ceramide species and insulin resistance. 
The authors concluded that these 
conflicting results may be due to 
experimental techniques or limited 
sample size (ter Horst et al., 2017).   
Human liver studies in NAFLD. Only one 
study has examined the total 
concentration of ceramides in the human 
liver in NAFLD (Kotronen et al., 2009). 
In this study, 8 subjects with NAFL were 
compared to 8 age-, sex- and body mass 
index-matched controls without NAFL, 
and no significant difference in total liver 
ceramide content was found. Of note, 
there were no significant differences in 
fasting serum insulin concentrations, a 
surrogate for insulin resistance, between 
these groups.  
 
Human plasma studies in IR and CVD. In 
the postabsorptive conditions, plasma 
ceramides reside in liver-derived very-low 
and low density lipoprotein particles in 
humans (Kotronen et al., 2009). Cross-
sectionally, plasma ceramide 
concentrations have been reported to 
correlate with insulin resistance (Haus et 
al., 2009; de Mello et al., 2009; Bergman 
et al., 2015). The plasma ceramide 
concentrations are also reported to 
correlate with the improvement in insulin 
sensitivity during thiazoledinedione 
treatment, and after bariatric surgery 
(Huang et al., 2011; Warshauer et al., 
2015). In addition to insulin resistance, 
plasma ceramide concentrations are 
reported to predict cardiovascular events 
and death in five prospective studies, 
even independently of LDL cholesterol 
(Tarasov et al., 2014; Cheng et al., 2015; 
Laaksonen et al., 2016; Havulinna et al., 
2016; Wang et al., 2017). Thus, ceramides 
may have, in addition to insulin 
resistance and NAFLD, implications in 
cardiovascular disease (Summers, 2018). 
 
There are no studies reporting the 
concentrations of distinct ceramide 
species in the human liver, or which, if 




Phospholipids are a major lipid class 
which form the matrix of cellular 
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membranes. In addition, they serve as 
first and second messengers during 
cellular signal transduction (van Meer et 
al., 2008). They also serve as precursor 
pools of various lipid mediators, such as 
eicosanoids derived from polyunsaturated 
fatty acids, e.g. arachidonic acid  
(Shindou et al., 2008). Phospholipids 





phosphatidyl-ethanolamines (PEs) and 
cardiolipins (CLs) (Shindou et al., 2009). 
 
In the de novo synthetic pathway (also 
known as the Kennedy pathway) of 
phospholipids, lysophosphatidic acid 
(LPA) is formed from glycerol 3-
phosphate by glycerol-3-phosphate acyl 
transferase (GPAT) (Figure 2). 
Subsequently, LPA is metabolized to 
phosphatidic acid (PA) by 
lysophosphatidic acid acyltransferase 
(LPAAT). PA is metabolized into one of 
two glycerol derivatives: DAG or cytidine 
diphospho-DAG. The former is can be 
converted to TG, PC or PE. PS is derived 
from either PC or PE. Cytidine 
diphospho-DAG can be metabolized into 
PI, PG and CL (Shindou et al., 2009). 
 
The fatty acyl composition of 
phospholipids have an important role in 
the membrane structure and cellular 
signaling. The composition can be altered 
in the remodeling pathway (also known as 
the Lands’ cycle) through removal of the 
existing fatty acyl group by phospholipase 
A2 (PLA2), and replacement by 
lysophospholipid acyltransferase (LPLAT) 
(Shindou et al., 2009) (Figure 4). 
Several isoforms of each enzymes exist, 
and more are being found (Shindou et al., 
2009).  
 
Phosphatidylcholines have an important 
role in triglyceride-rich lipoprotein 
metabolism and cardiovascular disease. 
Animal models with impaired PC 




lysophosphatidylcholine acyltransferase 3 
are characterized by hepatic steatosis, 
reduced hepatic TG secretion and reduced 
risk of atherosclerotic disease, but no 
features of insulin resistance (Sun et al., 
2013; Cole et al., 2012; Rong et al., 2014). 
A similar phenotype also characterizes 
animals consuming a PC deficiency-
inducing methionine-choline-deficient 
diet, a widely used experimental model 
for NAFLD and NASH (Cole et al., 2012; 
Rinella et al., 2004). 
 
Regarding PIs, alterations in their 
metabolism have been associated with 
various disorders, such as neural and 
cardiac development, neurological 
disorders, cancer, immune dysfunction, 
metabolic disease and inflammation 
(D’Souza et al., 2014). 
 
In the human liver, concentrations of PCs 
are reported to be 25% decreased in 9 
subjects with NAFL as compared to 9 
control subjects (Puri et al., 2007). In a 
study comparing the lipidome in 12 
normal, 17 steatotic and 9 cirrhotic 
human livers, hepatic concentrations of 
PI(38:3) and PI(38:4) decreased from 
normal to steatotic to cirrhotic livers 
(Gorden et al., 2011). In contrast, 
concentrations of PI(38:5), PI(36:3), 
PI(36:4), PI(34:1), PI(34:2) and PI(32:1) 
were increased with the severity of 
NAFLD.  
 
No studies have reported the contents or 
compositions of PCs or PIs in the human 
liver in NAFLD due to different 
aetiologies. 
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Figure 4. Phospholipid remodeling pathway, also known as the Lands’ cycle.  
 
2.2.1.3. Hepatocellular injury and 
fibrosis 
 
Histological scoring. In the histological 
assessment of a liver biopsy, 
macrovesicular steatosis, lobular 
inflammation, hepatocellular ballooning 
and fibrosis are evaluated (Brunt et al., 
1999; Bedossa et al., 2012).  
 
In the histological score developed by 
Brunt et al., macrovesicular steatosis is 
assessed as the percent of hepatocytes 
involved. Necroinflammation is evaluated 
using a grading from 1 to 3. Grade 1 
(mild) is characterized by steatosis up to 
66%, possible occasional ballooned 
perivenous hepatocytes; possible small 
amount of intra-acinar inflammatory 
infiltrates. This grade meets the 
minimum criteria for the diagnosis of 
non-alcoholic steatohepatitis. In grade 2 
(moderate), the steatosis may be of any 
degree; hepatocyte ballooning is always 
present and predominantly seen in the 
perivenous region; ballooning is seen 
adjacent to hepatocytes most distended 
by the steatosis; perivenous fibrosis may 
be present; mild to moderate portal and 
intra-acinar chronic inflammation is 
present. In grade 3 (severe), steatosis is 
panacinar; ballooning is always present 
and seen predominantly in the perivenous  
 
region; lobular inflammation is more 
pronounced as compared to grade 2 
(Brunt et al., 1999). 
 
Fibrosis is assessed by a staging from 1 to 
4. Stage 1 is characterized by focal or 
extensive perivenous fibrosis. In addition 
to these features, stage 2 includes various 
degrees of portal fibrosis. Stage 3 adds 
focal or extensive bridging fibrosis 
between perivenous and periportal 
regions. Stage 4 represents cirrhosis 
(Brunt et al., 1999). 
 
Mortality. Amongst these histological 
features, especially fibrosis has been 
shown to predict mortality from both 
overall and liver-related causes (Dulai et 
al., 2017). According to a recent meta-
analysis with 1,495 NAFLD patients with 
17,452 patient years of follow-up, all-
cause mortality rate ratio was 1.58 (95% 
CI 1.19-2.11) in stage 1; 2.52 (95% CI 1.85-
3.42) in stage 2; 3.48 (95% CI 2.51-4.83) 
in stage 3; and 6.40 (95% CI 4.11-9.95) in 
stage 4 as compared to subjects with no 
fibrosis (stage 0). The risk was more 
pronounced with respect to liver-related 
mortality ratio: 1.41 (95% CI 0.17-11.95) 
in stage 1; 9.57 (95% CI 1.67-54.93) in 
stage 2; 16.69 (95% CI 2.92-95.36) in 
stage 3; and 42.30 (95% CI 3.51-510.34) 
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in stage 4 as compared to subjects with 
stage 0 (Dulai et al 2017). 
 
Predictors. In paired biopsy studies, 
features that have predicted the 
progression of disease severity include 
changes in hepatic steatosis (Pais et al., 
2013; Ekstedt et al., 2006) and waist 
circumference (Wong et al., 2010). In 
addition, greater weight gain, more severe 
insulin resistance (Ekstedt et al., 2006), 
and higher prevalence of type 2 diabetes 
(McPherson et al., 2015; Nasr et al., 2017) 
characterize subjects with disease 
progression as compared to non-
progressors. In a recent meta-analysis 
with 411 subjects with biopsy-proven 
NAFLD and 2,145 patient-years of follow-
up, the rate of disease progression was 
slower in patients with NAFL (one 
fibrosis stage over 14.3 years; 95% CI 9.1-
50.0 years) compared to patients with 
NASH (7.1 years; 95% CI 4.8-14.3 years) 
(Singh et al., 2015). In addition to these 
acquired factors, genetic variants in 
PNPLA3, TM6SF2 and MBOAT7 
predispose to advanced liver disease (vide 
infra).  
 
Fibrogenesis. Hepatic stellate cells are the 
dominant source of extracellular matrix 
and fibrosis in the liver (Mederacke et al., 
2013). In a quiescent, non-proliferative 
state, stellate cells store retinyl esters, but 
they can also be activated into 
proliferative myofibroblasts characterized 
by enhanced extracellular matrix 
production (Tsuchida et al., 2017). A 
repetitive or chronic activation may 
promote progressive fibrogenesis, and 
can thereby lead to cirrhosis (Diehl et al., 
2017). Factors regulating the progression 
of NAFLD from NAFL to NASH to 
advanced fibrosis and cirrhosis are not 
fully known. Fatty acids and their 
lipotoxic intermediates, such as DAGs, 
ceramides and arachidonic acid-derived 
proinflammatory eicosanoids have been  
suggested to play a role (Neuschwander-
Tetri 2010; Chen et al., 1997; Nieto et al., 
2000; Ishihara et al., 2012; Loomba et 
al., 2015; Puri et al., 2009). In addition, 
deficiency of hepatic PCs (George et al., 
2003) and local hypoxia (Jungermann et 
al., 2000; Cannito et al., 2014) have been 
proposed to stimulate disease 
progression. 
 
There are no reports whether the hepatic 
lipid composition is associated with liver 
injury in NAFLD due to different causes 
in humans. 
2.2.1.4. Role of the gut in the 
pathogenesis of NAFLD 
 
Low-grade inflammation. It is well 
established that conditions related to 
insulin resistance, such as diabetes and 
obesity are characterized by a low-grade 
inflammation, which origin is unknown 
(Hotamisligil, 2006; Weisberg et al., 
2003). The human gut is estimated to 
harbour up to 100 trillion microbial cells, 
outnumbering the human cells by 10-fold 
(Ley et al., 2006). These microbes are a 
rich source of inflammatory mediators, 
such as endotoxin (a component of Gram-
negative bacteria, also known as 
lipopolysaccharide, LPS), and could 
thereby contribute to the low-grade 
inflammation in metabolic disease. 
 
Toll-like receptor 4 (TLR-4). One of the 
pathways via which endotoxin may 
mediate its proinflammatory action is 
through the TLR-4. In this pathway, 
endotoxin interacts with 
lipopolysaccharide-binding protein (LBP) 
and cluster of differentiation 14 (CD14, a 
glycoprotein) (Chow et al., 1999). CD14 
can exist in the circulation in a soluble 
form (soluble CD14; sCD14), or as a 
membrane protein. The former acts in 
neutralization of endotoxin, while the 
latter is a necessary co-receptor with 
TLR-4 in mediating the proinflammatory 
signal within the cell (Fernandez-Real et 
al., 2003). TLR-4 is expressed in various 
metabolic organs in the human body, 
such as in the adipose tissue (Bés-
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Houtmann et al., 2007), and in the liver 
(Sharifnia et al., 2015).  
 
Endotoxemia. Cross-sectional studies in 
humans have reported endotoxemia to 
associate with histological severity in 237 
patients with NAFLD (Pang et al., 2017). 
It is also associated with insulin 
resistance (Lassenius et al., 2011), the 
features of the metabolic syndrome, and 
type 2 diabetes (Pussinen et al., 2011). 
Infusion of endotoxin induces adipose 
tissue inflammation and insulin 
resistance in mice (Cani et al., 2007) and 
in humans (Mehta et al., 2010), and 
stimulates lipolysis in vitro (Zu et al., 
2009).  
 
Dietary regulation. Gut-derived 
endotoxin can enter the circulation by 
permeating the intestinal barrier. This 
occurs in humans in response to a single 
high-fat meal enriched in butter (Erridge 
et al., 2007) or cream (Deopurkar et al., 
2010), but not after consuming 
equicaloric amount of orange juice, or 
water (Deopurkar et al., 2010). 
Endotoxemia can also be elicited by a 4-
week saturated fat-enriched diet in 
humans (Pendyala et al., 2012). In mice, 
high-fat feeding increases the proportion 
of endotoxin-containing bacteria in the 
gut and plasma concentrations of 
endotoxin, and induces insulin resistance 
(Cani et al., 2007). Another study in mice 
reported that especially saturated but not 
polyunsaturated fat feeding increases the 
abundance of gram-negative Bilophila 
and Bacteroides, and induces 
endotoxemia and Toll-like receptor 
activation and inflammation in the 
adipose tissue (Caesar et al., 2015). 
 
In addition to TLR-4, several other 
receptors in the innate immune system 
can recognize bacterial structures, such as 
nucleotide-binding oligomerization 
domain-like (NOD)-like receptors (NLRs) 
(Stienstra et al., 2011). 
 
Gut flora and NAFLD. In a cross-
sectional study, Wong et al. reported 
lower abundance of Gram-positive 
Ruminococci in 16 subjects with biopsy-
proven NAFLD as compared to 22 control 
subjects (Wong et al., 2013). Mouzaki et 
al. described decreased abundance of 
Gram-negative Bacteroidetes in 22 
subjects with NASH and 11 subjects with 
NAFL compared to 17 controls (Mouzaki 
et al., 2013). Zhu et al. found that Gram-
negative Bacteroides and Proteobacteria 
were increased and Gram-positive 
Firmicutes were decreased in 22 children 
with biopsy-proven NASH compared to 
16 controls (Zhu et al., 2013). Munukka et 
al. studied 31 subjects with 1H-MRS, and 
reported low abundance of Gram-
positive, butyrate-producing 
Faecalibacterium prausnitzii, and high 
abundance of Gram-negative 
Enterobacteria in 21 subjects with high as 
compared to 10 subjects with low liver fat 
content (Munukka et al., 2014).  
 
There are no studies examining the effect 
of overfeeding of diets with different 
macronutrient composition on the gut 
microbiota in human NAFLD. 
2.2.2. ‘Genetic NAFLD’ 
2.2.2.1. The PNPLA3 I148M variant 
 
In 2008, a single-nucleotide 
polymorphism (rs738409 [G], encoding 
I148M) in the patatin-like phospholipase 
domain-containing 3 (PNPLA3, 
adiponutrin) was discovered in a 
genome-wide association study to 
increase liver fat content by more than 
two-fold (Romeo et al., 2008). The 
finding has been replicated in a large 
number of studies (Kotronen et al., 2009; 
Sookoian S et al., 2009; Sookoian et al., 
2011). In addition to steatosis, the variant 
allele predisposes to NASH (Sookoian et 
al., 2009; Sookoian et al., 2011), fibrosis 
(Valenti et al., 2010; Sookoian et al., 
2011) and cirrhosis (Shen et al., 2015). 
The variant allele also increases the risk 
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of hepatocellular carcinoma (Trépo et al., 
2014; Singal et al., 2014). Obesity 
potentiates these hepatic effects conferred 
by this gene variant (Stender et al., 2017). 
In addition to NAFLD, the PNPLA3 
I148M variant predisposes to alcoholic 
liver disease and alcoholic cirrhosis (Tian 
et al., 2010; Trépo et al., 2011). 
 
Depending on ethnicity, 20-50% of all 
subjects carry this gene variant (Romeo et 
al., 2008). In a Finnish population-based 
study, 39 % carried the variant allele 
(Hyysalo et al., 2013). 
 
In contrast to the ‘Metabolic NAFLD’, 
insulin resistance or dyslipidemia does 
not characterize NAFLD due to the I148M 
variant in PNPLA3 (‘PNPLA3 NAFLD’) 
(Romeo et al., 2008) (Figure 1). 
According to a recent systematic review 
with 14 studies, insulin sensitivity as 
determined by HOMA-IR, the 
hyperinsulinemic euglycemic clamp 
method, or fasting or post-glucose insulin 
or glucose, does not differ between 
carriers and non-carriers of this variant 
(Petäjä et al., 2016). 
 
In the majority of studies, serum 
triglycerides have been reported to be 
similar in carriers and non-carriers 
(Petäjä et al., 2016). However, some 
studies have reported that carriers have 
lower serum triglycerides as compared to 
non-carriers (Pirazzi et al., 2012; Del Ben 
et al., 2014; Di Constanzo et al., 2018; Liu 
et al., 2017). This decrease in circulating 
lipids may contribute to the paradoxical 
reduction in the risk of cardiovascular 
disease in subjects with ‘PNPLA3 NAFLD’ 
(Simons et al., 2017; Liu et al., 2017). 
 
With respect to sources of hepatic fatty 
acids available for IHTG synthesis, 
adipose tissue is not insulin-resistant in 
carriers as compared to non-carriers of 
the variant (Kotronen et al., 2009). 
Expression of inflammation-related genes 
in adipose tissue in carriers and non-
carriers of the variant is also unchanged 
(Lallukka et al., 2013). One study 
reported decreased hepatic de novo 
lipogenesis, as assessed by a stable 
isotope technique and indirectly by 
hepatic SREBP1c gene expression, in 
carriers of the variant as compared to 
non-carriers (Mancina et al., 2015). 
Taken together, neither adipose tissue 
lipolysis nor hepatic DNL seem to explain 
the increase in IHTG in ‘PNPLA3 
NAFLD’. 
 
In humans, PNPLA3 is mainly expressed 
in the liver, skin, adipose tissue and retina 
(Huang et al., 2010; Pirazzi et al., 2014). 
In the mouse liver, PNPLA3 is expressed 
predominantly in hepatocytes, and to a 
much lesser degree in hepatic stellate 
cells (Huang et al., 2010). 
 
In HuH7 cells, PNPLA3 is localized to the 
endoplasmic reticulum and lipid droplets 
(He et al., 2010). Wild-type human 
PNPLA3 protein was described to 
hydrolyze triolein time- and dose-
dependently, while PNPLA3-I148M 
virtually abolished this activity (He et al., 
2010). Adenovirus-mediated 
overexpression of human PNPLA3-I148M 
decreases TG hydrolase activity, and 
increases accumulation of TGs and CEs in 
the liver as compared to wild-type 
PNPLA3 overexpressing C57BL/6J mice. 
The authors concluded that PNPLA3-
I148M promotes TG accumulation by 
limiting TG hydrolysis (He et al., 2010).  
 
PNPLA3 has also been suggested to 
function as a lysophosphatidic acid 
acyltransferase (LPAAT) converting 
lysophosphatidic acid into phosphatitidic 
acid with palmitoyl-, oleyl-, linoleyl- and 
arachidonyl-CoAs as the preferred 
substrates (Kumari et al., 2012). Purified 
mouse and human PNPLA3 I148M 
protein derived by site-directed 
mutagenesis and overexpressed in E. coli 
was reported to increase this LPAAT 
activity by two-fold (Kumari et al., 2012). 
This finding was not replicated in primary 
hepatocytes from mice overexpressing 
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either human wild-type PNPLA3 or 
PNPLA3-I148M (Li et al., 2012), or in 
mouse PNPLA3 I148M knock-in mice 
(BasuRay et al., 2017). 
 
The PNPLA3 gene expression is regulated 
by liver X receptor and SREBP-1c, and 
increased by carbohydrate feeding and 
decreased by fasting in C57BL/6J mice 
(Huang et al., 2010). PNPLA3 is one of 
the most insulin-responsive genes in 
human adipose tissue (Soronen et al., 
2012). Post-translationally, saturated 
fatty acid palmitate (C16:0), 
monounsaturated fatty acid oleate (C18:1) 
and polyunsaturated fatty acid linoleate 
(C18:2) increased PNPLA3 protein 
expression, while very long chain 
polyunsaturated fatty acids, such as 
C20:4, C20:5 had no effect (Huang et al., 
2010). 
 
Purified human wild-type PNPLA3 but 
not PNPLA3-I148M hydrolyzes TGs, 
DAGs, monoacylglycerols and oleyl-CoA 
(Huang et al., 2011). Human PNPLA3 
hydrolyzes TGs containing C14:0, C16:0, 
C18:1, C18:2 and C20:4, of which TGs 
containing C18:1 were the preferred 
substrates (Huang et al., 2011). 
 
Chow-fed C57BL/6J mice constitutively 
overexpressing human PNPLA3-I148M in 
the liver develop hepatic steatosis due to 
accumulation of TGs and CEs in the liver 
as compared to mice expressing human 
wild-type PNPLA3 (Li et al., 2012). The 
hepatic fatty acid composition was 
enriched in monounsaturated fatty acids, 
while the abundance of polyunsaturated 
fatty acids was decreased in PNPLA3-
I148M transgenic as compared to wild-
type PNPLA3 transgenic mice. Steatosis 
was not accompanied by changes in body 
composition or features of insulin 
resistance, but was amplified by a high-
sucrose diet. There were no changes in TG 
synthesis in mice overexpressing human 
wild-type and PNPLA3-I148M as 
determined by incorporation of labeled 
glycerol, acetate and oleate into TG, or in 
the rate of VLDL-TG secretion. However, 
incorporation of tritium from tritiated 
water into fatty acids and TGs was 
increased in PNPLA3-I148M transgenic 
mice as compared to control mice, while 
there was no difference between wild-type 
and PNPLA3-I148M transgenic mice. No 
differences were found in VLDL-TG 
secretion rates, or in fatty acid oxidation 
in vivo or in primary hepatocytes of these 
mouse lines. In contrast, PNPLA3-I148M 
transgenic mice had significantly 
increased expression of SREBP-1c target 
genes associated with lipid synthesis, 
such as Acc2, Fas, Scd1, Acly and Elovl6 
(Li et al., 2012).  
 
Two studies reported that global deletion 
of PNPLA3 in mice by gene targeting does 
not affect body composition, insulin 
sensitivity, serum lipids or hepatic TG 
content (Chen et al., 2010; Basantani et 
al., 2011). Since neither deletion of wild-
type murine PNPLA3 nor overexpression 
of wild-type human PNPLA3 results in 
hepatic fat accumulation, the effects of 
the PNPLA3 I148M variant may not be 
attributable simply to a loss or gain of the 
activity of the wild type PNPLA3. 
 
C57BL/6J mice with an endogenous 
I148M mutation in mouse PNPLA3 
accumulated hepatic TGs on a high-
sucrose but not on a chow diet (Smagris 
et al., 2015). This was not accompanied 
by insulin resistance or changes in 
hepatic mRNA profile or in the fatty acid 
composition of major lipids (Smagris et 
al., 2015). There were no differences in 
fatty acid or TG synthesis as determined 
from incorporation of tritium from 
tritiated water into fatty acids and TGs, or 
from labeled palmitate into TGs in I148M 
knock-in mice as compared to control 
mice (BasuRay et al., 2017). There were 
also no differences in VLDL-TG secretion 
or fatty acid oxidation rates between the 
groups (BasuRay et al., 2017). However, 
the I148M knock-in mice accumulated 
PNPLA3 protein on hepatic lipid droplets 
as compared to controls (Smagris et al., 
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2015). This accumulation of PNPLA3 
protein was subsequently proposed to be 
due to disrupted ubiquitylation and 
proteosomal degradation (BasuRay et al., 
2017). The authors concluded that the 
I148M variant in PNPLA3 does not cause 
hepatic steatosis by increasing TG 
synthesis, or by reducing TG removal 
through VLDL-TG secretion or fatty acid 
oxidation, but does so by impairing 
mobilization of TGs from lipid droplets 
(LDs) due to accumulation of PNPLA3-
I148M protein (BasuRay S et al., 2017). 
 
In addition to hepatocytes, PNPLA3 has 
been reported to function as a retinyl 
palmitate hydrolase in hepatic stellate 
cells and the I148M was shown to impair 
this activity (Pirazzi et al., 2014), and to 
promote a fibrogenic phenotype (Bruschi 
et al., 2017). 
 
One study reported the fatty acid 
composition of hepatic TGs to be 
relatively deficient in C18:0, C20:0, 
C24:0, C20:3, C20:4, C22:4 and C22:5, 
and relatively enriched in C18:3n3 in 19 
carriers (2 homozygous and 17 
heterozygous) as compared to 33 non-
carriers of the I148M variant allele (Peter 
et al., 2014).  
 
There are no studies on changes in 
distinct hepatic TG species with respect to 
carbons and double bonds, or DAGs or 
ceramides in ‘PNPLA3 NAFLD’ and no 
data comparing NAFLD attributable to 
the PNPLA3 I148M gene variant to that 
characterizing NAFLD associated with 
insulin resistance. 
2.2.2.2. The MBOAT7 rs641738 C>T 
variant 
 
In 2015, a rs641738 C>T mutation in the 
membrane bound O-acyltransferase 
domain containing 7 (MBOAT7) gene was 
discovered to predispose to alcohol-
related cirrhosis (Buch et al., 2015). The 
variant was subsequently reported to 
increase the risk of NAFLD (Mancina et 
al., 2016). Depending on the ethnicity, 
58-67% of all subjects carry the variant 
(Mancina et al., 2016). 
 
Among 2,736 subjects studied with 1H-
MRS in the Dallas Heart Study, carriers of 
the MBOAT7 variant had increased IHTG 
content compared to non-carriers 
(Mancina et al., 2016). The variant allele 
carriers also had more severe histological 
steatosis, necroinflammation and fibrosis 
in a cohort of 1,149 subjects in the Liver 
Biopsy Cross-Sectional Cohort (Mancina 
et al., 2016). In a study including 218 
subjects with NAFLD and 227 controls, 
the MBOAT7 T allele was significantly 
associated with the presence of NAFLD 
(Di Costanzo et al., 2018). The association 
of MBOAT7 rs641738 variant with 
fibrosis was replicated in a study 
comprising 320 subjects (Krawczyk et al., 
2017). The variant allele was also 
associated with increased risk of 
hepatocellular carcinoma (OR 2.0, 1.33-
3.31) in a cohort of 913 subjects (Donati et 
al., 2017). In addition to NAFLD, the 
variant allele in MBOAT7 confers an 
increased risk of inflammation and 
fibrosis in subjects with hepatitis B and C 
(Thabet et al., 2017; Thabet et al., 2016). 
 
There were no differences in BMI, 
prevalence of impaired fasting glucose or 
type 2 diabetes, or of concentrations of 
total, LDL and HDL cholesterol or TGs in 
the circulation between the MBOAT7 
genotype groups in 4,591 subjects in the 
Dallas Heart Study, or in the 1,149 
subjects in the Liver Biopsy Cross-
Sectional Cohort (Mancina et al., 2016). 
In keeping with these data, in a study 
including 218 subjects with NAFLD and 
227 controls, subjects with NAFLD 
carrying the variant allele were not 
characterized by any differences in 
clinical, anthropometric and biochemical 
measures as compared to non-carriers (Di 
Costanzo et al., 2018). The MBOAT7 
genotype at rs641738 has not been 
associated with changes in the risk of 
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cardiovascular disease (Simons et al., 
2017). 
 
In humans, MBOAT7 is expressed in the 
liver, ovaries, uterus, brain, lymphocytes, 
bone marrow and retina (Mancina et al., 
2016). In the liver, MBOAT7 is expressed 
in hepatocytes, hepatic stellate and 
sinusoidal epithelial cells (Mancina et al., 
2016). Endogenous MBOAT7 locates in 
the endoplasmic reticulum, 
mitochondria-associated membrane and 
lipid droplets in the human liver. Carriers 
of the variant have lower expression of 
both the gene and the MBOAT7 protein in 
the liver as compared to non-carriers 
(Mancina et al., 2016).  
 
In mice, MBOAT7 functions as a 
lysophosphatidylinositol acyltransferase, 
catalyzing the fatty acyl-chain remodeling 
of polyunsaturated phosphatidylinositols 
(PIs) (Anderson et al., 2013). In 
Caenorhabditis elegans, MBOAT7 was 
identified to be required for incorporation 
of especially PUFAs, such as arachidonic 
acid (C20:4) and eicosapentaenoic acid 
(C20:5n3) into lysophosphatidylinositols 
to form PIs (Lee et al., 2008). MBOAT7 
was also found to function as a 
lysophosphatidylinositol acyltransferase 
with substrate specificity towards 
arachidonyl-CoA in human neutrophils, 
where it regulates the availability of free 
arachidonic acid for the synthesis of 
eicosanoids and thereby the inflammatory 
response (Gijón et al., 2008). Consistent 
with the proposed function in the fatty 
acyl-chain remodeling of PIs, the plasma 
concentration of PI species 32:1, 34:1, 
34:2, 36:1, 36:2 and 36:3 were increased, 
while those of 36:4, 38:3, 38:5, 38:6, 40:4 
and 40:5 were decreased in carriers as 
compared to non-carriers of the MBOAT7 
variant (Mancina et al., 2016). 
 
There are no studies comparing the lipid 
composition of the human liver between 
carriers and non-carriers of the MBOAT7 
variant. 
2.2.2.3. The TM6SF2 E167K variant 
 
In 2014, a variant in transmembrane 6 
superfamily member 2 (TM6SF2) at 
rs58542926 ([T], encoding E167K) was 
reported to increase liver fat content 
(Kozlitina et al., 2014). Approximately 10-
17% of all subjects carry the variant allele 
(Kozlitina et al., 2014).  
 
In addition to steatosis, the variant 
increased the risk of steatohepatitis and 
fibrosis in 349 NAFLD patients (Liu et al., 
2014) and 983 bariatric surgery patients 
(O’Hare et al., 2017). Adiposity 
potentiates the effects of this gene variant 
on hepatic outcomes (Stender et al., 
2017). The variant allele was shown to 
independently predict the development of 
fatty liver in a 21-year follow-up study of 
2,042 children (Suomela et al., 2016). In 
addition to NAFLD, the TM6SF2 variant 
allele increases the risk of alcohol-related 
cirrhosis (Buch S et al., 2015), the risk of 
hepatocellular carcinoma in alcoholic 
cirrhosis (Falleti et al., 2016), and the risk 
of steatosis, fibrosis and cirrhosis in 
hepatitis C (Liu et al., 2017). 
 
In several studies, carriers of the variant 
have neither been more obese nor insulin-
resistant compared to non-carriers 
(Kozlitina et al., 2014; Zhou et al., 2015; 
Sookoian et al., 2015; Goffredo et al., 
2016; Grandone et al., 2016; Eslam et al., 
2016; Mancina et al., 2016b; Musso et al., 
2016; Dongiovanni et al., 2015; Kim et 
al., 2017; Petäjä et al., 2016). 
 
Hepatic and adipose tissue insulin 
sensitivities, as assessed by the 
euglycemic hyperinsulinemic clamp 
technique combined with a glucose tracer, 
are unchanged in carriers as compared to 
non-carriers of the variant in 111 subjects 
(Zhou et al., 2015). 
 
In studies with less than 400 subjects, 
fasting serum TG concentrations have 
been reported to be unchanged between 
carriers and non-carriers of the variant 
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(Zhou et al., 2015; Sookoian et al., 2015; 
Musso et al., 2016; Goffredo et al., 2016). 
In contrast, in studies with more than 
400 and up to 300,000 subjects, carriers 
of the variant have consistently had lower 
circulating TG concentrations in the 
fasting state than non-carriers (Kozlitina 
et al., 2014; Grandone et al., 2016; Eslam 
et al., 2016; Mancina et al., 2016; 
Dongiovanni et al., 2015; Kim et al., 2017; 
O’Hare et al., 2017; Liu et al., 2017; Di 
Costanzo et al., 2018). 
 
Lower concentrations of circulating TGs 
in carriers as compared to non-carriers 
have also been reported under 
postprandial conditions (Musso et al., 
2016; O’Hare et al., 2017). Humans 
carrying the TM6SF2 E167K variant have 
reduced concentrations of large, 
triglyceride-rich VLDL1 particles in the 
postprandial state (Musso et al., 2016). In 
6,929 Finnish men, the T allele was 
associated with lower circulating 
apolipoprotein B-100, VLDL and LDL 
particles, lower total, VLDL and LDL 
triglyceride concentrations, and lower 
total, VLDL and LDL cholesterol 
concentrations (Kim et al., 2017). The T 
allele was not associated with body mass 
index or insulin sensitivity as determined 
by Matsuda index (Kim et al., 2017). 
 
Consistent with the reduced circulating 
TG concentrations, carriers of the E167K 
variant have a reduced risk of 
cardiovascular disease (Dongiovanni et 
al., 2015; Holmen et al., 2014; Simons et 
al., 2017; Liu et al., 2017). 
 
In humans, TM6SF2 mRNA is expressed 
in the liver and the intestine (Mahdessian 
et al., 2014; O’Hare et al., 2017). In HuH7 
and HepG2 human hepatoma cells, 
TM6SF2 is located in the endoplasmic 
reticulum (Mahdessian et al., 2014). In 
primary hepatocytes of C57BL/6N mice, 
TM6SF2 is located in the endoplasmic 
reticulum, cis/medial Golgi, and Golgi 
matrix (Smagris et al., 2016).  
 
Carriers of the E167K variant have lower 
TM6SF2 mRNA concentrations in the 
liver than non-carriers (Mahdessian et al., 
2014). In hepatocytes, the TM6SF2 E167K 
variant allele decreases TM6SF2 protein 
expression (Kozlitina et al., 2014). It was 
suggested that in Huh7 cells stably 
expressing E167K, reduced protein 
stability might contribute to decreased 
protein expression (Ehrhardt et al., 2017). 
 
Silencing of TM6SF2 by small interfering 
RNA in HuH7 and HepG2 cells increases 
cellular TG content and decreases TG 
secretion, while overexpression of 
TM6SF2 has the opposite effect 
(Mahdessian et al., 2014). In C57BL/6J 
mice, knockdown of TM6SF2 in the liver 
by adeno-associated virus-mediated small 
hairpin RNA induced hepatic steatosis 
due to accumulation of hepatic TGs and 
cholesterol esters (CEs), the main 
components of the hydrophobic core of 
very low-density lipoprotein particles 
(Kozlitina et al., 2014).  
 
Mice with chronic inactivation of Tm6sf2 
develop hepatic steatosis due to a 3-fold 
decrease in VLDL-TG secretion, resulting 
in increased TG and cholesteryl ester 
concentrations in the liver (Smagris et al., 
2016). This decrease in VLDL-TG 
secretion was not due to reduced 
apolipoprotein B-100 secretion, but 
rather due to reduced TG content per 
particle. The VLDL particles in knockout 
mice were significantly smaller than in 
wild-type mice. The livers in these mice 
were deficient in lipid species with 
polyunsaturated fatty acyl chains, such as 
20:4 and 22:6 (Smagris et al., 2016). 
These mice were also characterized by 
modestly decreased TG and cholesterol 
absorption, and TG accumulation in the 
intestine after a high-fat diet  (Smagris et 
al., 2016). 
 
There are no data on the lipid 
composition of the human liver between 
carriers and non-varriers of the TM6SF2 
E167K variant allele. 
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2.3. NUTRITIONAL 
MODULATION OF NAFLD 
2.3.1. Energy intake 
 
Excess energy intake is the most 
important nutritional determinant of 
hepatic fat accumulation (Yki-Järvinen, 
2015). Overfeeding human subjects 
increases IHTG content (Kechagias et al., 
2008; van der Meer et al., 2008; 
Bortolotti et al., 2009; Sobrecases et al., 
2010; Sevastianova et al., 2012; Rosqvist 
et al., 2014; Fabbrini et al., 2016). 
 
Overfeeding 1000 extra kilocalories per 
day of a diet with similar macronutrient 
composition as their habitual diet in 27 
obese subjects lead to an increase in body 
weight by ~6%, and an increase in IHTG 
from 4.8 to 7.1% (1H-MRS) (Fabbrini et 
al., 2016). The mechanisms underlying 
the increase in IHTG was attributed to an 
increase in DNL and a decrease in hepatic 
fatty acid oxidation as determined by 
beta-hydroxybutyrate turnover (Fabbrini 
et al., 2016).  
 
Hypocaloric diets have been consistently 
shown to reduce liver fat content 
(Petersen et al., 2005; Tamura et al., 
2005; Larson-Meyer et al., 2006; Shah et 
al., 2009; Sevastianova et al., 2011; 
Browning et al., 2011; Haufe et al., 2011). 
This is why weight loss is recommended 
to all overweight and obese subjects with 
NAFLD (European Association for the 
Study of the Liver (EASL) et al., 2016). 
2.3.2. Macronutrient composition 
of the diet 
 
Hypocaloric studies. Hypocaloric diets 
decrease liver fat content very rapidly as 
compared to the decrease in body weight. 
For example, two to six days of daily 
energy deficiency of 1000 kilocalories 
results in 30-45% loss in liver fat content 
in the face of small weight loss (Kirk et 
al., 2009; Sevastianova et al., 2011). 
Ketogenic low-carbohydrate diets 
decreased liver fat content more than 
standard hypocaloric diets in the face of 
similar caloric deficiency in two (Kirk et 
al., 2009; Browning et al., 2011) but not 
in one study (Haufe et al., 2011).  
 
A hypocaloric diet lowers plasma glucose 
and insulin concentrations and increases 
the basal rate of adipose tissue lipolysis 
(Sevastianova et al., 2011). Despite 
increased lipolysis, liver fat content 
decreases on a hypocaloric diet, since free 
fatty acids are channeled towards 
oxidation and ketogenesis rather than 
triglyceride synthesis (Sevastianova et al., 
2011). Since glucose and insulin also 
upregulate de novo lipogenesis, the lower 
plasma insulin concentrations during the 
hypocaloric diet would also be expected to 
result in reduced rates of DNL (Topping 
et al., 1982; Hellerstein et al., 1996). This 
indeed happens during a 5-day 
hypocaloric low-carbohydrate diet 
(Schwartz et al., 1995). 
 
Isocaloric studies. Cross-sectionally, 
intake of saturated fat correlates with 
liver fat content (Tiikkainen et al., 2003). 
Similarly, higher intakes of saturated fatty 
acids and cholesterol and lower intakes of 
fiber, protein and polyunsaturated fatty 
acids characterize subjects with NASH as 
compared to age-, gender-, and body 
mass index-matched controls (Musso et 
al., 2003). In another cross-sectional 
study, increased intakes of simple sugars 
from soft drinks and protein from meat, 
and decreased intakes of fish rich in 
omega-3 polyunsaturated fatty acids were 
associated with increased risk of NAFLD 
(Zelber-Sagi et al., 2007). 
 
Isocaloric studies comparing high-fat, 
low-carbohydrate as compared to low-fat, 
high-carbohydrate diets lasting for two 
(Westerbacka et al., 2005), three (van 
Herpen et al., 2011) and four 
(Utzschneider et al., 2013) weeks in 
humans have consistently shown the 
former to increase IHTG content 
compared to the latter.  
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Regarding the quality of fat, in an 
isocaloric study comparing high-
saturated fat/low polyunsaturated fat diet 
to low-saturated fat/high-
polyunsaturated fat, the former increased 
liver fat content as compared to the latter 
(Bjermo et al., 2012).  
 
Hypercaloric studies. In a 7-week 
overfeeding study comparing a diet 
enriched with saturated fat to a diet 
enriched with polyunsaturated fat, only a 
diet enriched in saturated fat but not that 
enriched with polyunsaturated fat 
increased liver fat content in the face of 
similar energy excess (Rosqvist et al., 
2014). In another overfeeding study, 7 
days of overfeeding of fat (30% energy 
excess) increased liver fat content by 
86%, overfeeding of fructose (35% energy 
excess) by 16%, and overfeeding of both 
fat and fructose (65% energy excess) 
increased liver fat content by 116% but 
these differences were not statistically 
significant (Sobrecases et al., 2010). 
 
Regarding the causes underlying 
increased deposition of FAs into IHTG 
during overfeeding, pathways leading to 
IHTG need to be considered. DNL has 
been shown to increase and lead to liver 
fat accumulation in response to excess 
sugar intake (Sevastianova et al., 2012). 
However, there are no studies comparing 
effects of overfeeding saturated or 
unsaturated fat or sugars on lipolysis in 
humans. In addition, no studies have 
compared effects of such diets on DNL.
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3. AIMS OF THE STUDY 
 
The aims of this series of studies were: 
i. to determine whether the human liver lipidome (triglycerides, free fatty acids and 
insulin resistance-inducing lipids such as ceramides and diacylglycerols) differs 
between ‘Metabolic NAFLD’ and ‘PNPLA3 NAFLD’ (study I); 
ii. to determine which, if any, pathway of ceramide metabolism is altered in ‘Metabolic 
NAFLD’ (study I); 
iii. to determine whether the human liver lipidome (phosphatidylinositols) is altered in 
‘MBOAT7 NAFLD’ (study II); 
iv. to determine whether the human liver and serum lipidome (phosphatidylcholines, 
triglycerides and cholesteryl esters) and hepatic gene expression are altered in 
‘TM6SF2 NAFLD’ (study III); 
v. to determine whether the incorporation of different fatty acids into complex lipids is 
altered in TM6SF2 knockdown cells (study III); and 
vi. to determine in healthy overweight humans whether three weeks of overfeeding diets 
enriched either in saturated or unsaturated fat or simple sugars differentially 
influences IHTG content, rates of adipose tissue lipolysis and hepatic de novo 
lipogenesis, adipose tissue transcriptome, insulin resistance, plasma lipidome, gut 
microbiota and markers of endotoxemia (study IV). 
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4. SUBJECTS AND METHODS 
 
4.1. SUBJECTS AND STUDY 
DESIGNS  
 
The ethics committee of the Hospital 
District of Helsinki and Uusimaa 
approved the study protocols of all 
studies. All studies were conducted in 
accordance with the Declaration of 
Helsinki. Each participant provided 
written informed consent after being 
explained the nature and potential risks 
of the study. 
4.1.1. Studies I-III  
 
In studies I-III (the ‘Liver Biopsy 
Cohort’), the subjects were recruited 
amongst those undergoing laparoscopic 
bariatric surgery. The inclusion criteria 
were: a) age 18 to 75 years; b) no known 
acute or chronic disease except for obesity 
or type 2 diabetes or hypertension on the 
basis of medical history, physical 
examination and standard laboratory 
tests (vide infra); c) alcohol consumption 
less than 20 g/day for women and less 
than 30 g/day for men; d) no evidence of 
pre-existing liver conditions other than 
NAFLD such as autoimmune, drug-
induced or viral liver disease. Subjects 
with diabetes were excluded from the 
study III. 
 
One week before surgery, all subjects 
arrived for a clinical visit after an 
overnight fast for metabolic 
characterization. Body weight, height and 
waist circumference were measured. An 
intravenous cannula was inserted in an 
antecubital vein for withdrawal of blood 
for measurement of HbA1c, serum insulin 
and adiponectin, plasma glucose, LDL- 
and HDL-cholesterol, triglyceride, 
albumin, AST, ALT, ALP and GGT 
concentrations and for genotyping of 
PNPLA3 rs738409, MBOAT7 rs641738 
and TM6SF2 rs58542926. After basal 
blood sampling and anthropometric 
measurements, an oral glucose (75 
grams) tolerance test (OGTT) was 
performed (DeFronzo et al., 2010). 
During the day of surgery, wedge biopsies 
were obtained at the beginning of surgery. 
One part was flash-frozen in liquid 
nitrogen and another part was sent to 
pathologist for histological assessment. 
 
In study I, the subjects (N=125) were 
divided into two groups based on HOMA-
IR, a surrogate of insulin resistance. 
Because of a lack of universally accepted 
consensus regarding the cut-off threshold 
of HOMA-IR between the insulin-
resistant and sensitive subjects, median 
HOMA-IR was used to divide the subjects 
into 'High HOMA-IR' (HOMA-IR > 3.19) 
and 'Low HOMA-IR' (HOMA-IR ≤ 3.19) 
groups. The same subjects were divided 
into two groups based on their PNPLA3 
rs738409 genotype (I148M variant 
carriers, ‘PNPLA3148MM/MI’; and non-
carriers,  ‘PNPLA3148II’. In study II, the 
subjects (N=115) were divided into three 
groups based on their MBOAT7 genotype 
at rs641738 (CC, CT and TT). In study III, 
the subjects (N=90) were divided into 
groups based on their TM6SF2 
rs58542926 genotype (E167K variant 
allele carriers, TM6SF2EK/KK; and non-
carriers, TM6SF2EE).  
4.1.4. Study IV  
 
In study IV, the subjects (N=38) were 
recruited by newspaper advertisements or 
by contacting subjects who had previously 
participated in metabolic studies. The 
exclusion criteria were: a) type 1 or 2 
diabetes; b) pre-existing autoimmune, 
viral or drug-induced liver disease; c) 
alcohol consumption over 20 g/day for 
women and over 30 g/day for men; d) 
evidence of any other acute or chronic 
disease; e) extreme obesity (BMI ≥ 40 
kg/m2); f) use of drugs influencing 
glucose or lipid metabolism; g) pregnancy 
or lactation.  
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One day before the metabolic study visit, 
a blood sample was taken for 
measurement of background enrichment 
of 2H in plasma water and palmitate in 
VLDL-TG for measurement of de novo 
lipogenesis. Subjects consumed 
deuterated water (2H2O) (3 g/kg body 
water) in the evening prior to the 
metabolic study visit, to achieve a plasma 
water enrichment of 0.3% for the 
measurement of DNL. IHTG was 
measured by proton magnetic resonance 
spectroscopy (1H-MRS). Subjects 
collected fecal samples which were stored 
immediately at −20°C, and within 24 h at 
-80°C until analysis. 
 
The subjects arrived at the clinical 
research unit after an overnight fast on 
the following morning. Body composition 
(InBody 720, Biospace, Seoul, Korea), 
weight, height and waist circumference 
were measured. After indirect calorimetry 
measurements, an intravenous cannula 
was inserted in an antecubital vein for 
withdrawal of blood for measurement of 
DNL and for liver function tests, fasting 
glucose, FFA, insulin, total, HDL and LDL 
cholesterol and TG concentrations. A 
needle aspiration biopsy from abdominal 
subcutaneous adipose tissue was 
obtained. After the basal sampling, a 
euglycemic-hyperinsulinemic clamp 
combined with infusion of [2H5]glycerol 
for measurement of lipolysis was 
performed.  
 
The subjects were randomized to one of 
three dietary intervention groups to 
consume a 3-week hypercaloric (1000 
excess kcal/day) diet enriched either in 
saturated fat (SAT, 76% from saturated 
fatty acids, 21% from monounsaturated 
fatty acids and 3% from polyunsaturated 
fatty acids), unsaturated fat (UNSAT, 57% 
from monounsaturated fatty acids, 22% 
from polyunsaturated fatty acids, 21% 
from saturated fatty acids), or simple 
sugars (CARB, 100% simple sugars). The 
extra energy was provided to participants 
as foodstuffs, which consisted in the SAT 
group of 30 g coconut oil, 40 g butter and 
100 g of 40% fat-containing blue cheese; 
in the UNSAT group of 36 g olive oil, 26 g 
pesto, 54 g pecan nuts and 20 g of butter; 
and in the CARB group of 2.8 dl orange 
juice, 4.3 dl of a sugar-sweetened 
beverage, and 200 g of candy. Of the extra 
energy, 2%, 91% and 7% came from 
carbohydrate, fat and protein in the 
UNSAT group, and 1%, 86% and 13% 
from these sources in the SAT group, 
respectively and 100% from simple sugars 
in the CARB group. Baseline 
measurements were repeated after 3 
weeks of consuming the hypercaloric 
diets. 
 
Adherence was reinforced by the study 
dietician, who contacted the subjects on a 
weekly basis. The subjects filled 3-day 
dietary records before and after 3 weeks 
on the diet. The food records were 
analyzed using the AivoDiet software 
(version 2.0.2.3, Aivo Finland, Turku, 
Finland). As an objective biomarker of 
recent dietary intake, the FA composition 
of fasting VLDL-TG was measured 
(Hodson et al., 2008). 
4.2. METHODS 
4.2.1. Liver fat content (I-IV) 
 
Biopsies. During the day of surgery, 
wedge biopsies from the liver were 
obtained at the beginning of surgery. One 
part was flash-frozen in liquid nitrogen 
for subsequent analysis of hepatic 
lipidome, and another part was sent to 
pathologist for histological assessment. 
The time from obtaining the biopsy to 
flash-freezing of the sample in liquid 
nitrogen was approximately one minute. 
An experienced liver pathologist (J.A.) 
performed the histological assessment of 
the liver biopsy in a blinded fashion 
according to the criteria by Brunt et al. 
(Brunt et al., 1999). Liver fat content in 
liver biopsies was quantified as the 
percentage of hepatocytes with 
macrovesicular steatosis.   
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MRS. Liver fat content was determined by 
1H-MRS using 1.5T Siemens Avantofit 
(Siemens Healthcare Diagnostics, 
Erlangen, Germany). MR spectra were 
acquired using a point resolved 
spectroscopy sequence with TE (echo 
time) of 30 ms and 16 acquisitions. Prior 
to MRS measurements, transaxial and 
coronal T2-weighted localization images 
were collected. A 25x25x25 mm3 voxel 
was carefully positioned in the right lobe 
of the liver avoiding large vessels, bile 
ducts, and gall bladder. Respiratory 
motion was triggered using a navigator 
belt keeping TR (repetition time) > 3000 
ms. All spectra were analyzed with the 
jMRUI v5.2 software using AMARES 
algorithm (Stefan et al., 2009; 
Vanhamme et al., 1997). Resonances of 
methylene groups in the fatty acid chains 
and water were determined using line-
shape fitting with prior knowledge. Signal 
intensities were corrected for T2 
relaxation using the equation Im= 
I0exp(−TE/T2). T2 values of 46 ms and 
58 ms were used for water and fat, 
respectively. Liver fat content was 
expressed as a ratio of signal from 
methylene group to total signal of 
methylene and water. Liver fat content 
was converted from signal ratio to a 
weight fraction, applying method 
validated by Longo et al. (Longo et al., 
1995) and Szczepaniak et al. (Szczepaniak 
et al., 2005). The following 
experimentally determined factors were 
used: (1) the ratio of the number of lipid 
protons in the fitted (CH2)n-2 signal to the 
total number of lipid protons is 0.6332 
(Szczepaniak et al., 1999); (2) proton 
densities of fat and water are 110 and 111 
mol/l, respectively; (3) 1 g liver tissue 
contains 711 mg water; (4) densities of the 
liver tissue, fat in the liver, and water are 
1.051 g/ml, 0.900 g/ml, and 1.000 g/ml; 
respectively. This measurement has been 
validated against histologically 
determined lipid content and against 
estimates of fatty infiltration by computed 
tomography (Ryysy et al., 2000). The 
coefficient of variation of repeated 
measurements of liver fat in non-diabetic 
subjects as determined on two separate 
occasions in our laboratory was 11%. 
 
4.2.2. Lipidomics (I-IV) 
 
Hepatic lipidomics analyses using 
UHPLC-MS (I-III). Liver tissue (approx. 5 
mg) was homogenized when frozen 
(Covaris, CryoPrep CP02, MA), and 
weighted. An aliquot (20 μL) of an 





phosphatidic acid(17:0/17:0) (Avanti 
Polar Lipids, Alabaster, AL), 
monoacylglycerol(17:0/0:0/0:0)[rac], 
DAG(17:0/17:0/0:0)[rac] and 
TAG(17:0/17:0/17:0) were added.  The 
lipids were extracted using a mixture of 
HPLC-grade chloroform and methanol 
(2:1; 400 μL). 50 μl of 0.9% sodium 
chloride was added and the lower phase 
(200 μL) was collected and 20 μL of an 
internal standard mixture containing 
labeled PC(16:1/0:0-D3), PC(16:1/16:1-
D6) and TAG(16:0/16:0/16:0-13C3) was 
added. The extracts were run on a Waters 
Q-TOF Premier mass spectrometer 
combined with an Acquity Ultra 
Performance LCTM.  
 
The column (at 50 °C) was an Acquity 
UPLCTM BEH C18 2.1 × 100 mm with 1.7 
μm particles. The solvent system included 
A. ultrapure water (1% 1 M NH4Ac, 0.1% 
HCOOH) and B. LC/MS grade 
acetonitrile/isopropanol (1:1, 1% 1M 
NH4Ac, 0.1% HCOOH). The gradient 
started from 65% A / 35% B, reached 80% 
B in 2 min, 100% B in 7 min and 
remained there for 7 min. The flow rate 
was 0.400 ml/min and the injected 
amount was 2.0 μl (Acquity Sample 
Organizer, at 10 °C). Reserpine was used 
as the lock spray reference compound. 
The lipid profiling was carried out using 
electrospray ionization mode and the data 
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were collected at a mass range of m/z 
300-1200 with a scan duration of 0.2 sec.  
 
The data processing included alignment 
of peaks, peak integration, normalization 
and identification. The lipid identification 
was based on an internal library which 
had been constructed based on accurate 
mass measurements in combination with 
tandem mass measurements. For specific 
lipids, the composition of fatty acid 
chains had been determined with 
separate measurements, and for those the 
fatty acid composition was specified, e.g. 
TAG(14:0/16:0/18:0). The data were 
normalized using one or more internal 
standards representative of each class of 
lipid present in the samples: the intensity 
of each identified lipid was normalized by 
dividing it with the intensity of its 
corresponding standard and multiplying 
it by the concentration of the standard.  
 
All monoacyl lipids except cholesterol 
esters, such as monoacylglycerols and 
monoacylglycerophospholipids, were 
normalized with PC(17:0/0:0), all diacyl 
lipids except ethanolamine phospholipids 
were normalized with PC(17:0/17:0), all 
ceramides with Cer(d18:1/17:0), all diacyl 
ethanolamine phospholipids with 
PE(17:0/17:0), and TAG and cholesterol 
esters with TAG(17:0/17:0/17:0). Other 
(unidentified) molecular species were 
normalized with PC(17:0/0:0) for 
retention times < 300 s, PC(17:0/17:0) for 
a retention time between 300 s and 410 s, 
and TAG(17:0/17:0/17:0) for longer 
retention times.  
 
Quality control of the method showed 
that the day-to-day repeatability of 
control serum samples, and the relative 
standard deviation for identified lipids 
was on average 14.1% in electrospray 
ionization positive mode and 9.5% in 
electrospray ionization negative mode. 
The internal standards added to all 
samples in the study had an average 
relative standard deviation of 10.8% in 
electrospray ionization positive mode and 
8.0% in electrospray ionization negative 
mode. 
 
Hepatic lipidomics analyses using GC-
MS (I-III). Liver tissue was homogenized 
when frozen (Covaris, CryoPrep CP02, 
MA) and weighted (ca. 10 mg). The 
homogenate was spiked with 10 μl of 
internal standard mixture (DL-Valine at 
37 mg/l, heptadecanoic acid at 186.5 
mg/l, succinic acid-d4 at 62.9 mg/l and 
DL-Glutanic acid-d5 at 103.5 mg/l) and 
the samples were extracted with 400 μl 
MeOH/H2O 1:1 (v/v). The supernatant 
was collected and evaporated to dryness 
under gentle flow of nitrogen. The fatty 
acids were then converted into their 
methoxime and trimethylsilyl derivatives 
by a two-step derivatization. First, 25 μL 
of methoxamine reagent was added to the 
residue, and the mixture was incubated 
for 60 min at 45 °C. Next, 25 μL of N-
methyl-N-
trimethylsilyltrifluoroacetamide was 
added, and the mixture was incubated for 
60 min at 45 °C. Finally, a retention index 
standard mixture (n-alkanes) and an 
injection standard (4,4’-
dibromooctafluorobiphenyl), both in 
hexane, were added to the mixture. 
 
Two-dimensional gas chromatography-
time-of-flight mass spectrometry 
(GC×GC–TOFMS) experiments were 
performed on an Agilent 6890 gas 
chromatograph equipped with a 
split/splitless injector (Agilent 
Technologies, Santa Clara, CA), cryogenic 
dual-stage modulator and time-of-flight 
mass spectrometer (Leco Corp., St. 
Joseph, MI, USA). A multipurpose 
sampler with Maestro software (Gerstel, 
Mülheim an der Ruhr, Germany) was 
used for derivatization and sample 
introduction. A 10 m × 0.18 mm I.D. Rxi-
5ms (Restek Corp., Bellefonte, PA, USA) 
column with film thickness 0.18 μm was 
used as the first column and a 1.5 m × 0.1 
mm I.D. BPX-50 (SGE Analytical Science, 
Austin, TX, USA) column with film 
thickness of 0.1 μm as the second column.  
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A phenyl methyl deactivated retention 
gap column (1.5 m × 0.53 mm I.D.) was 
installed in front of the first column. The 
injector was used in the splitless mode at 
240 °C for injecting 1 μl of a sample. The 
splitless period was 90 s. High-purity 
helium (Aga, Espoo, Finland) was used as 
the carrier gas in a constant-pressure 
mode with initial pressure of 276 kPa. 
The first column oven temperature 
program was as follows: 50 °C 
(isothermal for 2 min) then 7 °C/min to 
240 °C, and, finally, 25 °/min to 300 °C 
(3 min). The second dimension column 
oven temperature was maintained 20 °C 
higher and the programming rate and 
hold times were similar than in the first 
dimension. The temperature of the 
transfer line was maintained at 260 °C 
and ion source at 200 °C. Modulation 
time was 4 s. Electron impact ionization 
was applied at 70 eV, and the mass range 
from 45 to 700 amu with 100 spectra/s 
were measured.  
 
Automatic peak detection and mass 
spectrum deconvolution were carried out 
using a peak width set to 0.2 s. Peaks with 
signal-to-noise values lower than 100 
were rejected. The signal-to-noise values 
were based on the masses chosen by the 
software for quantification. ChromaTOF 
version 4.32 was used for the raw data 
processing. The peak areas from total ion 
chromatography were used for most of 
the compounds; for compounds that were 
quantified with the ChromaTOF software, 
peak areas of selected characteristic m/z 
were used. Next, the data files obtained 
by the ChromaTOF software were 
exported to text files and in-house 
developed software Guineu16 was used 
for aligning and normalization of 
compounds in different data sets for 
further analyses. The original GC×GC–
TOFMS data includes retention times, 
retention indices (I), spectral information 
for possible identification, spectral 
similarity value (S=0-999), and peak 
response data. The linear retention 
indices were calculated based on the total 
(=sum of the first and the second 
dimension) retention times of the 
compounds and the retention times of the 
retention index standards (n-alkanes). 
The second dimension retention time is 
so short (1-3.5 s) that its contribution to 
the retention index is not significant. The 
alignment of the data was performed 
based on retention indices, second 
dimension retention times and spectra. 
After alignment of the GC×GC–TOFMS 
data, two filtration criteria was utilised 
for positive identification: spectral 
similarity > 850 and maximum allowed 
difference in retention index between 
experimental and literature values < 25. 
The literature values were obtained from 
NIST 2008 Mass Spectral Library or they 
were determined experimentally with 
GC×GC-TOFMS instrument in our 
laboratory with authentic standards (in-
house determined library). Golm 
metabolome database was used for 
further identification of the metabolites. 
 
Quantitation was based on external 
calibration of each specific fatty acid, 
normalised by the internal standard. 
Quality control of the method showed 
that the day-to-day repeatability of 
control serum samples, and the relative 
standard deviation for fatty acids was on 
average 10.3%. The internal standards 
added to all samples in the study had an 
average relative standard deviation of 
12.3%. 
 
Serum/plasma lipidomics using UHPLC-
MS (III and IV). The plasma samples 
were analysed for global profiling of lipids 
using an ultra-high-performance liquid 
chromatography quadrupole time-of-
flight mass spectrometry method 
(UHPLC-Q-TOF-MS) developed for 
lipidomics purposes. The samples were 
prepared following the Folch procedure 
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TG(16:0/16:0/16:0)-13C3 and 
TG(8:0/8:0/8:0)-13C3 were used as 





TG(17:017:0/17:0) and CE(18:2)) was 
prepared to the following concentration 
levels: 100, 500, 1000, 1500, 2000, 2500, 
3000, 3500, 4000, 4500 and 5000 ng/ml 
including 250 ng/ml of each quality 
control standard. All samples were 
randomized before sample preparation 
and again before the analysis.  
 
10 μL of 0.9% NaCl, 40 μl of CHCl3: 
MeOH (2:1, v/v) and 80 μL of the 3.5 
μg/ml working standards solution were 
added to 10 μl of each plasma sample. 
The samples were vortex mixed and 
allowed to stand on ice for 30 min after 
which they were centrifuged (9400 × g, 3 
min, 4 °C). 60 μL from the lower layer of 
each sample was then transferred to a 
glass vial with an insert and 60 μL of 
CHCl3:MeOH (2:1, v/v) was added. The 
samples were then stored at -80 °C until 
analysis. 
 
The UHPLC system used in this study was 
1290 Infinity system from Agilent 
Technologies. The system was equipped 
with a multisampler using 10% DCM in 
MeOH and ACN:MeOH:IPA:H2O (1:1:1:1, 
v/v/v/v) + 0.1% HCOOH as needle wash 
solutions after each injection for 7.5 s 
each, a quaternary solvent manager and a 
column thermostat (maintained at 50 °C). 
Separations were performed in a 
ACQUITY UPLC® BEH C18 column (2.1 
mm × 100 mm, particle size 1.7 μm) by 
Waters (Milford, USA). The flow rate was 
0.4 mL/min and the injection volume was 
1 μL. H2O + 1% NH4Ac (1M) + 0.1% 
HCOOH (A) and ACN:IPA (1:1, v/v) + 1% 
NH4Ac + 0.1% HCOOH (B) were used as 
the mobile phases for the gradient 
elution. The gradient was as follows: from 
0 to 2 min 35-80% B, from 2 to 7 min 80-
100% B and from 7 to 14 min 100% B. 
Each run was followed by a 7 min re-
equilibration period under initial 
conditions (35% B). 
 
A 6550 iFunnel quadrupole time of flight 
(Q-TOF) mass spectrometer from Agilent 
Technologies (Agilent) interfaced with a 
dual jet stream electrospray ion source. 
Nitrogen generated by a nitrogen 
generator (PEAK Scientific, Scotland, UK) 
was used as the nebulizing gas at a 
pressure of 21 psi, as the drying gas at a 
flow rate of 14 L/min  (at 193 °C) and as 
the sheath gas at a flow rate of 11 L/min 
(at 379 °C). Pure nitrogen from Praxair 
(Fredericia, Denmark) was used as the 
collision gas. The capillary voltage and 
the nozzle voltage were kept at 3643 V 
and 1500 V, respectively. The reference 
mass solution including ions at m/z 
121.0509 and 922.0098 was prepared 
according to instructions by Agilent and 
was introduced to the mass spectrometer 
through the other nebulizer in the dual 
electrospray ionization ion source using a 
separate Agilent series 1290 isocratic 
pump at a constant flow rate of 4 mL/min 
(split to 1:100 before the nebulizer). The 
acquisition mass range was m/z 100-1700 
and the instrument was run using the 
extended dynamic range with an 
approximate resolution of 30,000 FWHM 
(full width at half maximum) measured 
on the ion at m/z 1521.9715 (which is 
included in the tune mixture) during 
calibration of the instrument. 
MassHunters B.06.01 (Agilent) was used 
for all data acquisition. MS data 
processing was performed using MZmine 
2.17.  
 
VLDL-TG fatty acid composition (IV). To 
determine the fatty acid composition of 
VLDL-TG, VLDL was isolated by 
ultracentrifugation (Havel et al., 1955). 
VLDL total lipids were extracted 
according to the method of Folch et al 
(Folch et al., 1957) and fatty acid methyl 
esters (FAMEs) prepared from 
triglyceride as previously described 
(Heath et al., 2003). Separation and 
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quantification (expressed as mol%) of 
FAMEs was performed on a HP6890 GC 
(Agilent Technologies, Stockport, UK) 
with flame ionisation detection.  
4.2.3. Hepatic gene expression (III) 
 
Hepatic gene expression analyses were 
carried out using RNA sequencing. Of the 
original cohort of Study III, liver samples 
were available from 69 subjects and an 
additional 25 subjects were recruited 
using the same criteria as the original 
cohort.  
 
For RNA sequencing, samples were 
prepared using Illumina’s TruSeq RNA 
Sample preparation kit and sequencing 
was performed using a paired-end 101 bp 
protocol on HiSeq2000 platform 
(Illumina, San Diego, CA). STAR (v2.4.1a) 
(Dobin et al., 2013) was used to align 
output reads to human reference genome 
(GRCh38). FeatureCounts program (Liao 
et al., 2014) was used to count uniquely 
mapped fragment against genomic 
features defined by the genecode 
annotation file 
(gencode.v22.annotation.gtf). The read 
counts were adjusted for aligned library, 
size counts per million and log2 adjusted. 
In the analysis, we used autosomal genes 
present in >= 80% samples with an 
average expression >= 1 counts per 
million. 
 
To evaluate whether genes significantly 
correlated with TM6SF2 are enriched in 
specific biological pathways, over-
representation tests were performed of 
this set of genes against 737 Reactome 
(Fabregat et al., 2014; Milacic et al., 
2012) database pathways downloaded 
from 
https://data.broadinstitute.org/mpg/depi
ct/documentation.html (October 4, 
2016). Those 1485 genes (out of 13,644 
tested autosomal genes) for which the P-
value for Pearson correlation passed the 
1% false discovery rate threshold (i.e. q-
value < 0.01, q-values were calculated 
using the qvalue R package) were focused 
on. P-values for over-representation of 
this gene set in the tested Reactome 
pathways were calculated using 
hypergeometric test in R. To account for 
possible biases in the over-representation 
analysis, we performed permutations to 
further test the significance of the 
enrichment of our gene set in the 
Reactome pathways. Specifically, we 
sampled 1000 random sets of genes of the 
size of the original significantly correlated 
gene set from the full set of 13,644 genes 
and tested the enrichment of these gene 
sets in the pathways as above. Finally, we 
computed a permuted P-value for each 
pathway by taking the proportion 
permutations, which gave a more extreme 
P-value than the original gene set in the 
over-representation test. We 
conservatively considered only pathways 
where permuted P-value was below 
0.001, i.e. none of 1000 permutations 
gave a P-value as significant as the 
original gene set, significantly enriched. 
4.2.4. Adipose tissue gene 
expression (IV) 
 
In study IV, needle aspiration biopsies 
from abdominal subcutaneous adipose 
tissue were obtained under 1% lidocaine 
anesthesia and immediately frozen in 
liquid nitrogen and stored at −80°C until 
analysis. Total RNA was isolated using 
the RNeasy Lipid Tissue Mini Kit 
(Qiagen, Valencia, CA).  
 
Bioinformatics. The Illumina 
HumanHT12v4 microarray chips 
(Illumina, San Diego, CA) were annotated 
using the IlluminaHumanv4.db from 
Bioconductor. A standard non-specific 
filtering approach was used to extract 
genes most likely to be expressed in the 
tissue and to ultimately limit the number 
of tests to genes of interest. Specifically, 
probes without annotation to a gene were 
removed, and if multiple probes matched 
to a gene, only the probe with the highest 
interquartile range across samples was 
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included. Only genes with inter-quartile 
range greater than the median of all genes 
were included. Kyoto Encyclopedia of 
Genes and Genomes (KEGG) pathways 
were downloaded from the Molecular 
Signatures Database 
(http://software.broadinstitute.org/gsea/
msigdb/collections.jsp#C2). To limit the 
number of tests to pathways of interest, 
unrelated pathways were removed e.g. 
Huntington’s disease. 
 
Statistical analysis. The pre/post 
comparisons within each diet were 
computated using LIMMA 
(Bioconductor). Specifically, the two 
factors (time and diet) were converted 
into a single factor with 6 levels, and after 
running the full model, contrast tests 
between levels of interest were performed 
(e.g. Diet 1-Pre vs. Diet 1-Post). The 
model was analyzed as a multi-level 
model to account for repeated measures. 
Array-quality weights were estimated and 
included in the model. For the reporter 
features analysis, log2 fold-change and 
unadjusted p-values from the LIMMA 
analysis were used as input.  Statistical 
significance was determined from the null 
distribution and gene sets were limited to 
those with more than 3 and no more than 
200 genes. Otherwise, default parameters 
were used. Distinctly up- and down-
regulated pathways were used to 
determine pathway enrichment in the 
specific direction. P-values were adjusted 
to the Benjamini-Hochberg false 
discovery rate. 
4.2.5. Adipose tissue lipolysis (IV) 
 
Insulin action on serum FFA and glycerol 
rate of appearance (Ra) were determined 
using the euglycemic hyperinsulinemic 
clamp technique (Yki-Järvinen et al., 
1991). The duration of the insulin infusion 
was 120 min (120-240 min) and rate of 
the continuous insulin infusion was 0.4 
mU/kg·min (DeFronzo et al., 1979). The 
low insulin infusion rate was chosen to 
optimize the conditions detecting changes 
in lipolysis, which is half-maximally 
suppressed already at insulin 
concentrations of 13 mU/L in normal 
subjects (Nurjhan et al., 1986). The 
concentrations needed to inhibit hepatic 
glucose production or stimulate glucose 
disposal in normal subjects are ~50 
mU/L and ~100 mU/L (Yki-Järvinen et 
al., 1987). Before start of the infusions, 
two 18 gauge catheters (Venflon, Viggo-
Spectramed, Helsingborg, Sweden) were 
inserted, one in an antecubital vein and 
another retrogradely in a heated (+65 °C) 
dorsal hand vein for sampling of 
arterialized venous blood for insulin (0, 
120, 180 and 240 min), FFA (0, 100, 120, 
130, 135, 140, 150, 180, 240 min), and 
concentrations of glycerol and its isotopic 
enrichment (0, 100, 120, 130, 140, 150, 
180, 240 min). 
 
The rate of whole-body lipolysis and 
effect of insulin on lipolysis were 
determined by infusing [2H5]glycerol for 
120 min before (0-120 min) and for 120 
min during the insulin infusion (120-240 
min).  
 
[2H5]glycerol enrichment was measured 
by GC/MS (Gastaldelli et al., 1999). After 
deproteinization, plasma samples were 
derivatized with pyridine and acetic 
anhydride (1:1), and then reconstituted 
with ethyl acetate (80 μl). Thereafter, 
samples were injected (2 μl) in the 
GC/MS (Agilent, Palo Alto, CA), and 
enrichment was assessed as the peak area 
ratio between fragments of mass 148 and 
145, after correction for baseline values. 
During the last 20 min of the tracer 
equilibration period, both plasma glycerol 
concentrations and [2H5]glycerol 
enrichments were stable in all subjects. 
Therefore, the Ra of endogenous glycerol 
was calculated as the ratio of the tracer 
infusion rate to the plasma tracer 
enrichment (mean of 3 
determinations). During the clamp, 
glycerol Ra was calculated from 
[2H5]glycerol enrichment using the 
Steele’s equation (Gastaldelli et al., 1999).  
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4.2.6. De novo lipogenesis (IV) 
 
Fasting de novo lipogenesis was assessed 
based on the incorporation of deuterium 
from 2H2O in plasma water (Finnigan 
GasBench-II, ThermoFisher Scientific, 
UK) into VLDL-TG palmitate using gas 
chromatography/mass spectrometry 
(GC/MS) with monitoring ions with 
mass-to-charge ratios (m/z) of 270 (M+0) 
and 271 (M+1) (Semple et al., 2009). 
Absolute DNL was calculated by 
multiplying %DNL and the concentration 
of TG in VLDL (Santoro et al., 2015). 
4.2.7. Body composition (I-IV) 
 
Body weight was measured to the nearest 
0.1 kg using a calibrated digital scale 
(Soehnle, Monilaite-Dayton, Finland) 
wearing light indoor clothing without 
shoes. Height was measured to the 
nearest 0.5 cm using a non-stretching 
tape. Body mass index (BMI) was 
calculated as weight in kilograms divided 
by the square of height in meters. Waist 
circumference was measured from the 
midway between the lower rib margin and 
the superior iliac spine, and hip 
circumference at the greater trochanter 
level. Visceral and subcutaneous fat was 
determined by magnetic resonance 
imaging using 1.5T Siemens Avantofit 
(Siemens Healthcare Diagnostics, 
Erlangen, Germany). A series of T1-
weighted trans-axial images with 
frequency selective fat excitation were 
obtained for the determination of visceral 
and subcutaneous fat by magnetic 
resonance imaging from a region 
extending from 8 cm above to 8 cm below 
the fourth and fifth lumbar intervertebral 
disk (16 slices; field of view, 437.5 x 500 
mm2; matrix size, 448 x 512; slice 
thickness, 10 mm; repetition time,  91 ms; 
echo time, 5.24 ms) in two breath holds. 
Visceral and subcutaneous fat areas were 
measured using an image analysis 
program (SliceOMatic v5.0, Tomovision, 
Montreal, Quebec, Canada, 
http://www.perceptive.com/ALICE.HTM
). The areas of subcutaneous and visceral 
fat measured for each slice using a region-
growing routine. The results were 
expressed as total volumes of visceral and 
subcutaneous fat.  Body fat percentage, 
body water mass and fat free mass were 
determined using the bioelectric 
impedance method (InBody 720, 
Biospace, Seoul, Korea). 
4.2.8. Energy expenditure and 
substrate oxidation (IV) 
 
Indirect calorimetry using a computerized 
flow-through canopy system (Deltatrac, 
Datex, Helsinki, Finland) was used to 
measure respiratory gas exchange and 
rates of resting energy expenditure for 40 
min before, and for 40 min during 
euglycemic hyperinsulinemia (Yki-
Järvinen et al., 1991). Protein oxidation 
was calculated from urinary urea nitrogen 
excretion (Ferrannini et al., 1988). Rates 
of carbohydrate and lipid oxidation were 
calculated from the gas exchange data as 
described (Yki-Järvinen et al., 1991). 
4.2.9. Intestinal microbiota (IV)  
 
Bacterial DNA was extracted from fecal 
samples using mechanical cell lysis. 
Illumina MiSeq paired-end sequencing of 
the hypervariable V3-V4 regions of the 
16S rRNA gene was performed according 
to the manual, except that the libraries 
were prepared with single-step 
polymerase chain reaction, i.e. by 
amplifying the 16S rRNA gene fragment 
together with barcoded primers, adapted 
from Kozich et al (Kozich et al., 2013).  
The multiplex polymerase chain reaction 
was comprised of 1 ng/ul template, 1X 
Phusion® Master Mix (ThermoFisher, F-
531L), 0.25 uM V3-V4 locus specific 
primers and 0.375 uM dual-index 
barcodes. The polymerase chain reaction 
was run under the following settings: 98 
°C for 30 s, 27 cycles of 98 °C for 10 s, 62 
°C for 30 s, 72 °C for 15 s and finally 10 
min at 72 °C, where after the samples 
were stored at 4 °C. The size of the 
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polymerase chain reaction product was 
expected to be ~640 base pairs (bp) and 
verified on a Bioanalyzer DNA 1000 chip 
(Agilent Technology, Santa Clara, CA, 
USA). The polymerase chain reaction 
clean-up was performed with AMPure XP 
beads (Beckman Coulter, Copenhagen, 
Denmark) and confirmation of the right 
size of the target was performed on a 
Bioanalyzer DNA 1000 chip (Agilent 
Technology, CA, USA). The pooled 
libraries were sequenced at the 
sequencing unit of the Institute for 
Molecular Medicine Finland, Helsinki, 
Finland with an Illumina MiSeq 
instrument using paired end 2 × 300 bp 
reads and a MiSeq v3 reagent kit with 5% 
PhiX as spike-in.  
 
Sequencing data preprocessing, analysis 
and statistics. The forward reads were 
truncated to length of 150 bases with 
mare’s “ProcessReads” command. We 
used default settings for minimum quality 
score and maximum expected errors. 
Reads with prevalence below 0.01% were 
removed. Chimera removal and 
dereplication of the reads was done using 
USEARCH8 (Edgar et al., 2010). 
Truncated, filtered and dereplicated reads 
were annotated using the Silva database 
(Quast et al., 2012). The median read 
count per sample after preprocessing was 
68797 (range 296 –148 604). The data 
analysis was done without rarefaction or 
transformations utilizing statistical and 
visualization tools included in the mare-
package (Korpela 2016). The number of 
reads was used as an offset in all 
statistical models. Community 
dissimilarity was estimated with principal 
coordinates analysis using Bray-Curtis 
dissimilarity as the distance measure. 
This was calculated with capscale 
function of R package vegan and Bray-
Curtis dissimilarities with function 
vegdist of the same package (Oksanen et 
al., 2011). Permutational multivariate 
analysis of variance using distance 
matrices was performed with adonis 
function in package vegan to calculate the 
relative contribution of different factors 
in the microbiota variation. Taxonomic 
richness was estimated as the number of 
observed operational taxonomic units 
after clustering the reads to operational 
taxonomic units using USEARCH8. 
Comparison of the abundance of bacterial 
genera between two time points in each 
intervention group was performed using 
generalized linear mixed models within 
“GroupTest” function of the mare package 
using subject as the random factor. This 
function uses the glmmADMB package 
(generalized linear mixed models built on 
AD Model Builder) of R software on 
background and assumes negative 
binomial distribution of abundance. 
4.2.10. Genotyping (I-IV) 
 
The TaqMan polymerase chain reaction 
method (Applied Biosystems, Foster City, 
CA, USA) was used according to the 
manufacturer’s instructions for 
genotyping of PNPLA3 at rs739409, 
MBOAT7 at rs641738 and TM6SF2 at 
rs58542926 from approximately 10 ng of 
genomic DNA extracted from whole 
blood. Post-polymerase chain reaction 
allelic discrimination was performed by 
allele-specific fluorescence measurements 
by an ABI Prism Sequence Detection 
System ABI 7900HT (Applied 
Biosystems). The success rate for 
genotyping was >95%. 
4.2.11. Other analytical procedures 
(I-IV) 
 
Fasting plasma glucose was measured 
using a hexokinase method on an 
autoanalyser (Roche Diagnostics Hitachi 
917; Hitachi, Tokyo, Japan) and fasting 
serum insulin concentration by time-
resolved fluoroimmunoassay using the 
Insulin Kit (AUTOdelfia; Wallac, Turku, 
Finland). Homeostasis model assessment 
of insulin resistance (HOMA-IR) and 
Matsuda insulin sensitivity index were 
used as surrogates for IR. HOMA-IR was 
calculated by using the formula: HOMA-
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IR = fS-insulin (mU/l) x fP-glucose 
(mmol/l) / 22.5 (Matthews et al., 1985). 
Matsuda insulin sensitivity index was 
calculated from insulin and glucose 
concentrations measured at 0, 30 and 120 
minutes during the OGTT (DeFronzo et 
al., 2010). HbA1c (%) was measured by 
HPLC using a fully automated 
Glycosylated Hemoglobin Analyzer 
System (BioRad, Richmond, CA, USA), 
and HbA1c (mmol/mol) was calculated 
from the formula: (HbA1c 
[%] − 2.15) × 10.929. LDL- and HDL-
cholesterol and triacylglycerol 
concentrations were measured with the 
respective enzymatic kits (Roche 
Diagnostics Hitachi 917). Serum 
creatinine, alanine aminotransferae 
(ALT), aspartate aminotransferase (AST), 
alkaline phosphatase (ALP) and gamma 
glutamyltransferase (GGT) were 
measured as recommended by the 
European Committee for Clinical 
Laboratory Standards. Free fatty acids 
were measured by an enzymatic 
colorimetric assay (NEFA-HR, Wako 
Chemicals, Neuss, Germany) using a 
Konelab 60i Analyzer (Thermo Electron 
Corporation, Vantaa, Finland). Plasma 
albumin was measured using a 
photometric method on an autoanalyzer 
(Modular Analytics EVO; Hitachi High-
Technologies Corporation, Tokyo, Japan). 
Serum adiponectin was measured using 
the Human Adiponectin ELISA kit from 
B-Bridge International (Cupertino, CA, 
USA). Serum lipopolysaccharide-binding 
protein (LBP) and soluble cluster of 
differentiation 14 (sCD14) were measured 
by quantitative enzyme-linked 
immunosorbent assay (ELISA) using 
human LBP DuoSet® ELISA and human 
CD14 DuoSet® ELISA kits (R&D 
Systems, Minneapolis, MN, USA).  
4.2.12. In vitro experiments (III) 
 
HuH-7 human hepatoma derived cell line 
was cultured in Minimal essential 
medium Eagle AQTM media (Sigma-
Aldrich, St. Louis, MO) containing 10% 
fetal bovine serum, 100 U/ml penicillin, 
100 μg/ml streptomycin. At 70% 
confluency the cells were transduced with 
lentiviral particles expressing shRNA 
against TM6SF2 (TRCN0000254085, 
Sigma-Aldrich) according to the 
manufacturer’s protocol. Sigma-Aldrich 
SHC002V was used as control non-
targeting shRNA. Control and TM6SF2 
shRNA transduced cell pools were 
selected using 5 μg/ml of puromycin.  
 
Quantitative PCR. To analyse TM6SF2 
knockdown efficiency in transduced 
HuH-7 cells and transiently silenced 
HuH-7 cells, RNA from the puromycin 
selected cells was isolated using 
PureLink® RNA Mini Kit 
(Ambion/Thermo Fisher, Waltham, MA) 
according to the manufacturer’s protocol. 
Reverse transcription was carried out 
with Moloney murine leukemia virus 
reverse transcriptase (Invitrogen, 
Carlsbad, CA) and Oligo dT priming. Real 
time quantitative polymerase chain 
reaction was performed in Light Cycler 
480 II (Roche Applied Science, Penzberg, 
Germany) using Roche SYBR-Green® 
master mix. The primers used for 
TM6SF2 were forward: 
ACAGCTATGTGGTGGGCTTC; reverse: 
CCCAGCCAGTAGAGTCCAAA. Data were 
normalised to the geometric mean of two 
house keeping genes, Succinate 





C and β-actin, forward: 
GACAGGATGCAGAAGGAGATT, reverse:  
TGATCCACATCTGCTGGAAGG.  
 
Lipid droplet quantification. Control and 
TM6SF2 knockdown HuH-7 cells were 
fixed using 4% paraformaldehyde in 
phosphate buffered saline. Cells were 
then permeabilised using 0.1% Triton X-
100 for 5 mins and washed twice with 
phosphate buffered saline, followed by 
staining with BODIPY® 493/503 
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(Molecular Probes, Eugene, OR). Cells 
were washed three-times in phosphate 
buffered saline and mounted in Mowiol 
(Calbiochem, La Jolla, CA) containing 50 
mg/ml 1,4-Diazabicyclo-[2.2.2] octane, 5 
(Sigma–Aldrich)  and 5 μg /ml DAPI 
(Molecular Probes). The cells were 
imaged using Zeiss Axio Observer Z1 
microscope (Carl Zeiss Imaging Solutions 
GmbH, Oberkochen, Germany) with a 
60X objective with numerical aperture 1.4 
and Colibri laser. The lipid droplet area in 
each cell was quantified (total lipid area 
in a field/number of cells in the field) by 
using FIJI (ImageJ) software; 150 cells 
from both control and TM6SF2-silenced 
specimens were analysed.  
 
Incorporation of labeled fatty acids to 
lipids. HuH-7 control and TM6SF2 
knockdown cells were cultured in 6 well 
plates as described above. Cells were 
incubated with radioactive lipids in full 
media for 24 hours after 48 hours of 
reaching confluency. [9,10-3H(N)]-oleic 
acid (1.5 μCi/mL), [9,10-3H(N)]-palmitic 
acid (1.5 μCi/mL) and [5,6,8,9,11,12,14,15-
3H(N)]-arachidonic acid (100nCi/mL) 
(PerkinElmer, Waltham, MA) were used. 
Total lipids were isolated using the Bligh 
and Dyer method and the extracts were 





(50:30:8:3.5 V/V) were used as solvents 
for separating neutral and phospholipids, 
respectively. After the run thin layer 
chromatography plates were stained with 
iodine. Triolein, DOPC and CE(18:1) were 
used as standards to identify TGs, PCs 
and CEs. These lipid spots were scraped 
and the radioactivity was measured using 
a liquid scintillation counter. The 
radioactivity values were normalised to 
total cell protein content. Fatty acid 
incorporation experiments were also 
carried out in transiently silenced HuH-7 
and control cells using tritiated [9,10-
3H(N)]-palmitic acid and 
[5,6,8,9,11,12,14,15-3H(N)]-arachidonic 
acid as described above. Silencing was 
done in HuH-7 cells using siRNA (65 nM) 
against TM6SF2 (SI04187946, Qiagen) 
for 48 hours and labeled for another 24 
hours with radioactive fatty acids. 
Lipofectamine® RNAiMAX transfection 
reagent was used for transfecting siRNA 
according to manufacturers protocol. 
AllStars Negative Control siRNA 
(SI03650318, Qiagen) was used as 
negative control. 
4.2.13. Statistical analyses (I-IV) 
 
Studies I-III. Continuous variables were 
tested for normality using the 
Kolmogorov-Smirnov test. The 
independent two-sample Student t test 
and Mann-Whitney U test were used to 
compare normally and non-normally 
distributed data, respectively. Normally 
distributed data were reported in means 
± standard error of means while non-
normally distributed were reported in 
medians and interquartile ranges. 
Pearson χ2 test was used to evaluate if the 
distribution of categorical variables differ 
between the groups. Pearson’s correlation 
coefficients were calculated as a measure 
of statistical dependence between two 
variables after log-transformation if 
necessary. Linear regression analyses 
were performed to evaluate whether the 
differences in lipids between the groups is 
dependent on their number of carbons 
and number of double bonds. 
 
Study IV. Continuous variables were 
tested for normality using the 
Kolmogorov-Smirnov test. Changes 
between groups were compared using 
one-way analysis of variance followed by 
Fisher least significant differences test. 
Nonparametric variables were log-
transformed for analysis and back-
transformed for presentation or analyzed 
nonparametrically with the Kruskal-
Wallis test. The paired Students t test was 
used to explore within-group effects of 
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overfeeding. Categorical variables were 
analyzed with the Fisher exact test. 
 
Cluster analysis of lipids. In study I, 
Bayesian model-based clustering analysis 
was performed to identify the groups of 
lipids with similar profiles across all the 
samples. A total of 1,458 lipids were 
measured and 324 identified. The data 
were decomposed into 11 lipid clusters. 
After log2 transformation, lipidomics data 
of each lipid species were scaled to zero 
mean and unit variance. The average 
profile of each cluster was represented by 
the mean value of all lipids contained. 
The comparisons of clusters between 
subgroups were visualized by bar plots. 
 
Assessment of abundances of lipid 
species. After log2 transformation, the 
mean values of concentrations of all lipids 
were compared between subgroups based 
on HOMA-IR, and PNPLA3 and TM6SF2 
genotypes. In study II, median values of 
concentrations of lipids were compared 
using Kolmogorov-Smirnov and Mann-
Whitney U tests. The multiple hypotheses 
testing was done by the Benjamini-
Hochberg's method (Hochberg et al., 
1990). The comparisons of concentrations 
of lipids were illustrated by heatmaps, 
which plot chain length against the 
number of double bonds. The 
comparisons of concentrations of 
ceramides and their precursors were 
illustrated by heatmaps, which plot fatty 
acyl chain against sphingoid base. The 
color intensity of each cell in the heatmap 
represents the log2 transformed ratio of 
mean values of individual lipid molecules 
of the cases divided by the controls. The 
concentrations of dihydroceramides as 
markers of the de novo ceramide 
synthetic pathway, sphingomyelins as 
markers of sphingomyelin hydrolysis 
pathway, and hexosylceramides as 
markers of the salvage pathway.  
 
All statistical analyses were performed by 
using R 3.1.1 (http://www.r-project.org/), 
IBM SPSS Statistics 22.0.0.0 version 
(IBM, Armonk, NY) and GraphPad Prism 
6.0f for Mac OS X (GraphPad Software, 
La Jolla, CA). A p value of less than 0.05 














Clinical characteristics of the subgroups 
based on median HOMA-IR and the 
PNPLA3 genotype in study I, and those 
based on the TM6SF2 genotype in study 
III are shown in Table 1. All groups were 
similar with respect to gender 
distribution and body mass index (Table 
1, Figure 5).   
 
Study I – Subgroups based on median 
HOMA-IR. Macrovesicular steatosis as 
determined by histological assessment 
was significantly and 3-fold higher in the 
‘High HOMA-IR’ (15 [5–33]) than in the 
‘Low HOMA-IR’ group (5 [0–20], 
p<0.002) (Table 1, Figure 5). The ‘High 
HOMA-IR’ group had significantly higher 
concentrations of fasting serum insulin 
(18 mU/l [14–22] vs. 7 mU/l [6–10], 
p<0.0001) and plasma glucose (6.1 
mmol/l [5.6–6.8] vs. 5.5 mmol/l [4.7–
6.0], p<0.0001) as compared to the ‘Low 
HOMA-IR’ group (Table 1, Figure 5). In 
the 75-gram oral glucose tolerance test, 
the concentrations of insulin (82 mU/l 
[56–124] vs. 39 mU/l [21–49], p<0.05) 
and glucose (9.2 mmol/l [6.9–12.0] vs. 
7.5 mmol/l [5.4–10.4], p<0.001) at two 
hours were higher in the ‘High HOMA-IR’ 
than the ‘Low HOMA-IR’ group (Figure 
1). Concentrations of plasma triglycerides 
were higher, and concentrations of HDL 
cholesterol and adiponectin were lower 
subjects in the ‘High HOMA-IR’ as 
compared to the ‘Low HOMA-IR’ group 
(Table 1 and Figure 5). The PNPLA3 
genotypes were similarly distributed 
between 'High HOMA-IR' and 'Low 
HOMA-IR' groups (Table 1). 
 
Study I – Subgroups based on the 
PNPLA3 genotype. Macrovesicular 
steatosis was significantly and 3-fold 
higher in the ‘PNPLA3148MM/MI’ (15 [5–
30]) as compared to the ‘PNPLA3148II’ 
group (5 [0–28], p<0.04) (Table 1, 
Figure 5). Glucose and insulin 
concentrations during OGTT, HOMA-IR, 
Matsuda insulin sensitivity index, and 
serum lipid and adiponectin 
concentrations were similar between the 
PNPLA3 subgroups (Table 1 and 
Figure 5). By definition, the 
distributions of PNPLA3 genotypes were 
different between the ‘PNPLA3148MM/MI’ 
and ‘PNPLA3148II’ groups (p<0.001, 
Table 1). 
 
Study II. The groups defined based on the 
MBOAT7 genotype at rs641738 (n=35 for 
CC, n=60 for CT and n=20 for TT) were 
similar with respect to age, gender, BMI, 
waist circumference, PNPLA3 I148M and 
TM6SF2 E167K genotypes. Histologically 
determined scoring of macrovesicular 
steatosis (the percentage of grades 
0/1/2/3 were 23/60/3/14, 25/62/12/2 
and 20/55/25/0, p=0.03 in CC, CT and 
TT groups, respectively), 
necroinflammation (the percentage of 
grades 0/1/2/3 were 74/26/0/0, 
87/13/0/0 and 60/35/0/5, p=0.04, 
respectively) were significantly different 
between the MBOAT7 groups. The 
prevalence of subjects with fibrosis stage 
2 or greater increased with number of 
MBOAT7 variant alleles (0 vs. 5 vs. 25 %, 
p=0.001, Figure 6). Concentrations of 
fasting serum insulin (13.7 [8.4–17.1], 11.2 
[6.5–18.3] and 12.3 [7.0–18.8] mU/l in 
CC, CT and TT groups), plasma glucose 
(5.9 [5.0–6.6], 5.8 [5.4–6.6] and 5.7 [5.1–
6.1] mmol/l), plasma triglycerides (1.24 
[1.06–1.55], 1.29 [0.91–1.69] and 1.08 
[1.00–1.59] mmol/l), HDL (1.15 [0.98–
1.33], 1.09 [0.93–1.38] and 0.98 [0.86–
1.13] mmol/l) and LDL (2.5 [1.9–3.4], 2.3 
[1.7–2.9] and 2.4 [1.5–3.5] mmol/l) 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 5. (A) Body mass index (top panels on the left), fasting serum insulin 
concentrations (top panels on the right), liver fat content (bottom panels on the left), and 
serum adiponectin concentrations (bottom panels on the right) in the ’Low HOMA-IR’ vs. 
’High HOMA-IR’ (leftmost panels in each comparison) and in the ’PNPLA3148II’ vs. 
’PNPLA3148MM/MI’ (rightmost panels in each comparison) groups. Data are in mean ± 
SEM (bars and whiskers) or in medians and interquartile ranges (box plots), as 
appropriate. (B) Plasma glucose and serum insulin concentrations in the groups during 
oral glucose tolerance test. Data are in means ± SEM. n.s. p>0.05, *p<0.05, **p<0.01, 
***p<0.001. Adapted from Luukkonen et al., Journal of Hepatology. 2016; 64:1167-75 and 
reproduced with the permission of Elsevier. 
 
Study III. Clinical characteristics of the 
TM6SF2 genotype groups are shown in 
Table 1. Histologically determined 
macrovesicular steatosis was 2-fold 
higher in the TM6SF2EK/KK than the 
TM6SF2EE group (27.5 ± 9.5 % vs. 13.8 ± 
2.0 %, p<0.05, Table 1). By definition, 
the distribution of TM6SF2 genotypes 
differed between the TM6SF2 groups 
(Table 1). Indices of insulin sensitivity, 
circulating lipid concentrations and the 
distribution of PNPLA3 rs738409 
genotype were comparable between the 
TM6SF2 groups (Table 1). The 
TM6SF2EK/KK group tended to have 
higher prevalence of hepatic fibrosis 
(stage 1 or greater) compared to the 
TM6SF2EE group (60 vs. 31 %, p=0.09). 
 
Study IV. The clinical characteristics of 
the subjects in study IV at baseline are 
shown in Table 2. The groups consuming 
hypercaloric diets enriched either in 
saturated fat (SAT), mono- and 
polyunsaturated fat (UNSAT) and simple 
sugars (CARB) were similar with respect 
to age, gender distribution, body mass 
index, body composition, IHTG content, 
blood pressure, the PNPLA3 genotype 
distribution, and circulating insulin, 
lipids and liver enzymes (Table 2).  
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Figure 6. Prevalence of fibrosis (top panel on the left) and concentrations of hepatic 
phosphatidylinositols PI(40:5) (top panel on the right), PI(36:4) (bottom panel on the 
left), and PI(38:3) (bottom panel on the right) in groups according to the MBOAT7 
genotype at rs641738. Data are in % and median (25th-75th percentile), and were tested 
using Pearson χ2 test, Kolmogorov-Smirnov test and Mann-Whitney U test, as 
appropriate. * p<0.05, ** p<0.01. Adapted from Luukkonen et al., Journal of Hepatology. 
2016; 65:1263-1265 and reproduced with the permission of Elsevier. 
 
5.2. HUMAN LIVER LIPIDOME 
(I-III) 
 
In total, 1,458 lipids were measured, of 
which 324 were identified. The data were 
decomposed into 11 lipid clusters (LCs). 
The abundance of LCs containing 
ceramides and dihydroceramides (LC1), 
DAGs, saturated and monosaturated TGs 
(LC5), and polyunsaturated TGs (LC8, 
LC10 and LC11) were increased in the 
‘High HOMA-IR’ vs. ‘Low HOMA-IR’ 
group. The abundance of LCs containing 
mostly polyunsaturated TGs (LC8, LC9, 
LC10 and LC11) differed significantly 
between the PNPLA3148MM/MI and the 
PNPLA3148II groups. We therefore focused 
on analyses of these lipid species (TGs, 
DAGs, ceramides and dihydroceramides) 
in study I.  
5.2.1. 'Metabolic NAFLD' (I) 
 
The increase in liver fat content in ‘High 
HOMA-IR’ as compared to the ‘Low 
HOMA-IR’ group was predominantly due 
to increase in TG species with 0 to 3 
double bonds and 48 to 54 carbons, i.e. 
species with mostly saturated and 
monounsaturated long chain acyl-groups 
(Figure 7).  
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54 








Age (years) 48 ± 2 52 ± 3 45 ± 3 
Gender (n, 
women/men) 8/6 7/5 6/6 
BMI (kg/m2) 30 ± 2 31 ± 2 33 ± 2 
Fat free mass (kg) 58.6 ± 2.6 60.2 ± 3.8 61.9 ± 3.6 
Liver fat (1H-MRS, 
%) 4.9 ± 1.8 4.8 ± 1.4 4.3 ± 1.3 
Visceral adipose 




4770 ± 575 4732 ± 708 5133 ± 622 
Waist 
circumference (cm) 97 ± 5 98 ± 4 102 ± 3 
Waist-to-hip ratio 0.90 ± 0.03 0.90 ± 0.02 0.92 ± 0.02 
LBP-to-sCD14 ratio 4.3 ± 0.3 4.6 ± 0.3 4.9 ± 0.5 
fP-Glucose 
(mmol/l) 5.6 ± 0.2 5.7 ± 0.2 5.9 ± 0.2 
fS-Insulin (mU/l) 8.1 (5.8 – 11.9) 9.1 (6.5 – 14.6) 10.3 (6.2 – 19.2) 
HOMA-IR 1.9 (1.3 – 3.2) 2.3 (1.6 – 4.0) 2.8 (1.7 – 5.0) 
Systolic blood 
pressure (mmHg) 133 ± 4 134 ± 5 139 ± 6 
Diastolic blood 
pressure (mmHg) 80 ± 3 83 ± 2 85 ± 4 
fP-Triglycerides 
(mmol/l) 1.1 ± 0.3 1.1 ± 0.1 1.4 ± 0.2 
fP-HDL cholesterol 
(mmol/l) 1.62 ± 0.10 1.61 ± 0.14 1.53 ± 0.11 
fP-LDL cholesterol 
(mmol/l) 3.2 ± 0.3 3.4 ± 0.2 3.5 ± 0.2 
fS-FFA (μmol/l) 556 ± 58 610 ± 52 639 ± 65 
fP-ALT (IU/l) 28 ± 4 26 ± 3 24 ± 3 
fP-AST (IU/l) 26 ± 1 27 ± 2 26 ± 2 
PNPLA3 
(CC/CG/GG) (n) 9/5/0 7/4/1 5/4/2 
Data are in n (%), means ± SEM or median (25th-75th percentile), as appropriate. There were no 
significant differences in any variable between the groups using ANOVA, Kruskal-Wallis and 
Chi-squared test, as appropriate.  © 2018 by the American Diabetes Association ®. Adapted 
from Luukkonen et al., Diabetes Care 2018 May; dc180071 and reproduced with the permission 
from the American Diabetes Association ®. 
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Figure 7. Fold-change of distinct hepatic TGs between groups (‘High HOMA-IR’ vs. ‘Low 
HOMA-IR’, panel on the left;  ‘PNPLA3148MM/MI’ vs. ‘PNPLA3148II’, panel on the right). The 
color code represents the log of the ratio between means of the groups for an individual 
TAG. The y-axes denote the number of carbons and the x-axes the number of double 
bonds. The brighter the red color, the greater increase of absolute concentration of the 
individual TG in the ‘High HOMA-IR’ compared to the ‘Low HOMA-IR’ group or the 
PNPLA3148MM/MI’ compared to the ‘PNPLA3148II’ group. *p<0.05, **p<0.01, ***p<0.001. 
Adapted from Luukkonen et al., Journal of Hepatology. 2016; 64:1167-75 and reproduced 
with the permission of Elsevier. 
 
The concentrations of free palmitate 
(C16:0) (372 [296–502] vs. 333 [279–
402] nmol/g, p<0.05), stearate (C18:0) 
(202 [149–250] vs. 164 [135–200], 
p<0.05) and oleate (C18:1) (188 [140–
254] vs. 164 [126– 207], p<0.05) in the 
liver were greater in the ‘High HOMA-IR’ 
group vs. the ‘Low HOMA-IR’ group. 
There were no differences in hepatic 
concentrations of free polyunsaturated 
fatty acids linoleate (C18:2) and 
arachidonate (C20:4) in the ‘High 
HOMA-IR’ group vs. the ‘Low HOMA-IR’ 
group.  
 
The concentrations of 13 out of 17 hepatic 
ceramide species were significantly 
increased in the ‘High HOMA-IR’ vs. the 
‘Low HOMA-IR’ group (Figure 8). 
 
Regarding the pathways of ceramide 
synthesis, hepatic concentrations of 
dihydroceramides were used as markers 
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of de novo ceramide synthetic pathway, 
sphingomyelins as markers of 
sphingomyelin hydrolysis pathway, and 
hexosylceramides as markers of the 
salvage pathway (Figure 9). 
Concentrations of 4 out of 5 
dihydroceramide species in the liver were 
significantly increased in ‘High HOMA-
IR’ group vs. the ‘Low HOMA-IR’ group 
(Figure 9). There were no differences in 
the hepatic concentrations of 
sphingomyelins and hexocylceramides 
between the groups (Figure 9). 
 
The concentrations of 4 out of 5 DAG 
species in the liver (DAG(32:1), 
DAG(34:1), DAG(36:2) and DAG(36:3)) 
were significantly (p<0.05) increased in 













  Figure 8. Fold-changes of distinct hepatic 
ceramides between the groups (‘High 
HOMA-IR’ vs. ‘Low HOMA-IR’, panel on 
the left; ‘PNPLA3148MM/MI’ vs. ‘PNPLA3148II’ 
groups panel on the right). The top panel 
represents the structure of a ceramide. In 
the heatmaps, the color code indicates the 
log of the ratio between means of the 
groups for an individual ceramide. The y-
axes denote the fatty acyl chain and the x-
axes the sphingoid base species. The 
brighter the red color, the greater increase 
of absolute concentration of the individual 
ceramide in the ‘High HOMA-IR’ 
compared to the ‘Low HOMA-IR’ group or 
the PNPLA3148MM/MI’ compared to the 
‘PNPLA3148II’ group. *p<0.05, **p<0.01, 
***p<0.001. Adapted from Luukkonen et 
al. Journal of Hepatology. 2016; 64:1167-
75 and reproduced with the permission of 
Elsevier. 
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Figure 9. Pathways of ceramide metabolism. The diagram (panel on the left) depicts the 
pathways of ceramide metabolism. Ceramides can be synthesized via the de novo synthetic 
pathway in which palmitate is metabolized to dihydroceramides (DihydroCer) prior to 
formation of ceramides (heatmap on the left). They can also be formed via the salvage 
pathway from hexosylceramides (HexCer, middle heatmap) and via sphingomyelin 
hydrolysis (SM, heatmap on the right). Ceramides are degraded by ceramidase, which is 
upregulated by adiponectin. In the heatmaps, the color code indicates the log of the ratio 
between means of the ’High’ vs. ’Low HOMA-IR’ groups for an individual lipid. The y-axes 
denote the fatty acyl chain and the x-axes the sphingoid base. The brighter the red color, 
the greater increase of absolute concentration of the individual lipid. *p<0.05, **p<0.01. 
Adapted from Luukkonen et al., Journal of Hepatology. 2016; 64:1167-75 and reproduced 
with the permission of Elsevier.
5.2.2. 'PNPLA3 NAFLD' (I) 
 
In contrast to the differences between the 
subgroups based on median HOMA-IR, 
increase in liver fat content in the 
PNPLA3148MM/MI vs. the PNPLA3148II  
group was predominantly due to increase 
 
in TG species with 4 to 11 double bonds 
and 50 to 60 carbons, i.e. species with 
mostly polyunsaturated very long chain 
acyl-groups (Figure 7).  
 
There were no differences in hepatic free 
fatty acids or ceramides 
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between the PNPLA3 groups (Figure 8). 
Amongst hepatic DAGs, concentration of 
one polyunsaturated species, DAG(36:3), 
was significantly (p<0.05) increased in 
the PNPLA3148MM/MI as compared to the 
PNPLA3148II  group. 
5.2.3. 'MBOAT7 NAFLD' (II) 
 
Amongst 7 distinct phosphatidylinositols 
which were identified in the human liver, 
concentrations of two species, i.e. 
PI(36:4) and PI(38:3), decreased 
significantly as a function of the number 
of MBOAT7 variant alleles (Figure 6). 
The concentration of one species, i.e. 
PI(40:5), increased with increasing 
number of MBOAT7 variant alleles 
(Figure 6). No significant differences in 
the concentrations of any other lipid 
classes, such as triglycerides, cholesterol 
esters, ceramides, sphingomyelins, 
hexosylceramides, other phospholipids, 
or free fatty acids in the liver were 
observed in the groups based on the 
MBOAT7 genotype. 
5.2.4. 'TM6SF2 NAFLD' (III) 
 
The increase in the liver fat content in the 
TM6SF2EK/KK as compared to the 
TM6SF2EE group (Table 1) was 
predominantly due to an increase in 
hepatic TG species with saturated and 
monounsaturated long-chain fatty acyl- 
groups (Figure 10, top panel in the 
middle).
 
Figure 10. The difference in liver free fatty acids (FFA) as % total in TM6SF2EK/KK as 
compared to TM6SF2EE (top panel on the left); linear regressions between the number of 
double bonds in liver TGs and fold-change of liver TG species (top panel in the middle); 
between the number of double bonds in PCs and fold-change of liver PCs (top panel on the 
right) in TM6SF2EK/KK and TM6SF2EE. TM6SF2 mRNA expression in control shRNA 
(shNT) and TM6SF2 shRNA (shTM6SF2) expressing HuH-7 cells (bottom panel on the 
left). The relative incorporation of (3H)-palmitic acid, (3H)-oleic acid and (3H)-arachidonic 
acid into triglycerides (bottom panel in the middle), and phosphatidylcholines (bottom 
panel on the right) expressed in percentage relative to control. Each circle denotes a 
different lipid. Data are shown as mean ± SD; Student t-test; * p < 0.05, ** p < 0.01, *** p 
< 0.001. Adapted from Luukkonen et al., Journal of Hepatology. 2017; 67:128-136 and 
reproduced with the permission of Elsevier.
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In contrast, concentrations of TGs with 8 
or more double bonds, i.e. TGs containing 
predominantly polyunsaturated fatty 
acyl-groups were decreased in the 
TM6SF2EK/KK as compared to the 
TM6SF2EE group (Figure 10, top panel 
in the middle). As a consequence, the 
fold-change of concentrations of hepatic 
TGs between the TM6SF2 groups was 
inversely correlated (r=-0.27, p<0.005) 
with the number of double bonds in the 
TGs (Figure 10, top panel in the 
middle). In addition to TGs, the total 
concentration of hepatic CEs was 
significantly higher in the TM6SF2EK/KK 
as compared to the TM6SF2EE group 
(+20%, p<0.05). 
 
Total concentration of hepatic 
phosphatidylcholines (PCs) was 
significantly lower in the TM6SF2EK/KK as 
compared to the TM6SF2EE group (-11%, 
p<0.05). Amongst distinct PC species, 
concentrations of those with high number 
of double bonds, i.e. PCs containing 
predominantly polyunsaturated fatty 
acyl-groups were decreased in the 
TM6SF2EK/KK as compared to the 
TM6SF2EE group (Figure 10, top panel 
on the right). Consequently, the fold-
change of concentrations of hepatic PCs 
between the TM6SF2 groups was 
inversely correlated with the number of 
double bonds (r=-0.39, p<0.001) 
(Figure 10, top panel on the right). In 
addition to the liver, similar inverse 
correlations between the fold-changes of 
concentrations of TGs and PCs with the 
number of double bonds in these lipids 
were observed in the serum (p<0.0001 
for both TGs and PCs). 
 
In contrast to hepatic TGs and PCs, which 
were characterized by deficiency of 
species with highly polyunsaturated acyl-
chains, the relative abundance of a such 
fatty acids, i.e. arachidonic acid (C20:4), 
was significantly higher in the amongst 
the hepatic free fatty acids in the 
TM6SF2EK/KK as compared to the 
TM6SF2EE group (Figure 10, top panel 
on the left). 
 
The absolute concentration of total 
hepatic free fatty acids was significantly 
lower in the TM6SF2EK/KK (700 [595 – 
822] nmol/g) as compared to the 
TM6SF2EE group (904 [755 – 1098] 
nmol/g, p<0.01).  Amongst the distinct 
FFAs, the concentrations of palmitate 
(16:0, 286 [254 – 346] vs. 383 [307 – 
456] nmol/g, p<0.01), stearate (18:0, 131 
[125 – 188] vs. 195 [160 – 231] nmol/g, 
p<0.01), oleate (18:1, 140 [131 – 168] vs. 
191 [141 – 247] nmol/g, p<0.05) and 
linoleate (18:2, 67 [50 – 81] vs. 84 [67 – 
102] nmol/g, p<0.05) were significantly 
lower in the TM6SF2EK/KK as compared to 
the TM6SF2EE group. 
5.3. IN VITRO EXPERIMENTS 
(III) 
 
The relative deficiency of TGs and PCs 
with polyunsaturated fatty-acyl groups in 
the liver and serum in the face of relative 
excess of polyunsaturated fatty acids in 
the nonesterified pool lead us to consider 
whether TM6SF2 plays a role in the 
incorporation of fatty acids into complex 
lipids, such as TGs and PCs. In the human 
liver, the expression of TM6SF2 is 
decreased in carriers of the E167K variant 
(Mahdessian et al., 2014). Therefore, we 
performed in vitro experiments in 
TM6SF2 silenced cells to determine the 
incorporation of fatty acids with different 
degree of saturation into complex lipids. 
 
HuH-7 cells were transduced with 
lentiviral particles expressing short 
hairpin RNA against TM6SF2, which 
resulted in 52% lower TM6SF2 mRNA 
expression than in control HuH-7 cells 
(p<0.001) (Figure 10, bottom panel on 
the left). The incorporation of palmitic 
acid (+117 %, p<0.01) and oleic acid 
(+39%, p<0.05) into TGs in the TM6SF2 
silenced HuH-7 cells were significantly 
increased, while that of arachidonic acid 
was significantly decreased (-34%, 
Results 
60 
p<0.001) (Figure 10, bottom panel in 
the middle). Similarly, the incorporation 
of palmitic acid (+236%, p<0.001) and 
oleic acid (+65%, p<0.05) into PCs were 
increased, while the incorporation of 
arachidonic acid was significantly 
decreased in TM6SF2 knockdown HuH-7 
cells as compared to control cells (-32 %, 
p<0.05) (Figure 10, bottom panel on the 
right). Transient silencing (-78% TM6SF2 
mRNA expression as compared to control 
cells) of TM6SF2 with small interfering 
RNA in HuH-7 cells induced similar 
changes in fatty acid incorporation into 
TGs and PCs.  
5.4. HEPATIC GENE 
EXPRESSION (III) 
 
To further elucidate the function of 
TM6SF2, RNA sequencing was performed 
in the human liver samples. As reported 
previously by Mahdessian et al., 
(Mahdessian et al., 2014),  the expression 
of TM6SF2 was significantly lower in 
variant allele carriers as compared to 
non-carriers as determined from the 
relationship between TM6SF2 gene 
expression and the number of variant 
alleles at rs58542926, β=-0.41±0.11, 
p<0.001).  
 
In the pathway analyses of the RNA 
sequencing data, 3 pathways related to 
lipids were enriched with genes co-
expressing with TM6SF2, i.e. ‘metabolism 
of lipids and lipoproteins’, ‘peroxisomal 
lipid metabolism’ and ‘triglyceride 
synthesis’. Distinct genes whose 
expression correlated positively with 
TM6SF2 (and were therefore decreased in 
carriers of the TM6SF2 E167K variant) 
included those associated with synthesis 
of fatty acids (fatty acid synthase, acetyl-
CoA carboxylase beta) and triglycerides 
(diacylglycerol acyltransferases 1 and 2), 
and metabolism of very low-density 
lipoproteins (apolipoprotein C-III). In 
contrast, genes that correlated negatively 
with TM6SF2 (and were therefore 
increased in carriers of the TM6SF2 
E167K variant) included genes related to 
fatty acid oxidation (carnitine 
palmitoyltransferase 1), peroxisome 
proliferator-activator receptors alpha 
and gamma and synthesis of 
polyunsaturated fatty acid-derived 
eicosanoids (arachidonate 5-
lipoxygenase). 
5.5. METABOLIC EFFECTS OF 
DIFFERENT OVERFEEDING 
DIETS (IV) 
5.5.1. Macronutrient composition of 
the diet 
 
At the end of the overfeeding period, fat 
constituted 60 [54–64] and 59 [53–61] % 
of total energy intake in the SAT and 
UNSAT groups. These percentages of fat 
were 2-fold higher as compared to the 
CARB group (24 [20–26] %). Saturated 
fat intake was 2-fold higher in the SAT 
(33 [28–36] %) compared to the UNSAT 
(14 [14–18] % (p<0.001) group. Intakes of 
monounsaturated (28 [23–30] vs. 13 [12–
15] %, UNSAT vs. SAT, p<0.001) and 
polyunsaturated (11 [10–14] vs. 5 [4–5] 
%, respectively, p<0.001) fat were 2-fold 
higher in the UNSAT compared to the 
SAT group. The percentage of total energy 
intake from carbohydrates was 2.8-fold 
higher in the CARB (64 [58–68] %) as 
compared to the UNSAT (23 [19–29] %, 
p<0.001) or the SAT (26 [23–32] %, 
p<0.001) groups. 
5.5.2. Fatty acid composition of 
VLDL-TG 
 
In addition to dietary records, analysis of 
fatty acid composition of fasting plasma 
VLDL-TG was used to as an objective 
marker of recent dietary intake to 
monitor compliance (Figure 11). During 
the SAT diet, the relative abundance of 
saturated fatty acids C16:0 (26.2±1.0 vs. 
30.7±1.0 mol% (p<0.001)), C18:0 
(3.1±0.3 vs. 4.1±0.3 mol% (p<0.01)) and 
C14:0 (1.8±0.2 vs. 4.8±0.5 mol% 
(p<0.001)) in VLDL-TG increased 
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Figure 11. Overfeeding-induced changes in fatty acid composition of VLDL-TG in the 
groups. Black bars denote the saturated fat (SAT); white bars the unsaturated fat 
(UNSAT); and hatched bars the simple sugar (CARB) group. The x-axis shows the change 
in % FA in VLDL-TG after versus before overfeeding and the y-axis the specific fatty acids 
in VLDL-TG. * p<0.05, ** p<0.01, *** p<0.001. © 2018 by the American Diabetes 
Association ®. Adapted from Luukkonen et al., Diabetes Care 2018 May; dc180071 and 
reproduced with the permission from the American Diabetes Association ®. 
 
significantly. The abundance of 
unsaturated fatty acids C18:1 and C18:2 
decreased significantly during the SAT 
diet. During the UNSAT diet, the relative 
abundance of unsaturated fatty acid 
C18:2 increased significantly (p<0.01). 
During the CARB diet, the abundance of 
C16:0, C14:0 and C16:1 increased, while 
that of C18:2 decreased significantly 
(p<0.05) (Figure 11).   
5.5.3. Body composition and energy 
expenditure 
 
In all subjects, body weight increased by 
1.4±0.2 % from 92.1±2.8 to 93.3±2.8 kg 
(p<0.001). The increases in body weight 
were 1.4±0.3 kg in the SAT, 0.9±0.3 kg in 
the UNSAT and 1.4±0.5 kg in the CARB 
groups (NS). Visceral and subcutaneous 
fat contents did not change significantly 
during overfeeding.  
 
In all subjects, overfeeding increased 
resting energy expenditure significantly 
from 7.49±0.22 to 7.62±0.24 MJ/day 
(p<0.05). Rates of substrate oxidation 
expressed per kg body weight or fat free 
mass did not change with overfeeding. 





5.5.4. Liver fat content 
 
Intrahepatic triglyceride content 
increased by 55% (4.9±1.8 vs. 7.6±2.4% 
(p<0.001)) in the SAT group, by 15% 
(4.8±1.4 vs. 5.5±1.4% (p<0.02)) in the 
UNSAT group, and by 33% (4.3±1.3 vs. 
5.7±1.6% (p<0.02)) in the CARB group. 
The increase in intrahepatic triglyceride 
content was significantly greater in the 
SAT as compared to the UNSAT group 
(p<0.01). This difference was 
independent of changes in body weight as 
determined from the significantly 
different intercepts between the 
regression lines relating change in IHTGs 
and change in body weight in the SAT as 
compared to the UNSAT group (p<0.05). 
5.5.5. De novo lipogenesis and 
adipose tissue lipolysis  
 
Hepatic de novo lipogenesis increased 
significantly during the CARB diet (96 
[47–116] vs. 190 [61–303] μmol/L, 
p<0.05) but not during the other diets 
(Figure 12).  
 
In the basal state, whole-body glycerol 
rate of appearance (Ra) remained 
unchanged in all groups. After 
overfeeding compared to baseline, whole-
body glycerol Ra during euglycemic 
hyperinsulinemia increased in the SAT 
(2.08±0.12 vs. 2.31±0.16 μmol/kg·min, 
p<0.05), decreased in the UNSAT 
(2.59±0.25 vs. 2.14±0.22 μmol/kg·min, 
p<0.05), and did not change in the CARB 
(2.15±0.21 vs. 2.27±0.19 μmol/kg·min, 
p=NS) group (Figure 12). Whole-body 
glycerol Ra during hyperinsulinemia 
increased significantly more in the SAT 
compared to the UNSAT (p<0.001) and 
the CARB compared to the UNSAT 
(p<0.01) group (Figure 12).   
5.5.6. Insulin resistance 
 
HOMA-IR, a marker of insulin resistance, 
increased significantly during the 
overfeeding in the SAT group by 23% (1.9 
[1.3–3.2] vs. 2.2 [1.4–3.3], p<0.05), but 
remained unchanged in the other groups 
(Figure 12). 
5.5.7. Ceramides and endotoxemia 
 
Total plasma ceramide concentration 
increased significantly by 49% in the SAT 
group with overfeeding (p<0.001, Figure 
12). There were no changes in total 
plasma ceramides in the other groups. 
The increase in total plasma ceramides 
was significantly higher in the SAT 
compared to the UNSAT (p<0.05) or 
CARB (p<0.001) groups. This difference 
was independent of changes in body 
weight as determined from significantly 
different intercept of the regression lines 
between changes in total plasma 
ceramides and those in body weight in the 
SAT as compared to the UNSAT (p<0.05) 
or the CARB (p<0.001) groups. The 
increase in total plasma ceramides in the 
SAT groups was due to increases in 
several long-chain ceramides and 
dihydroceramides (markers of de novo 
ceramide synthesis). 
 
Regarding circulating lipids, plasma HDL 
cholesterol increased significantly by 17% 
in the SAT group (+0.3±0.1 mmol/l, 
p<0.01 for after vs. before) but not in the 
other groups. Plasma LDL cholesterol 
increased by 10% in the SAT group 
(+0.3±0.1 mmol/l, p<0.01) but not in the 
other groups. Plasma triglyceride 
concentrations remained unchanged in all 
groups. 
 
The ratio of serum lipopolysaccharide-
binding protein and soluble cluster of 
differentiation 14 (LBP-to-sCD14 ratio), a 
marker of endotoxemia, increased 
significantly in the SAT group (4.3±0.3 
vs. 4.7±0.3, p<0.01) and remained 
unchanged in the UNSAT and CARB 
groups. The increase in LBP-to-sCD14 
ratio was significantly higher in the SAT 
as compared to the UNSAT (p<0.05) or 
the CARB (p<0.001) groups.  
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Regarding gut microbiota, the abundance 
of gram-negative Proteobacteria 
increased by 3.6-fold in the SAT group 
with overfeeding (p<0.05). There were no 


















Figure 12. Overfeeding-induced changes in hepatic de novo lipogenesis (top panel on the 
left), glycerol Ra during euglycemic hyperinsulinemia (top panel on the right), HOMA-IR 
(bottom panel on the left), total plasma ceramides (bottom panel on the right). Black bars 
denote the saturated fat (SAT), white bars the unsaturated fat (UNSAT), and hatched bars 
the simple sugar (CARB) group. The y-axes indicate fold-change of mean values after 
versus before overfeeding within groups. Data are reported as mean ± SEM. *p<0.05, ** 
p<0.01, *** p<0.001. X = p<0.05 between groups. © 2018 by the American Diabetes 
Association ®. Adapted from Luukkonen et al., Diabetes Care 2018 May; dc180071 and 
















































Figure 13. Overfeeding-induced changes in adipose tissue transcriptome in the groups. 
The bubble grid depicts the reporter test statistics (proportional to size and color intensity) 
comparing post- relative to pre-overfeeding gene expression. Only the pathways which 
were significant at <5% false discovery rate in at least one diet are shown. SAT = saturated 
fat, UNSAT = unsaturated fat, CARB = simple sugar group. © 2018 by the American 
Diabetes Association ®. Adapted from Luukkonen et al., Diabetes Care 2018 May; 
dc180071 and reproduced with the permission from the American Diabetes Association ®. 
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5.5.8. Adipose tissue gene 
expression 
 
A total of 28 reporter pathways out of 134 
KEGG pathways were identified in the 
gene set analysis at a 5% false discovery 
rate. Both the SAT and CARB diets 
changed 18 pathways, and the UNSAT 
diet changed 5 pathways. These changes 
were highly specific for each of the diets, 
and only 3 pathways overlapped between 
all diets (Figure 13). The SAT diet 
upregulated pathways related to 
inflammation, such as ‘pathogenic E. coli 
infection’, ‘natural killer cell mediated 
cytotoxicity’, ‘NOD like receptor signaling 
pathway’ and ‘leukocyte transendothelial 
migration’, and also to ‘glycerolipid 
metabolism’. Changes in some pathways 
related to inflammation, such as ‘antigen 
processing and presentation’, ‘chemokine 
signaling pathway’, and ‘hematopoietic 
cell lineage’ were similar in the SAT and 
CARB groups. In addition, the CARB diet 
upregulated pathways related to 
carbohydrate metabolism, such as 
‘fructose and mannose metabolism’, 
‘pentose phosphate pathway’ and 
‘glycolysis gluconeogenesis’. The UNSAT 
diet upregulated pathways such as 
‘oxidative phosphorylation’ and ‘ECM 




















Insulin-resistant NAFLD is associated 
with features of the metabolic syndrome 
and an increased risk of type 2 diabetes 
and cardiovascular disease (‘Metabolic 
NAFLD’) (Yki-Järvinen 2014). In 
contrast, NAFLD due to the common 
genetic variants in PNPLA3, MBOAT7 
and TM6SF2 (‘PNPLA3 NAFLD’, 
‘MBOAT7 NAFLD’ and ‘TM6SF2 NAFLD’, 
respectively) is not associated with any of 
these features (Sookoian et al., 2011; 
Mancina et al., 2016; Kozlitina et al., 
2014). All subtypes of NAFLD increase 
the risk of NASH, liver cirrhosis and 
hepatocellular carcinoma. The present 
series of studies aimed to determine 
whether these marked differences in the 
phenotypes in ‘Metabolic NAFLD’, 
‘PNPLA3 NAFLD’, ‘MBOAT7 NAFLD’ and 
‘TM6SF2 NAFLD’ is associated with 
distinct hepatic lipidomes that could offer 
insights to the underlying mechanisms. In 
addition, while excess energy intake is the 
major risk factor for NAFLD, not all obese 
subjects develop NAFLD (Yki-Järvinen, 
2014). Study IV was undertaken to 
investigate the effect of dietary 
macronutrient composition on the 
metabolic effects of a hypercaloric diet. 
6.1. ‘METABOLIC NAFLD’ 
 
In study I, the human liver lipidome was 
analyzed in two subtypes of NAFLD, one 
defined based on insulin resistance 
(’Metabolic NAFLD’) and the other based 
on the PNPLA3 genotype at rs738409 
(’PNPLA3 NAFLD’, vide infra). Both 
subtypes of NAFLD had a similar increase 
in liver fat content and prevalence of 
NASH as compared to respective control 
groups. In addition, the subtypes were 
characterized by almost identical sample 
size, age, gender distribution and body 
mass index, thereby allowing study of 
effects of insulin resistance and those of 
the PNPLA3 I148M gene variant on the 
human liver lipidome independent of 
these confounders (Table 1, Figure 5).   
In ’Metabolic NAFLD’, the liver lipidome 
was enriched in saturated and 
monounsaturated TGs and free fatty acids 
(Figure 7). The liver in ‘Metabolic 
NAFLD’ was also characterized by a 
marked increase in insulin resistance-
inducing DAGs and ceramides 
synthesized via the de novo ceramide 
synthetic pathway (Figures 8 and 9). 
 
To investigate the effect of insulin 
resistance on the human liver lipidome in 
‘Metabolic NAFLD’, the subjects were 
divided based on median HOMA-IR, a 
marker of insulin resistance. Median 
value was selected because of the lack of 
universally accepted cutoff threshold of 
HOMA-IR between insulin-sensitive and 
insulin-resistant subjects. 
 
By definition, subjects in the ‘High 
HOMA-IR’ group were more insulin 
resistant than those in the ‘Low HOMA-
IR’ group (Table 1). The ‘High HOMA-
IR’ group was characterized by a 3-fold 
increase in liver fat content and a higher 
plasma triglyceride concentrations and 
lower plasma HDL cholesterol 
concentrations as compared to the ‘Low 
HOMA-IR’ (Table 1, Figure 5). These 
data are consistent with previous reports 
showing associations between insulin 
resistance, liver fat content, 
hypertriglyceridemia and low HDL 
cholesterol concentrations (Seppälä-
Lindroos et al., 2002; Kotronen et al., 
2007). 
 
Although there are no previous reports 
regarding the human liver lipidome in 
NAFLD defined by insulin resistance, the 
enrichment in saturated and 
monounsaturated lipid species is 
consistent with a previous study with 18 
subjects with NAFLD and 9 controls (Puri 
et al., 2007). The liver biopsies were 
obtained after an overnight fast, when 
adipose tissue lipolysis and de novo 
lipogenesis are the major sources of fatty 
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acids for synthesis of IHTGs (Donnelly et 
al., 2005). The majority of the fatty acids 
in adipose tissue TGs are saturated 
(approximately 25%) or monounsaturated 
(approximately 50%) (Hodson et al., 
2008). DNL produces exclusively 
saturated fatty acids from non-lipid 
substrates such as simple sugars and 
amino acids (Hellerstein et al., 1996). 
These saturated fatty acids can be 
metabolized into monounsaturated fatty 
acids by stearoyl-CoA desaturase 1 (SCD-
1) (Hellerstein et al., 1996). Thus, the 
increase in free saturated and 
monounsaturated fatty acids in the ’High 
HOMA-IR’ vs. the ’Low HOMA-IR’ group 
could reflect increases in both lipolysis 
and DNL. These data are consistent with 
previous studies reporting impaired 
insulin-mediated suppression of adipose 
tissue lipolysis (Marchesini et al., 2001; 
Seppälä-Lindroos et al., 2002; Bugianesi 
et al., 2005; Gastaldelli et al., 2007; 
Kotronen et al., 2008) and increased 
rates of hepatic DNL (Diraison et al., 
2003; Lambert et al., 2014) in subjects 
with high liver fat content as compared to 
those with low liver fat content.  
 
The concentrations of virtually all hepatic 
ceramide species were significantly 
increased in the ‘High HOMA-IR’ vs. the 
‘Low HOMA-IR’ group (Figure 8). 
Previous human studies have failed to 
detect correlation between hepatic 
ceramide concentrations and insulin 
resistance. This may be due to small 
sample sizes in these studies, with 37 
(Kumashiro et al., 2011), 16 (Magkos et 
al., 2012) and 29 (ter Horst et al., 2017) 
subjects, i.e. much smaller than in the 
present study (N=125). Most importantly, 
the former two studies did not measure 
the concentrations of individual species of 
ceramides, of which only distinct ones 
have been associated with insulin 
resistance in mice (Hla et al., 2014; Xia et 
al.,2015). Only one study in addition to 
the present study has examined the 
correlation of individual hepatic ceramide 
species and insulin resistance in humans 
(ter Horst et al., 2017). In this study, both 
total hepatic ceramides and total hepatic 
DAGs tended to be higher in the insulin 
resistant as compared to insulin sensitive 
subjects, but statistical significance was 
not reached in either comparison, and no 
correlation was found between hepatic 
ceramide species and insulin resistance. 
The authors concluded that these 
conflicting results may be due to 
experimental techniques or limited 
sample size (ter Horst et al., 2017).   
 
The de novo ceramide synthetic pathway, 
as determined from increased hepatic 
concentrations of 4 out of 5 
dihydroceramides, was increased in the 
‘High HOMA-IR’ as compared to the ‘Low 
HOMA-IR’ group, while markers of the 
other pathways were unchanged (Figure 
9). This is consistent with the increase in 
the availability of the first substrate in 
this pathway, i.e. free palmitate (C16:0). 
There are no previous reports on the 
distinct ceramide synthetic pathways in 
the human liver. In high-fat diet-fed mice, 
both whole-body and liver-specific 
knockout of CerS6 decreases 
concentrations of hepatic C16:0-
ceramides (i.e. ceramides with C16:0 
fatty-acyl group) and increases fatty acid 
oxidation and glucose tolerance (Turpin 
et al., 2014). Along the same lines, 
heterozygous CerS2 knockout mice fed a 
high-fat diet have increased hepatic 
C16:0-ceramide concentrations, 
decreased lipid oxidation, decreased 
glucose tolerance and hepatic steatosis 
(Raichur et al., 2014). In addition, 
knockdown of CerS6 by anti-sense 
oligonucleotides in mice decreases CerS6 
expression by ~80% selectively in the 
liver and decreases hepatic C16:0-
ceramide concentration by ~50% and 
increases glucose tolerance by ~50% as 
compared to control mice (Bielohuby et 
al., 2017). The increase in the C16:0-
dihydroceramides and C16:0-ceramides 
in the human liver in the ‘High HOMA-
IR’ as compared to the ‘Low HOMA-IR’ 
group (Figure 9) is compatible with 
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these reports in mice.  
 
Hepatic ceramide concentrations may 
also increase if their degradation is 
reduced. Adiponectin, an insulin-
sensitizing adipokine (Scherer et al., 
1995), regulates ceramide metabolism via 
ceramidase activity (Holland et al., 2011, 
Holland et al., 2017) (Figure 3). Serum 
concentrations of adiponectin were lower 
in the ‘High HOMA-IR’ group as 
compared to the ‘Low HOMA-IR’ group 
(Figure 5), which could contribute to the 
differences in hepatic concentrations of 
ceramides in the groups. The present data 
are consistent with a recent study in mice, 
in which overexpression of acid 
ceramidase in the liver was characterized 
by reduced hepatic concentrations of 
C16:0-, C18:0- and C20:0-ceramides, 
decreased liver fat content and hepatic 
glucose production, and improved glucose 
tolerance as compared to control mice 
(Xia et al., 2015).  
 
The concentrations of 4 out of 5 hepatic 
DAG species (DAG(32:1), DAG(34:1), 
DAG(36:2) and DAG(36:3)) were 
increased in the ‘High HOMA-IR’ as 
compared to the ‘Low HOMA-IR’ group. 
Subjects with NAFLD have been 
previously shown to have increased 
hepatic DAG concentrations as compared 
to healthy controls (Kotronen et al., 
2009; Puri et al., 2007). One study 
reported an increase in hepatic DAGs 
with 32 to 36 carbons and 0 to 3 double 
bonds in steatotic as compared to normal 
liver. These data are consistent with the 
present data, and also with previous 
smaller studies reporting correlation of 
hepatic DAG concentrations and insulin 
resistance in 37 (Kumashiro et al., 2011), 
16 (Magkos et al., 2012) and 29 (ter Horst 
et al., 2017) subjects. The latter study 
reported the correlation between 13 
distinct cytosolic DAG species and insulin 
resistance, and found significant 
correlation in four: DAG(34:1), 
DAG(36:0), DAG(32:0) and DAG(36:2), 
two of which are the same as those 
reported in the present study (DAG(34:1) 
and DAG(36:2)). 
 
A limitation in the present study, 
although representing the largest hitherto 
performed study on the human liver 
lipidome, is that the hepatic lipids were 
not measured in different subcellular 
compartments, in which they may confer 
differential metabolic effects. Also, some 
bioactive lipid species, such as 
eicosanoids, were not analysed in the 
present study. In addition, the majority of 
the subjects in the present study were 
women (66 %), which is not 
representative of epidemiologic studies, 
which report NAFLD to be more 
prevalent in men than in women (Lazo et 
al., 2013). However, the gender 
distributions were similar between the 
subgroups (Table 1). Another limitation 
is that the subjects were bariatric surgery 
patients, and therefore morbidly obese, 
which is not representative of population. 
However, this can also be considered as 
strength since all subjects were very 
similar with respect to body mass index, 
thus allowing analyses independent of 
BMI.  
 
In summary, the present data show that 
insulin resistance is associated with an 
excess of saturated and monounsaturated 
free fatty acids and triglycerides as well as 
ceramides and DAGs in the human liver. 
Ceramides originate especially from the 
de novo ceramide synthetic pathway. 
These data are consistent with previous 
reports in mice and with several known 
pathophysiological features of the human 
‘Metabolic NAFLD’.  
6.2. 'GENETIC NAFLD' 
6.2.1. ‘PNPLA3 NAFLD’ 
 
In a contrast to ‘Metabolic NAFLD’, the 
liver in ’PNPLA3 NAFLD’ was enriched 
with polyunsaturated TAGs with no 
changes in free fatty acids or ceramides 
(Figures 7 and 8).  
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To investigate the effect of the PNPLA3 
I148M variant on the human liver 
lipidome in ‘PNPLA3 NAFLD’, the 
subjects were divided based on their 
PNPLA3 genotype at rs738409. 
Approximately 49 % of the study subjects 
carried the variant allele, in keeping with 
previous reports showing 20-50 % of all 
subjects carry this gene variant (Romeo et 
al., 2008). The ‘PNPLA3148MM/MI’ group 
(variant allele carriers) as compared to 
‘PNPLA3148II’ group (non-carriers), had a 
similarly 3-fold higher liver fat content as 
the ‘High HOMA-IR’ (‘Metabolic 
NAFLD’) compared to the ‘Low HOMA-
IR’ group (Table 1, Figure 5). In 
contrast to the ‘Metabolic NAFLD’, there 
were no differences in insulin resistance 
as determined from HOMA-IR, Matsuda 
insulin sensitivity index and the glucose 
and insulin concentrations during the 
oral glucose tolerance test, or in 
concentrations of plasma lipids and 
serum adiponectin (Table 1, Figure 5). 
This is consistent with a recent systematic 
review of 14 studies showing that insulin 
sensitivity, as determined by HOMA-IR, 
the hyperinsulinemic-euglycemic clamp 
method, or fasting or post-glucose insulin 
or glucose concentrations, does not differ 
between carriers and non-carriers (Petäjä 
et al., 2016). Regarding plasma 
triglycerides, the present study supports 
the majority of previous studies reporting 
unchanged total triglyceride 
concentrations in variant allele carriers 
(Petäjä et al., 2016).  
 
Livers of the variant allele carriers were 
markedly enriched with polyunsaturated 
TGs as compared to non-carriers (Figure 
7). One previous study characterized 
relative fatty acid composition of hepatic 
TGs using thin layer chromatography 
between 19 carriers of the PNPLA3 I148M 
variant allele and 33 non-carriers 
undergoing liver surgery (Peter et al., 
2014). A decrease in the relative 
abundance of stearic acid was found in 
keeping with the present data. However, 
the subjects in this study were not 
characterized with respect to insulin 
resistance or hepatic ceramides and the 
hepatic TGs were not analyzed with 
respect to number of carbons and double 
bonds. 
 
Concentrations of hepatic free fatty acids, 
which accounted for 80% of previously 
described free fatty acids and 87% of all 
free polyunsaturated fatty acids in the 
human liver (Puri et al., 2007), were 
unchanged between the PNPLA3 groups. 
These data are consistent with a previous 
report showing unchanged adipose tissue 
insulin sensitivity in carriers as compared 
to non-carriers of the variant (Kotronen 
et al., 2009), and supports the idea that 
the increase in polyunsaturated hepatic 
TGs in ‘PNPLA3 NAFLD’ is induced by 
mechanisms other than substrate 
availability.  
 
One study suggested that PNPLA3 
functions as a lysophosphatidic acid 
acyltransferase (LPAAT) converting 
lysophosphatidic acid into phosphatitidic 
acid with palmitoyl-, oleyl-, linoleyl- and 
arachidonyl-CoAs as the preferred 
substrates, and the I148M variant to 
increase this activity by two-fold (Kumari 
et al., 2012). The increase in multiple 
hepatic polyunsaturated TGs and in one 
polyunsaturated DAG species 
(DAG(36:3)) in carriers as compared to 
non-carriers could be consistent with this 
study. However, subsequent studies have 
failed to replicate the LPAAT activity of 
PNPLA3 (Li et al., 2012; BasuRay et al., 
2017). 
 
In addition to LPAAT activity, PNPLA3 
has been reported to hydrolyze TGs, 
DAGs, monoacylglycerols and oleyl-CoA, 
and the I148M to impair these functions 
(Huang et al., 2011). Amongst distinct TG 
species, PNPLA3 hydrolysed TGs 
containing C14:0, C16:0, C18:1, C18:2 and 
C20:4, of which TGs containing C18:1 
were the preferred substrates (Huang et 
al., 2011). This mechanism could 
contribute to the hepatic TG profile seen 
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in carriers of the PNPLA3 I148M variant.  
 
However, since neither the deletion nor 
the overexpression of the wild-type 
PNPLA3 results in hepatic steatosis, the 
effects of the PNPLA3 I148M variant may 
not be attributable simply to a loss or gain 
of the activity of the wild type PNPLA3 
(Chen et al., 2011; Basantani et al., 2011; 
Li et al., 2012). Recently, the I148M 
variant was suggested to disrupt 
proteosomal degradation of PNPLA3, 
leading to accumulation of the PNPLA3 
protein in lipid droplets, and thereby to 
induce steatosis by impairing 
mobilization of TGs from lipid droplets 
(BasuRay et al., 2017). The exact 
pathophysiological mechanism by which 
PNPLA3 I148M induces NAFLD in 
humans remains to be solved. 
 
Etiology of liver injury. The subjects with 
’Metabolic NAFLD’ and ’PNPLA3 NAFLD’ 
had an equal prevalence of NASH (Table 
1) despite very different hepatic TG and 
bioactive lipid compositions (Figures 7 
and 8). Thus, bioactive lipids such as 
ceramides and DAGs do not seem to be 
necessary for the development of NASH 
in carriers of the PNPLA3 I148M variant. 
Previous studies have established that the 
PNPLA3 gene variant predisposes to 
NASH independent of features insulin 
resistance (Sookoian et al., 2011). Simple 
steatosis without hepatocellular injury 
has been shown in a paired-biopsy study 
to predict the development of NASH 
(McPherson et al., 2015). In NASH, fat 
accumulates first in the perivenous area 
in Zone 3 (Brunt et al., 1999), which is 
characterized by impaired 
microcirculation (Farrell et al., 2008) and 
a lower oxygen concentration as 
compared to periportal areas 
(Jungermann et al., 2000). Ballooning 
necrosis, the distinct feature of NASH, 
occurs amidst these fat-laden hepatocytes 
(Brunt et al., 1999). The PNPLA3 gene 
variant could therefore increase the risk 
of NASH simply by increasing steatosis.  
 
In summary, the human liver lipidome in 
‘PNPLA3 NAFLD’ is enriched with 
polyunsaturated TGs. In contrast to the 
‘Metabolic NAFLD’, the ‘PNPLA3 NAFLD’ 
is not enriched in bioactive lipids 
although both types of NAFLD similarly 
increase the prevalence of NASH, 
suggesting that these lipids are not 
required for the development of NASH. 
6.2.2. ‘MBOAT7 NAFLD’ 
 
In study II, the MBOAT7 variant allele at 
rs641738 was associated with increased 
severity of NAFLD in 115 morbidly obese 
subjects. Histological characteristics that 
were significantly altered included 
steatosis, necroinflammation and fibrosis. 
Especially the prevalence of moderate or 
more severe liver fibrosis increased as a 
function of the number of variant alleles 
carried (Figure 6). The groups based on 
the MBOAT7 genotype were similar with 
respect to body mass index, waist 
circumference, and circulating 
concentrations of insulin, glucose and 
lipids. Regarding hepatic lipidome, the 
variant allele carriers had changes 
exclusively in polyunsaturated 
phosphatidylinositols. Concentrations of 
all other lipid classes in the liver were 
unchanged. Specifically, the hepatic 
concentrations of PI(36:4) and PI(38:3) 
were reduced, while that of PI(40:5) was 
increased in carriers of the variant allele 
as compared to non-carriers. 
 
The findings are consistent with recent 
studies reporting increased severity of 
NAFLD in carriers of the MBOAT7 
variant allele at rs641738 (Mancina et al., 
2016; Krawczyk et al., 2017). The increase 
in the prevalence of moderate or more 
severe liver fibrosis is of particular 
concern, since fibrosis has been 
repeatedly shown to be the major 
determinant of overall and liver-related 
mortality in subjects with NAFLD (Dulai 
et al., 2017; Hagström et al., 2017). 
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The present data are also compatible with 
previous studies with up to 4,591 subjects 
reporting no differences in body 
composition, markers of insulin 
sensitivity or circulating lipids in carriers 
as compared to non-carriers of the 
MBOAT7 variant allele (Mancina et al., 
2016; Di Costanzo et al., 2018). Despite 
an increased risk and severity of NAFLD, 
and in contrast to the ‘Metabolic NAFLD’, 
carriers of the variant allele have an 
unaltered risk of cardiovascular disease as 
compared to non-carriers (Simons et al., 
2017). This dissociation may in part be 
due to unaltered insulin sensitivity and 
circulating lipids, and lack of change in 
harmful bioactive lipids in the liver such 
as ceramides, which are associated with 
risk of cardiovascular disease (Summers, 
2018).   
 
In addition to replicating results from 
earlier studies, study II extends previous 
data by showing distinct alterations in 
polyunsaturated PIs in livers of carriers of 
the MBOAT7 variant allele. MBOAT7, 
also known as lysophosphatidylinositol 
acyltransferase 1 (LPIAT1), functions in 
the acyl-chain remodeling of PIs and 
incorporates a polyunsaturated 
arachidonic acid into a lyso-PI to form a 
polyunsaturated PI (Lee et al., 2008). 
Carriers of the variant allele have lower 
expression of MBOAT7 in the liver as 
compared to non-carriers, and therefore 
are hypothesized to have decreased 
activity of this enzyme (Mancina et al., 
2016).  
 
In theory, decreased activity of an 
arachidonic acid-preferring 
lysophosphatidylinositol acyltransferase 
could increase the availability of free 
arachidonic acid (Robichaud et al., 2015). 
Arachidonic acid activates collagen gene 
expression time- and dose-dependently in 
rat stellate cells overexpressing ethanol-
inducible cytochrome P450 2E1 (Nieto et 
al., 2000). In contrast, knockout of group 
IVA phospholipase A2, which removes 
arachidonic acid from phospholipids, 
reduces the availability of free 
arachidonic acid and prevents stellate cell 
activation and hepatic macrophage 
infiltration in C57BL/6JJcl mice injected 
with carbon tetrachloride or fed a high-
fat, high-cholesterol diet (Ishihara et al., 
2012). Arachidonic acid can be 
metabolized into bioactive lipid mediators 
such as eicosanoids, which concentrations 
are increased in the circulation of subjects 
with NASH (Puri et al., 2009; Loomba et 
al., 2015). Further studies are needed to 
determine whether the availability of free 
arachidonic acid or some other 
mechanism mediates the increased 
susceptibility to NAFLD and liver fibrosis 
due to altered hepatic 
phosphatidylinositol remodeling.  
 
To summarize, study II confirms that the 
common variant in MBOAT7 at rs641738 
associates with histologically determined 
liver damage, particularly significant 
fibrosis. The study extends previous data 
by showing that altered polyunsaturated 
PI metabolism characterizes livers of 
carriers of the variant allele. These data 
are compatible with reports in plasma 
and a role for MBOAT7 in hepatic 
phosphatidylinositol remodeling 
(Mancina et al., 2016). 
6.2.3. ‘TM6SF2 NAFLD’ 
 
Carriers of the TM6SF2 E167K variant 
allele had higher hepatic TGs and CEs but 
lower hepatic PCs due to a decrease in 
polyunsaturated PCs. In addition to PCs, 
polyunsaturated fatty acyl-groups were 
also deficient hepatic TGs, but relatively 
enriched amongst hepatic free fatty acids. 
Consistent with this in vivo finding, 
knockdown of TM6SF2 in HuH-7 cells 
decreased incorporation of PUFAs into 
PCs and TGs in vitro. In the human liver, 
TM6SF2 was downregulated in variant 
allele carriers and co-expressed with 
genes regulated by PUFAs. Thus, TM6SF2 
downregulation may impair hepatic lipid 
synthesis from PUFAs, thereby leading to 
a relative deficiency of polyunsaturated 
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PCs and a relative excess of free PUFAs, 
both of which may disrupt hepatic export 
of TGs and CEs and lead to their 
accumulation (Noga et al., 2003; Pan et 
al., 2004). 
 
To investigate the effect of the TM6SF2 
E167K variant on the human liver 
lipidome in ‘TM6SF2 NAFLD’, the 
subjects were divided based on their 
TM6SF2 genotype at rs58542926 
(‘TM6SF2EK/KK’, variant allele carriers and 
‘TM6SF2EE’, non-carriers). Carriers of the 
variant variant allele had 2-fold higher 
liver fat content as compared to non-
carriers (Table 1). In contrast to 
‘Metabolic NAFLD, the groups did not 
differ with respect to insulin sensitivity as 
determined by HOMA-IR or the Matsuda 
index (Table 1). Preserved insulin 
sensitivity is consistent with previous 
reports (Kozlitina et al., 2014; Zhou et al., 
2015; Sookoian et al., 2015; Goffredo et 
al., 2016; Grandone et al., 2016; Eslam et 
al., 2016; Mancina et al., 2016; Musso et 
al., 2016; Dongiovanni et al., 2015; Kim 
et al., 2017; Petäjä et al., 2016). The 
distribution of the PNPLA3 genotype was 
also similar between the groups.  
 
Consistent with previous studies 
involving up to 400 subjects (Zhou et al., 
2015; Sookoian S et al., 2015; Musso et 
al., 2016; Goffredo et al., 2016), fasting 
plasma triglyceride concentrations were 
similar in the TM6SF2 genotype groups 
(Table 1). However, in larger studies, the 
variant allele has been associated with 
decreased concentrations of plasma 
triglycerides (Kozlitina et al., 2014; 
Grandone et al., 2016; Eslam et al., 2016; 
Mancina et al., 2016; Dongiovanni et al., 
2015; Kim et al., 2017; O’Hare et al., 
2017; Liu et al., 2017; Di Costanzo et al., 
2018). In the present study, variant allele 
carriers displayed relative deficiency of 
circulating polyunsaturated TGs and PCs 
as compared to non-carriers. This 
deficiency in the face of increased hepatic 
TG content suggests insufficient hepatic 
lipid export, consistent with previous 
studies (Kozlitina et al., 2014; 
Mahdessian et al., 2014; Musso et al., 
2016; Musso et al., 2017; O’Hare et al., 
2017; Kim et al., 2017).  
 
Livers of TM6SF2 E167K variant carriers 
had a relative deficiency of 
polyunsaturated TG and PC species, while 
the relative abundance of free 
polyunsaturated fatty acid C20:4 was 
increased as compared to non-carriers 
(Figure 10). In TM6SF2 silenced HuH-7 
cells, the incorporation of PUFAs into 
both PCs and TGs were decreased 
(Figure 10). These data suggest that the 
TM6SF2 E167K variant may coordinate 
the channeling of PUFAs into PC and TG 
synthesis. In keeping with these findings 
in vivo in humans and in vitro in 
hepatoma cells, a deficiency in the 
relative abundance of polyunsaturated 
fatty acids C20:4 and C22:6 was found in 
total hepatic lipids in TM6SF2 knockout 
mice (Smagris et al., 2016). 
 
This channeling starts by activation of a 
free polyunsaturated fatty acid into a fatty 
acyl-CoA by one of numerous acyl-CoA 
synthetase (ACS) enzymes (Cooper et al., 
2015). These isoenzymes have different 
substrate preferences and subcellular 
localisations, and thereby channel distinct 
fatty acids into different metabolic 
pathways (Ellis et al., 2010; Cooper et al., 
2015). For example, knockdown of acyl-
CoA synthetase long-chain family 
member 3 (ACSL3), which is expressed in 
the liver and intestine and localized in the 
endoplasmic reticulum similarly to 
TM6SF2, decreases incorporation of 
unsaturated fatty acids into PC, causes PC 
deficiency, and inhibits the secretion of 
apolipoprotein B, the major component of 
VLDL, in HuH-7 cells (Yao et al., 2008).  
 
In humans, large, lipid-rich VLDL1 
particles are markedly deficient in the 
circulation in the postprandial state in 
TM6SF2 E167K variant allele carriers 
compared to non-carriers (Musso et al., 
2016). Another study reported that 
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carriers of the variant have lower 
circulating concentration of 
apolipoprotein B100 as well as 
concentrations of triglycerides and 
cholesterol in liver-derived VLDL and 
LDL particles (Kim et al., 2017). This 
deficiency could result from defects in the 
assembly, secretion, or pre-secretory 
degradation of VLDL particles. The 
assembly of VLDL has two major steps 
(Olofsson et al., 2012). First, a nascent 
VLDL particle is synthesized in the ER, 
where it matures into a relatively lipid-
poor small VLDL2 particle (Olofsson et 
al., 2012). This small particle is 
translocated to the Golgi complex and 
may be secreted as such, or undergo a 
second lipidation step in which more TGs 
and CEs are added to the particle to form 
a large, lipid-rich VLDL1 particle 
(Olofsson et al., 2012). VLDL particles 
can be degraded before being secreted via 
mechanisms such as post-endoplasmic 
reticulum pre-secretory proteolysis  (Pan 
et al., 2008). 
 
A relative deficiency of PCs and a relative 
excess of free polyunsaturated fatty acids 
could interfere with VLDL metabolism. 
For example, in isolated mouse 
hepatocytes, decreased synthesis of PCs 
due to knockout of PEMT increases the 
post-ER pre-secretory degradation of 
VLDL particles, and decreases the 
secretion of especially highly-lipidated 
VLDL particles (Noga et al., 2003). 
Similarly, excess polyunsaturated fatty 
acids induce post-ER pre-secretory 
degradation of VLDL particles in rat 
hepatoma or primary rodent hepatocytes 
by inducing lipid peroxidation and 
oxidative stress (Pan et al., 2004). Thus, 
both PC deficiency and the relative excess 
in polyunsaturated FFA content in the 
liver in TM6SF2 variant carriers might 
lead to accumulation of TGs and CEs via 
degradation of lipid-rich VLDL particles, 
consistent with previous reports (Musso 
et al., 2016; Kim et al., 2017).    
In the human liver, mRNA expression of 
TM6SF2 was decreased in the E167K 
variant carriers, consistent with a 
previous report (Mahdessian et al., 2014). 
The expression of genes related to 
lipogenesis such as fatty acid synthase, 
acetyl-CoA carboxylase 2 were 
decreased, while that related to 
mitochondrial fatty acid oxidation, i.e. 
carnitine palmitoyltransferase I, was 
increased. These data are in keeping with 
a decrease in absolute concentrations of 
saturated and monounsaturated free fatty 
acids in the liver in carriers of the E167K 
variant in the present study. In addition, 
the expression of apolipoprotein C-III, 
which enhances the lipidation of VLDL 
particles and inhibits the lipoprotein 
remnant uptake by the liver, was 
decreased in variant carriers, providing 
another possible mechanism for the 
phenotype seen in E167K variant carriers 
(i.e. decreased plasma triglycerides in the 
face of increased liver triglycerides).  
 
Interestingly, all of the observed changes 
in hepatic gene expression can be induced 
by polyunsaturated fatty acids (Sampath 
et al., 2005), which are ligands for 
transcriptional factors such as 
peroxisome proliferator-activated 
receptor alpha (Forman et al., 1997). 
Indeed, the hepatic expression of 
peroxisome proliferator-activated 
receptor alpha was increased in the 
variant carriers, who had excess relative 
abundance of polyunsaturated fatty acids 
in the liver.  
 
Interestingly, silencing of acyl-CoA 
synthetase long-chain family member 3 
(ACSL3), which is expressed in the liver 
and intestine and localized in the 
endoplasmic reticulum similarly to 
TM6SF2, decreases incorporation of 
unsaturated fatty acids into PCs, causes 
PC deficiency and a relative excess of free 
unsaturated fatty acids, and inhibits 
secretion of apolipoprotein B in HuH-7 
cells (Yao et al., 2008). Silencing of this 
gene in rat hepatocytes decrease lipogenic 
gene expression and de novo lipogenesis 
(Bu et al., 2009). Together, these data 
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support the idea that differences in 
hepatic gene expression in carriers of the 
TM6SF2 E167K variant allele may have 
been driven by excess polyunsaturated 
fatty acids secondary to their impaired 
incorporation into complex lipids. 
 
Consistently with previous studies (Liu et 
al., 2014; O’Hare et al., 2017), carriers of 
the TM6SF2 E167K variant allele tended 
to have increased liver fibrosis as 
compared to non-carriers (60 vs 31 %, 
p=0.09). The relative deficiency of PC and 
the relative excess of arachidonic acid 
found in the present study could 
contribute to the development of NASH 
and fibrosis by several mechanisms. 
Deficiency of hepatic PCs induced by a 
methionine-choline-deficient diet induces 
lipid peroxidation, stellate cell activation 
and fibrosis in rats (George et al., 2003). 
As already discussed in section 6.2.2., 
excess arachidonic acid can stimulate 
fibrogenesis by regulating stellate cell 
activation.  
 
Arachidonic acid can be metabolized into 
proinflammatory eicosanoids (Cooper et 
al., 2015), which circulating 
concentrations are increased in subjects 
with NASH (Puri et al., 2007; Loomba et 
al., 2015). Expression of arachidonate 5-
lipoxygenase was increased in the 
TM6SF2 variant allele carriers in the 
present study. Interestingly, the 
corresponding enzyme produces 
arachidonic acid-derived 
proinflammatory eicosanoids such as 5-
hydroxyeicosatetraenoic acid, which 
appear increased in NASH (Puri et al., 
2007; Loomba et al., 2015). 
 
As a limitation, even though representing 
the largest study on the human liver 
lipidome, the number of variant allele 
carriers was low given the variant allele 
frequency of 7%. Thus, the observed 
differences may underestimate true 
differences between carriers and non-
carriers of the TM6SF2 E167K gene 
variant.  
 
To summarize, incorporation of 
polyunsaturated fatty acids into complex 
lipids is impaired in the livers of the 
TM6SF2 E167K gene variant carriers and 
leads to a relative deficiency of 
polyunsaturated PCs and a relative excess 
of polyunsaturated FFA in the human 
liver. These changes, based on a large 
body of experimental evidence, could 
impair VLDL lipidation via increased 
degradation, and explain the phenotype 
characterizing the carriers of the TM6SF2 
E167K variant, i.e. hepatic steatosis, lack 
of circulating hypertriglyceridemia and an 
increased risk of NASH. 




Even though obesity is the main acquired 
risk factor of NAFLD, it does not develop 
in all overweight subjects (Browning et 
al., 2004; Rosqvist et al., 2014). In study 
IV, the aim was to examine whether 
overfeeding-induced pathways of hepatic 
fatty acid supply and insulin resistance 
depend on the macronutrient 
composition of the diet. Consumption of a 
hypercaloric diet enriched either with 
saturated (SAT) or unsaturated fat 
(UNSAT), or simple sugars (CARB) for 3 
weeks increased IHTG content. The 
macronutrient composition of the diet 
had a distinct effect on pathways 
contributing to hepatic fatty acids. Only 
the CARB diet induced de novo 
lipogenesis, while only the SAT diet 
stimulated adipose tissue lipolysis 
(Figure 12), which may explain why this 
diet increased IHTG content more than 
the UNSAT diet in the face of similar 
energy excess. The SAT diet was also the 
only diet to induce insulin resistance, 
endotoxemia and an increase in plasma 
ceramides (Figure 12) during the 3-week 
overfeeding period. The diets had also 
markedly different  effects on the adipose 
tissue transcriptome (Figure 13). 
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The fatty acid composition of VLDL-TGs 
secreted from the liver after an overnight 
fast is similar to hepatic TGs and reflects 
the composition of their sources 
(Donnelly et al., 2005). In study IV, the 
fatty acid composition of VLDL-TGs was 
used as a biomarker of compliance and of 
the fatty acid composition of hepatic TGs. 
The SAT diet increased the relative 
abundance of saturated fatty acids and 
decreased that of polyunsaturated fatty 
acids while the UNSAT diet had an 
opposite effect (Figure 11). Similarly to 
the SAT diet, the CARB diet increased the 
relative abundance of saturated fatty 
acids, which are the exclusive products of 
DNL (Sevastianova et al., 2012), and 
decreased that of polyunsaturated fatty 
acids in VLDL-TG. These data 
demonstrate that subjects were 
compliant, and are novel in showing that 
diets with different macronutrient 
composition have distinct effects on the 
fatty acid composition of hepatic TGs as 
determined from that in VLDL-TG. 
Moreover, compliance was also confirmed 
by analysis of dietary records. 
6.3.1 Effects on sources of hepatic 
fatty acids 
 
It is well established that overfeeding 
increases IHTG content (Kechagias et al., 
2008; van der Meer et al., 2008; 
Bortolotti et al., 2009; Sobrecases et al., 
2010; Sevastianova et al., 2012; Rosqvist 
et al., 2014; Fabbrini et al., 2016). Study 
IV extends previous findings by showing 
that the magnitude and mechanisms by 
which overfeeding influences IHTG 
content depends on the composition of 
the diet.  
 
In the present study, the SAT diet 
increased IHTG content significantly 
more than the UNSAT diet in the face of 
similar hypercaloric energy intakes and 
changes in body weight. This greater 
increase in IHTG in the SAT group as 
compared to the UNSAT group is in line 
with a previous report that overfeeding a 
diet enriched with saturated as compared 
to polyunsaturated fat induces a greater 
increase in IHTG (Rosqvist et al., 2014).  
In an isocaloric study comparing high-
saturated fat/low-polyunsaturated fat diet 
to low-saturated fat/high-
polyunsaturated fat, the former increased 
liver fat content as compared to the latter 
(Bjermo et al., 2012). Cross-sectionally, 
higher intakes of saturated fatty acids and 
cholesterol and lower intakes of fiber, 
protein and polyunsaturated fatty acids 
characterize subjects with NASH as 
compared to age-, gender-, and body 
mass index-matched controls (Musso et 
al., 2003). Together these studies suggest 
that the macronutrient composition of the 
diet influences the magnitude of ectopic 
fat deposition in the liver, and that 
saturated fat induces a greater 
accumulation of IHTG than unsaturated 
fat.  
 
Regarding the mechanisms underlying 
the increased deposition of fatty acids 
into IHTGs during overfeeding, the fatty 
acid sources contributing to IHTG need to 
be considered. Direct measurements 
using stable isotopes in humans have 
shown that the majority of the fatty acids 
in IHTGs in subjects with NAFLD 
originate from lipolysis (59%) and DNL 
(26%) (Donnelly et al., 2005).  
 
In the present study, adipose tissue 
lipolysis increased in response to the SAT 
diet. There are no previous overfeeding 
studies measuring lipolysis in humans, 
but in mice high-fat feeding stimulates 
lipolysis (Perry et al., 2015). A saturated 
fat-enriched diet has been reported to 
increase the expression of inflammation-
related genes as compared to a diet 
enriched with monounsaturated fat in a 
parallel controlled-feeding trial with 20 
abdominally obese subjects (van Dijk et 
al., 2009). In keeping with these data, the 
SAT diet induced upregulation in multiple 
inflammation-related pathways, such as 
‘pathogenic E. coli infection’, ‘natural 
killer cell mediated cytotoxicity’, ‘NOD 
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like receptor signaling pathway’ and 
‘leukocyte transendothelial migration’ in 
the adipose tissue. The ability of the SAT 
but not UNSAT or CARB diet to stimulate 
lipolysis, the major contributor of fatty 
acids in IHTG, could explain why the SAT 
diet increased IHTG to a greater extent 
than the two other diets.   
 
Overfeeding of simple sugars has been 
shown to increase DNL and IHTGs 
(Sevastianova et al., 2012). DNL produces 
exclusively saturated fatty acids 
(Hellerstein et al., 1996). Consistent with 
these data, the CARB diet increased 
hepatic DNL (Figure 12) and the relative 
abundance of saturated fatty acids in 
VLDL-TG (Figure 11). However, the 
stimulation of DNL was not able to 
increase IHTG content to the same extent 
as the SAT diet, which stimulated adipose 
tissue lipolysis. These results are 
consistent with isocaloric studies showing 
that high-fat, low-carbohydrate diets 
increase IHTG more than low-fat, high-
carbohydrate diets (Westerbacka et al., 
2005; van Herpen et al., 2011; 
Utzschneider et al., 2013) in humans. The 
carbohydrates consumed in the present 
study were simple sugars, which may 
confer different metabolic effects as 
compared to complex carbohydrates. 
Therefore the data may not be 
generalizable to all carbohydrates. 
 
The UNSAT diet did not change the rate 
of DNL, but surprisingly and in contrast 
to the other diets, decreased lipolysis 
during hyperinsulinemia (Figure 12). 
These results and the predominant 
increase in the abundance of 
polyunsaturated C18:2 (Figure 11), 
which cannot be synthesized 
endogenously, in VLDL-TG, suggest that 
the increase in IHTG during the UNSAT 
diet was mainly derived from dietary fatty 
acids. The UNSAT diet induced 
upregulation in distinct pathways in 
adipose tissue, such as ‘oxidative 
phosphorylation’ (Figure 13). This 
pathway has previously been reported to 
be downregulated in omental adipose 
tissue in three obese subjects as 
compared to three gender-matched 
controls (Walewski et al., 2010), and 
upregulated in subcutaneous adipose 
tissue of 47 healthy men in response to a 
6-month exercise intervention (Rönn et 
al., 2014), implying that it might be a 
metabolically beneficial pathway. 
Polyunsaturated fatty acids suppress 
adipose tissue lipolysis via activation of 
GPR120 receptors in mice (Wang et al., 
2017), but the exact mechanism in 
humans is not known. 
6.3.2 Effects on insulin resistance 
 
During the 3-week overfeeding period, 
the SAT diet induced insulin resistance. 
Cross-sectionally, high intakes of 
saturated fat have been shown to 
associate with insulin resistance in 
subjects with NASH as compared to age-, 
gender-, and body mass index-matched 
controls (Musso et al., 2003). In addition, 
isocaloric substitution of saturated for 
monounsaturated fat (Vessby et al., 2001; 
Pérez-Jiménez et al., 2001), 
carbohydrates (Vessby et al., 2001), or 
polyunsaturated fat (Summers et al., 
2002) ameliorates insulin resistance. 
Recently, a large prospective study 
reported intake of foods enriched in 
saturated fat, such as butter and cheese, 
to increase the risk of type 2 diabetes 
(Guasch-Ferré et al., 2017). Even a single 
saturated fat-enriched meal compared to 
water is sufficient to induce insulin 
resistance in mice and humans 
(Hernández et al., 2017).  
 
Intrahepatic TGs by themselves are 
metabolically inert and do not confer 
insulin resistance (Amaro et al., 2010; 
Sun et al., 2013; Cohen et al., 2011). In 
the present study, the SAT diet-induced 
insulin resistance was associated with a 
marked increase in circulating ceramides 
(Figure 12). In mice, ceramides mediate 
saturated fat-induced insulin resistance 
(Chavez et al., 2012; Xie et al., 2017; 
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Holland et al., 2011; Holland et al., 2007; 
Raichur et al., 2014; Turpin et al., 2014; 
Xia et al., 2015). In keeping with these 
data, insulin resistance was associated 
with a marked increases in saturated fatty 
acids, dihydroceramides (markers of de 
novo ceramide synthesis) and ceramides 
in the human liver in study I.  
 
In addition to availability of the substrate, 
i.e. palmitoyl-CoA, the de novo ceramide 
synthetic pathway is upregulated by 
inflammatory ligands of TLR-4 such as 
endotoxin, a component of gram-negative 
bacteria (Holland et al., 2007; Holland et 
al., 2011). In the present study, the SAT 
diet induced endotoxemia, as determined 
from the LBP-to-sCD14 ratio in serum. 
This is consistent with previous studies 
demonstrating that endotoxemia occurs 
in humans in response to a single high-fat 
meal enriched in butter (Erridge et al., 
2007) or cream (Deopurkar et al., 2010) 
but not after consuming equicaloric 
amount of orange juice or a dose of water 
(Deopurkar et al., 2010). Endotoxemia is 
also induced by a 4-week saturated fat-
enriched diet in humans (Pendyala et al., 
2012). The upregulation of inflammatory 
gene expression pathways in adipose 
tissue during the SAT diet (Figure 13) 
could be a consequence of endotoxemia. 
In mice, high-fat feeding increases the 
proportion of endotoxin-containing 
bacteria in the gut and plasma 
concentrations of endotoxin, and induces 
insulin resistance (Cani et al., 2007). 
Another study in mice reported that 
saturated but not polyunsaturated fat 
feeding increases the abundance of gram-
negative gut bacteria, and induces 
endotoxemia, and Toll-like receptor 
activation and inflammation in the 
adipose tissue (Caesar et al., 2015). These 
data suggest that de novo synthesis of 
ceramides induced by increased 
availability of saturated fatty acids and 
endotoxin could contribute to SAT diet-
induced insulin resistance. The present 
data showing that the SAT diet stimulates 
adipose tissue lipolysis and increases 
HOMA-IR are also consistent with data 
showing hepatic gluconeogenesis to be 
indirectly regulated by hepatic acetyl-CoA 
originating from adipose tissue lipolysis 
(Perry et al., 2015). 
 
NAFLD increases the risk of 
cardiovascular disease (Anstee et al., 
2013), which is the most common cause 
of death in subjects with NAFLD (Ekstedt 
et al. 2006). Plasma ceramides have been 
recently reported in five prospective 
studies to predict cardiovascular events 
and death, even independent of LDL 
cholesterol concentrations (Tarasov et al., 
2014; Cheng et al., 2015; Laaksonen et 
al., 2016; Havulinna et al., 2016; Wang et 
al., 2017). Increased intake of saturated 
fat could therefore be harmful to 
cardiovascular health by increasing both 
LDL cholesterol and plasma ceramides. 
This is consistent with the advisory of the 
American Heart Association, which 
concluded that reducing the intake of 
saturated fat by replacing it with 
unsaturated fat decreases the incidence of 
cardiovascular disease (Sacks et al., 
2017). 
 
In conclusion, overfeeding diets enriched 
with saturated or unsaturated fat or 
simple sugars for 3 weeks increases IHTG 
content, but the magnitude and the 
associated metabolic changes depend on 
the macronutrient composition of the 
diet. Saturated fat induced the highest 
increase in IHTG by stimulating adipose 
tissue lipolysis, the major source of FAs in 
IHTG. Moreover, saturated fat induced IR 
and increased circulating concentrations 
of ceramides. In contrast to saturated fat, 
overfeeding of unsaturated fat led to a 
smaller increase in IHTG, decreased 
lipolysis, and no change in ceramides. 
Simple sugars increased IHTG by 
stimulating DNL. Consistent with current 
dietary recommendations (US 
Department of Health and Human 
Services et al., 2015), study IV 
demonstrates that saturated fat seems 
harmful not just in terms of the risk of 
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diabetes and cardiovascular disease but 
also in terms of the liver.  
6.4. ‘DOUBLE TROUBLE’ AND 
‘TRIPLE TROUBLE’ 
 
‘Double trouble’. Given the high 
prevalence of both metabolic and genetic 
risk factors for NAFLD, they can co-exist 
in an individual. Indeed, when the cohort 
in study I was divided into four groups of 
subjects who had both insulin resistance 
and carried the I148M variant allele 
(‘double trouble’), either (‘single trouble’), 
or neither risk factor, the effects of insulin 
resistance and the variant allele seemed 
to be additive with respect to increases in 
liver fat content and the prevalence of 
NASH (Figure 14). 
 
Very recently, a study in multiple large 
cohorts demonstrated that the effect of 
the PNPLA3 I148M variant allele on 
IHTG content is amplified by increasing 
adiposity (Stender et al., 2017). In normal 
weight subjects (BMI < 25 kg/m2), the 
average IHTG content among 
homozygous variant carriers and non-
carriers was 2.8% and 1.8%, respectively. 
In subjects with BMI > 35 kg/m2, the 
average IHTG content was threefold 
higher in homozygous variant carriers 
(14.2%) as compared to non-carriers 
(4.7%). Adiposity also intensified the 
effect of the PNPLA3 variant allele on 
serum ALT and the prevalence of liver 
cirrhosis. The same study demonstrated 
that the effect of the TM6SF2 E167K on 
IHTG content is also magnified by obesity 
(Stender et al., 2017). 
 
In addition to possible co-existence of 
metabolic risk factors with a single 
genetic risk allele, it is possible that 
several risk alleles are present in an 
individual. Mancina et al. demonstrated 
in a cohort of 2,736 subjects from the 
Dallas Heart Study, that the IHTG 
content determined by 1H-MRS increased 
additively as a function of the total 
number of PNPLA3, MBOAT7 and 
TM6SF2 risk variants (Mancina et al., 
2016). In this study, the average IHTG 
content increased from less than 5 % in 
subjects without any risk allele to over 15 
% in subjects with a total of 5 risk alleles 
(Mancina et al., 2016). Another study 
comprising 416 biopsy-proven NAFLD 
patients and 109 controls found that the 
PNPLA3 and TM6SF2 risk variants 
increased the risk of NASH and 
significant fibrosis in an additive fashion, 
even in subjects with low insulin 
resistance (Koo et al., 2017). Moreover, it 
was shown in a cohort of 765 Italian 
NAFLD patients that also the risk of 
hepatocellular carcinoma increases in a 
step-wise fashion as a function of the total 
number of PNPLA3, MBOAT7 and 
TM6SF2 risk variants (Donati et al., 
2017). The risk of hepatocellular 
carcinoma was over 9-fold higher (OR 
9.25, 95% CI 3.83-22.8) in subjects 
carrying 5 risk alleles as compared to 
those carrying none (Donati et al., 2017). 
 
‘Triple trouble’. In addition to the 
metabolic and genetic risk factors of fatty 
liver disease, a third common risk factor 
exists: alcohol. According to a recent 
review, alcohol consumption and 
metabolic risk factors have synergistic 
effects in the development of advanced 
liver disease and hepatocellular 
carcinoma (Boyle et al., 2018). This was 
elegantly demonstrated in a population-
based longitudinal study with 6,732 
participants, in which both the features of 
insulin resistance and the average alcohol 
intake independently predicted liver-
related events, such as hospitalization, 
death or diagnosis of liver cancer (Åberg 
et al., 2017). Of note, alcohol intake 
predicted these events within the current 
thresholds of alcohol intake defining 
NAFLD (Åberg et al., 2017). 
 
Alcoholic liver disease (ALD), similarly to 
NAFLD, is a spectrum of disease ranging 
from steatosis to steatohepatitis and 
cirrhosis (Greuter et al., 2017). It also
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Figure 14. The additive effect of the PNPLA3 I148M gene variant and insulin resistance 
on liver fat content and the prevalence of NASH. The upper left panel shows body mass 
index, the upper right panel fasting serum insulin, the lower left panel liver fat content and 
the lower right panel the prevalence of NASH in non-overlapping groups of subjects either 
carrying (+) or not carrying (-) the PNPLA3 I148M gene variant and having HOMA-IR 
value above (+) or below (-) 3.19. Adapted from Luukkonen PK et al., Journal of 
Hepatology. 2016; 64:1167-75 and reproduced with the permission of Elsevier.
increases the risk of hepatocellular 
carcinoma (Boyle et al., 2018). 
Histologically, NAFLD and ALD are 
characterized by similar features such as 
macrovesicular steatosis; and in 
steatohepatitis, hepatocellular ballooning, 
immune cell infiltration and fibrosis 
(Greuter et al., 2017) Moreover, these 
diseases share a common genetic 
background, as the PNPLA3, MBOAT7 
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and TM6SF2 variants predispose not only 
to NAFLD but also to ALD (Buch et al., 
2015). These data suggest that, contrary 
to current dogma, NAFLD and ALD may 
represent two extremes of a single fatty 
liver disease (Boyle et al., 2018). 
 
Taken together, the metabolic and genetic 
risk factors, and a high intake of alcohol 
exhibit additive effects in the 
pathogenesis of NAFLD, and these 
features may characterize the subjects 
who are at the highest risk of advanced 
liver disease and the associated mortality. 
 
  
 Summary and Conclusions 
    81
7. SUMMARY AND CONCLUSIONS 
 
The present series of studies aimed to 
characterize heterogeneity of human 
NAFLD, with a special emphasis on the 
regulation of hepatic lipid metabolism by 
genetic and nutritional factors.  
 
In study I, we determined whether the 
human liver lipidome differs between 
‘Metabolic NAFLD’ and ‘PNPLA3 
NAFLD’. The insulin-resistant human 
liver in ‘Metabolic NAFLD’ was enriched 
in saturated and monounsaturated free 
fatty acids and TGs as well as insulin 
resistance-inducing lipids i.e. ceramides 
and DAGs. The increase in hepatic 
ceramides appeared to be due to an 
increase in the de novo ceramide 
synthetic pathway, which produces 
ceramides from saturated fatty acids. In 
contrast to ‘Metabolic NAFLD’, the 
human liver lipidome in the insulin-
sensitive ‘PNPLA3 NAFLD’ lacked all of 
the aforementioned features and was 
characterized by increased concentrations 
of polyunsaturated TGs. These data are 
novel and document that the lipid 
composition of the human liver is 
markedly dependent upon the etiology of 
NAFLD.  
 
In study II, we studied the human liver 
histology and lipidome in the ‘MBOAT7 
NAFLD’. Histologically, carriers of the 
MBOAT7 gene variant had more liver 
fibrosis than non-carriers. With respect to 
liver lipidome, concentrations of several 
polyunsaturated phosphatidylinositols, 
but not other lipids, were significantly 
altered. Thus, ‘MBOAT7 NAFLD’ is also 
associated with distinct alterations in the 
human liver lipidome. 
 
In study III, we investigated the human 
liver and serum lipidome and hepatic 
gene expression in ‘TM6SF2 NAFLD’. In 
addition, the incorporation of different 
fatty acids into complex lipids was 
determined in TM6SF2 knockdown cells 
in vitro. A relative deficiency of 
polyunsaturated triglycerides and 
phosphatidylcholines, and a relative 
excess of polyunsaturated free fatty acids 
characterized the liver lipidome. The 
hepatic gene expression profile in the 
‘TM6SF2 NAFLD’ was characterized by 
alterations in genes regulated by PUFAs. 
The incorporation of polyunsaturated 
fatty acids into complex lipids was 
decreased in TM6SF2 knockdown cells. 
Together these data suggest that hepatic 
lipid synthesis from polyunsaturated fatty 
acids is impaired in carriers of the 
TM6SF2 E167K variant. 
 
In study IV, we demonstrated in healthy 
overweight humans that 3 weeks of 
overfeeding diets enriched either in 
saturated or unsaturated fat or simple 
sugars increases IHTG content, but the 
magnitude and the associated metabolic 
changes depend on  macronutrient 
composition of the diet.  
 
Saturated fat induced a higher increase in 
IHTG than unsaturated fat. The former 
diet stimulated while the latter decreased 
adipose tissue lipolysis, the major source 
of FAs in IHTG, which may explain the 
differential changes in IHTG in the face of 
similar energy excess. All diets had 
distinct effects on adipose tissue 
transcriptome, and particularly saturated 
fat induced multiple inflammation-
related pathways. Moreover, saturated fat 
induced IR, endotoxemia and an increase 
in circulating concentrations of harmful 
ceramides. Simple sugar-enriched diet 
increased IHTG content by stimulating 
DNL.  
 
Despite strikingly different liver 
lipidomes, all phenotypes of NAFLD in 
the present study were characterized by 
histological liver damage. Macrovesicular 
steatosis was a unifying characteristic in 
all phenotypes, and may be an obligate 
driver for intrahepatic damage. In 
addition, alterations in the metabolism of 
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polyunsaturated fatty acids emerged as a 
common characteristic of the genetic 
NAFLDs (i.e. the ’PNPLA3 NAFLD’, 
’MBOAT7 NAFLD’ and ’TM6SF2 
NAFLD’). These two characteristics may 
provide targets for treatment of 
intrahepatic damage in NAFLD. 
 
The insulin-resistant ’Metabolic NAFLD’, 
but not the genetic NAFLDs, confer an 
increased risk of diabetes and 
cardiovascular disease. ’Metabolic 
NAFLD’ was characterized by increases in 
triglycerides, especially insulin 
resistance-inducing ceramides. 
Consistent with these data, 
overconsumption of saturated fat for 3 
weeks induced a highly saturated, 
ceramide-enriched lipidome, insulin 
resistance, and a marked increase in 
IHTG content. Thus, consistent with the 
current dietary recommendations, 
avoidance of foods rich in saturated fats 
and replacing them with unsaturated fat 
may be beneficial for the liver.  
 
The phenotypes of NAFLD in the present 
study are not mutually exclusive. A 
subject may carry none, one, or several of 
these risk factors (insulin resistance and 
genetic risk alleles). Those with several 
risk factors may be at the highest risk of 
NAFLD-related morbidity and mortality.   
 
In conclusion, genetic and nutritional 
factors have a marked effect on the 
hepatic lipid metabolism and the 
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